U.S. patent application number 16/807891 was filed with the patent office on 2020-06-25 for aza-aryl 1h-pyrazol-yl benzene sulfonamides.
The applicant listed for this patent is ChemoCentryx, Inc.. Invention is credited to Xi CHEN, Junfa FAN, Pingchen FAN, Antoni KRASINSKI, Lianfa LI, Rebecca M. LUI, Jeffrey P. McMAHON, Jay P. POWERS, Yibin ZENG, Penglie ZHANG.
Application Number | 20200197386 16/807891 |
Document ID | / |
Family ID | 47844528 |
Filed Date | 2020-06-25 |
![](/patent/app/20200197386/US20200197386A1-20200625-C00001.png)
![](/patent/app/20200197386/US20200197386A1-20200625-C00002.png)
![](/patent/app/20200197386/US20200197386A1-20200625-C00003.png)
![](/patent/app/20200197386/US20200197386A1-20200625-C00004.png)
![](/patent/app/20200197386/US20200197386A1-20200625-C00005.png)
![](/patent/app/20200197386/US20200197386A1-20200625-C00006.png)
![](/patent/app/20200197386/US20200197386A1-20200625-C00007.png)
![](/patent/app/20200197386/US20200197386A1-20200625-C00008.png)
![](/patent/app/20200197386/US20200197386A1-20200625-C00009.png)
![](/patent/app/20200197386/US20200197386A1-20200625-C00010.png)
![](/patent/app/20200197386/US20200197386A1-20200625-C00011.png)
View All Diagrams
United States Patent
Application |
20200197386 |
Kind Code |
A1 |
CHEN; Xi ; et al. |
June 25, 2020 |
Aza-Aryl 1H-Pyrazol-yl Benzene Sulfonamides
Abstract
Compounds are provided that act as potent antagonists of the
CCR(9) receptor. Animal testing demonstrates that these compounds
are useful for treating inflammation, a hallmark disease for
CCR(9). The compounds are generally aryl sulfonamide derivatives
and are useful in pharmaceutical compositions, methods for the
treatment of CCR(9)-mediated diseases, and as controls in assays
for the identification of CCR(9) antagonists.
Inventors: |
CHEN; Xi; (E. Palo Alto,
CA) ; FAN; Junfa; (Foster City, CA) ; FAN;
Pingchen; (Fremont, CA) ; KRASINSKI; Antoni;
(San Jose, CA) ; LI; Lianfa; (San Jose, CA)
; LUI; Rebecca M.; (Santa Clara, CA) ; McMAHON;
Jeffrey P.; (San Francisco, CA) ; POWERS; Jay P.;
(Pacifica, CA) ; ZENG; Yibin; (Foster City,
CA) ; ZHANG; Penglie; (Foster City, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
ChemoCentryx, Inc. |
Mountain View |
CA |
US |
|
|
Family ID: |
47844528 |
Appl. No.: |
16/807891 |
Filed: |
March 3, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16170752 |
Oct 25, 2018 |
10596163 |
|
|
16807891 |
|
|
|
|
14541637 |
Nov 14, 2014 |
10137120 |
|
|
16170752 |
|
|
|
|
13781412 |
Feb 28, 2013 |
8916601 |
|
|
14541637 |
|
|
|
|
61604998 |
Feb 29, 2012 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 31/00 20180101;
C07D 401/04 20130101; A61P 1/04 20180101; A61K 31/4725 20130101;
A61K 31/517 20130101; A61P 11/00 20180101; A61P 37/08 20180101;
A61P 17/04 20180101; A61P 1/00 20180101; A61P 1/16 20180101; A61P
19/02 20180101; A61K 45/06 20130101; A61K 31/4709 20130101; A61P
35/02 20180101; A61P 11/02 20180101; A61P 9/10 20180101; A61P 29/00
20180101; C07D 405/14 20130101; C07D 401/10 20130101; A61K 31/5377
20130101; C07D 403/04 20130101; A61K 31/502 20130101; A61P 43/00
20180101; A61P 15/02 20180101; A61P 37/00 20180101; A61P 37/02
20180101; A61P 3/10 20180101; C07D 403/10 20130101; A61P 11/06
20180101; A61P 27/02 20180101; A61K 31/415 20130101; A61P 37/06
20180101; C07D 401/06 20130101; A61P 17/00 20180101; A61P 25/28
20180101; C07D 231/42 20130101; A61P 17/06 20180101; A61P 13/12
20180101; A61P 35/00 20180101; A61P 39/06 20180101; A61P 19/00
20180101 |
International
Class: |
A61K 31/4709 20060101
A61K031/4709; C07D 403/04 20060101 C07D403/04; C07D 401/06 20060101
C07D401/06; A61K 31/4725 20060101 A61K031/4725; C07D 401/04
20060101 C07D401/04; A61K 31/5377 20060101 A61K031/5377; A61K
31/502 20060101 A61K031/502; A61K 31/415 20060101 A61K031/415; C07D
231/42 20060101 C07D231/42; A61K 31/517 20060101 A61K031/517; C07D
403/10 20060101 C07D403/10; A61K 45/06 20060101 A61K045/06; C07D
401/10 20060101 C07D401/10; C07D 405/14 20060101 C07D405/14 |
Claims
1. A compound or salt thereof of formula (I): ##STR00159## wherein:
R.sup.1 is selected from the group consisting of substituted or
unsubstituted C.sub.2-8 alkyl, substituted or unsubstituted
C.sub.1-8 alkoxy, unsubstituted C.sub.1-8 alkylamino, and
substituted or unsubstituted C.sub.3-10 heterocyclyl; and R.sup.2
is H, F, Cl, or substituted or unsubstituted C.sub.1-8 alkoxy; or
R.sup.1 and R.sup.2 together with the carbon atoms to which they
are attached form a non-aromatic carbocyclic ring or a heterocyclic
ring; R.sup.3 is H, substituted or unsubstituted C.sub.1-8 alkyl,
substituted or unsubstituted C.sub.1-8 alkoxy, or halo; R.sup.4 is
H or F; R.sup.5 is H, F, Cl, or --CH.sub.3; and R.sup.6 is H, halo,
--CN, --CO.sub.2R.sup.a, --CONH.sub.2, --NH.sub.2, substituted or
unsubstituted C.sub.1-8 alkyl, substituted or unsubstituted
C.sub.1-8 alkoxy, or unsubstituted C.sub.1-8 aminoalkyl, wherein
R.sup.a is H or substituted or unsubstituted C.sub.1-8 alkyl; or
R.sup.5 and R.sup.6 together with the carbon atoms to which they
are attached form a carbocyclic ring; L is a bond, --CH.sub.2--, or
--CH(CH.sub.3)--; each of A.sup.1, A.sup.2, A.sup.3, A.sup.4,
A.sup.5, A.sup.6, A.sup.7, and A.sup.8 are independently selected
from the group consisting of N, N--O, and --CR.sup.8--; wherein at
least one and not more than two of A.sup.1, A.sup.2, A.sup.3,
A.sup.4, A.sup.5, A.sup.6, A.sup.7, and A.sup.6 are N or N--O;
R.sup.8 is each independently selected from the group consisting of
H, halo, --CN, --OH, oxo, substituted or unsubstituted C.sub.1-8
alkyl, substituted or unsubstituted C.sub.1-8 alkoxy,
--NR.sup.20R.sup.21, substituted or unsubstituted aryl, substituted
or unsubstituted heteroaryl, and substituted or unsubstituted
heterocyclyl; R.sup.20 and R.sup.21 are each independently H or
substituted or unsubstituted C.sub.1-8 alkyl; and the compound is
not
3,4-dimethoxy-N-(3-methyl-1-(4,6,8-trimethylquinolin-2-yl)-1H-pyrazol-5-y-
l)benzenesulfonamide,
N-(1-(4,8-dimethylquinolin-2-yl)-3-methyl-1H-pyrazol-5-yl)-3,4-dimethoxyb-
enzenesulfonamide,
3,4-dimethoxy-N-(3-methyl-1-(4-methylquinolin-2-yl)-1H-pyrazol-5-yl)benze-
nesulfonamide,
3,4-dimethoxy-N-(3-methyl-1-(quinolin-2-yl)-1H-pyrazol-5-yl)benzenesulfon-
amide,
2,3-dihydro-N-[3-methyl-1-(4-methyl-2-quinolinyl)-1H-pyrazol-5-yl]--
2-oxo-6-benzoxazolesulfonamide,
2,3-dihydro-N-[3-methyl-1-(4,8-dimethyl-2-quinolinyl)-1H-pyrazol-5-yl]-2--
oxo-6-benzoxazolesulfonamide,
3,4-dimethoxy-N-(1-(8-methoxy-4-methylquinolin-2-yl)-3-methyl-1H-pyrazol--
5-yl)benzenesulfonamide,
2,3-dihydro-N-[3-methyl-1-(2-quinolinyl)-1H-pyrazol-5-yl]-2-oxo-6-benzoxa-
zolesulfonamide,
2,3-dihydro-N-[1-(8-methoxy-4-methyl-2-quinolinyl)-3-methyl-1H-pyrazol-5--
yl]-2-oxo-6-benzoxazolesulfonamide, or
2,3-dihydro-N-[3-methyl-1-(4,6,8-trimethyl-2-quinolinyl)-1H-pyrazol-5-yl]-
-2-oxo-6-benzoxazolesulfonamide.
2. The compound claim 1 or salt thereof, wherein the compound or
salt thereof is of formula (II): ##STR00160## wherein: R.sup.1 is
selected from the group consisting of substituted or unsubstituted
C.sub.2-8 alkyl, substituted or unsubstituted C.sub.1-8 alkoxy,
unsubstituted C.sub.1-8 alkylamino, and substituted or
unsubstituted C.sub.3-10 heterocyclyl; and R.sup.2 is H, F, Cl, or
substituted or unsubstituted C.sub.1-8 alkoxy; or R.sup.1 and
R.sup.2 together with the carbon atoms to which they are attached
form a non-aromatic carbocyclic ring or a heterocyclic ring;
R.sup.3 is H, substituted or unsubstituted C.sub.1-8 alkyl,
substituted or unsubstituted C.sub.1-8 alkoxy, or halo; R.sup.4 is
H or F; R.sup.5 is H, F, Cl, or --CH.sub.3; R.sup.6 is H, halo,
--CN, --CO.sub.2R.sup.a, --CONH.sub.2, --NH.sub.2, unsubstituted
C.sub.1-8 aminoalkyl, substituted or unsubstituted C.sub.1-8 alkyl,
or substituted or unsubstituted C.sub.1-8 alkoxy; R.sup.a is H or
substituted or unsubstituted C.sub.1-8 alkyl; L is a bond; and Z is
selected from the group consisting of ##STR00161## wherein the Z
group is unsubstituted or substituted with 1 to 3 independently
selected R.sup.8 substituents; each R.sup.8 is independently
selected from the group consisting of H, halo, --CN, --OH, oxo,
substituted or unsubstituted C.sub.1-8 alkyl, substituted or
unsubstituted C.sub.1-8 alkoxy, --NR.sup.20R.sup.21, substituted or
unsubstituted aryl, substituted or unsubstituted heteroaryl, and
substituted or unsubstituted heterocyclyl; and R.sup.20 and
R.sup.21 are each independently H or substituted or unsubstituted
C.sub.1-8 alkyl.
3. The compound of claim 2 or salt thereof, wherein R.sup.1 is
selected from the group consisting of: --CH.sub.2CH.sub.3,
--CH(CH.sub.3).sub.2, --C(CH.sub.3).sub.3,
--C(CH.sub.3).sub.2CH.sub.2CH.sub.3, --C(CH.sub.2CH.sub.2)CN,
--C(OH)(CH.sub.3).sub.2, --OCH.sub.3, --OCH.sub.2CH.sub.3,
--OCH(CH.sub.3).sub.2, --OC(CH.sub.3).sub.3,
--OCH.sub.2CH(CH.sub.3).sub.2, --OCF.sub.3, and morpholino; R.sup.2
is H, F, or Cl; or R.sup.3 is H, --CH.sub.3, or --OCH.sub.3;
R.sup.4 is H or F; R.sup.5 is H; R.sup.6 is H, --CH.sub.3,
--CH.sub.2CH.sub.3, --CH(CH.sub.3).sub.2, --C.sub.3H.sub.7,
--CH.sub.2F, --CHF.sub.2, --CF.sub.2CH.sub.3, --CF.sub.3,
--CH.sub.2OCH.sub.3, --CH.sub.2OH, --CH.sub.2CN, --CN, or
--CONH.sub.2; and each R.sup.8 is independently selected from the
group consisting of H, F, Cl, Br, --CH.sub.3, --OH, --OCH.sub.3,
--OCH.sub.2CH.sub.3, --NH.sub.2, --N(CH.sub.3).sub.2, and --CN.
4. The compound of claim 2 or salt thereof, wherein R.sup.1 is
--C(CH.sub.3).sub.3; R.sup.2 is H or F; R.sup.3 is H; R.sup.4 is H;
R.sup.5 is H; and R.sup.6 is --CH.sub.3, --CH.sub.2F, --CHF.sub.2,
or --CF.sub.3.
5. The compound of claim 3 or salt thereof, wherein R.sup.1 is
--C(CH.sub.3).sub.3.
6. The compound of claim 5 or salt thereof, wherein R.sup.2 is H or
F; R.sup.3 is H; R.sup.4 is H; and R.sup.6 is --CH.sub.3,
--CH.sub.2F, --CHF.sub.2, or --CF.sub.3.
7. A composition comprising a pharmaceutically acceptable carrier
and a compound or salt of formula (I): ##STR00162## wherein:
R.sup.1 is selected from the group consisting of substituted or
unsubstituted C.sub.2-8 alkyl, substituted or unsubstituted
C.sub.1-8 alkoxy, unsubstituted C.sub.1-8 alkylamino, and
substituted or unsubstituted C.sub.3-10 heterocyclyl; and R.sup.2
is H, F, Cl, or substituted or unsubstituted C.sub.1-8 alkoxy; or
R.sup.1 and R.sup.2 together with the carbon atoms to which they
are attached form a non-aromatic carbocyclic ring or a heterocyclic
ring; R.sup.3 is H, substituted or unsubstituted C.sub.1-8 alkyl,
substituted or unsubstituted C.sub.1-8 alkoxy, or halo; R.sup.4 is
H or F; R.sup.5 is H, F, Cl, or --CH.sub.3; and R.sup.6 is H, halo,
--CN, --CO.sub.2R.sup.a, --CONH.sub.2, --NH.sub.2, substituted or
unsubstituted C.sub.1-8 alkyl, substituted or unsubstituted
C.sub.1-8 alkoxy, or unsubstituted C.sub.1-8 aminoalkyl, wherein
R.sup.a is H or substituted or unsubstituted C.sub.1-8 alkyl; or
R.sup.5 and R.sup.6 together with the carbon atoms to which they
are attached form a carbocyclic ring; L is a bond, --CH.sub.2--, or
--CH(CH.sub.3)--; each of A.sup.1, A.sup.2, A.sup.3, A.sup.4,
A.sup.5, A.sup.6, A.sup.7, and A.sup.8 are independently selected
from the group consisting of N, N--O, and --CR.sup.8--; wherein at
least one and not more than two of A.sup.1, A.sup.2, A.sup.3,
A.sup.4, A.sup.5, A.sup.6, A.sup.7, and A.sup.1 are N or N--O;
R.sup.8 is each independently selected from the group consisting of
H, halo, --CN, --OH, oxo, substituted or unsubstituted C.sub.1-8
alkyl, substituted or unsubstituted C.sub.1-8 alkoxy,
--NR.sup.20R.sup.21, substituted or unsubstituted aryl, substituted
or unsubstituted heteroaryl, and substituted or unsubstituted
heterocyclyl; R.sup.20 and R.sup.21 are each independently H or
substituted or unsubstituted C.sub.1-8 alkyl; and the compound is
not
3,4-dimethoxy-N-(3-methyl-1-(4,6,8-trimethylquinolin-2-yl)-1H-pyrazol-5-y-
l)benzenesulfonamide,
N-(1-(4,8-dimethylquinolin-2-yl)-3-methyl-1H-pyrazol-5-yl)-3,4-dimethoxyb-
enzenesulfonamide,
3,4-dimethoxy-N-(3-methyl-1-(4-methylquinolin-2-yl)-1H-pyrazol-5-yl)benze-
nesulfonamide,
3,4-dimethoxy-N-(3-methyl-1-(quinolin-2-yl)-1H-pyrazol-5-yl)benzenesulfon-
amide,
2,3-dihydro-N-[3-methyl-1-(4-methyl-2-quinolinyl)-1H-pyrazol-5-yl]--
2-oxo-6-benzoxazolesulfonamide,
2,3-dihydro-N-[3-methyl-1-(4,8-dimethyl-2-quinolinyl)-1H-pyrazol-5-yl]-2--
oxo-6-benzoxazolesulfonamide,
3,4-dimethoxy-N-(1-(8-methoxy-4-methylquinolin-2-yl)-3-methyl-1H-pyrazol--
5-yl)benzenesulfonamide,
2,3-dihydro-N-[3-methyl-1-(2-quinolinyl)-1H-pyrazol-5-yl]-2-oxo-6-benzoxa-
zolesulfonamide,
2,3-dihydro-N-[1-(8-methoxy-4-methyl-2-quinolinyl)-3-methyl-1H-pyrazol-5--
yl]-2-oxo-6-benzoxazolesulfonamide, or
2,3-dihydro-N-[3-methyl-1-(4,6,8-trimethyl-2-quinolinyl)-1H-pyrazol-5-yl]-
-2-oxo-6-benzoxazolesulfonamide.
8. The composition of claim 7, wherein the compound or salt thereof
is of formula (II): ##STR00163## wherein: R.sup.1 is selected from
the group consisting of substituted or unsubstituted C.sub.2-8
alkyl, substituted or unsubstituted C.sub.1-8 alkoxy, unsubstituted
C.sub.1-8 alkylamino, and substituted or unsubstituted C.sub.3-10
heterocyclyl; and R.sup.2 is H, F, Cl, or substituted or
unsubstituted C.sub.1-8 alkoxy; or R.sup.1 and R.sup.2 together
with the carbon atoms to which they are attached form a
non-aromatic carbocyclic ring or a heterocyclic ring; R.sup.3 is H,
substituted or unsubstituted C.sub.1-8 alkyl, substituted or
unsubstituted C.sub.1-8 alkoxy, or halo; R.sup.4 is H or F; R.sup.5
is H, F, Cl, or --CH.sub.3; R.sup.6 is H, halo, --CN,
--CO.sub.2R.sup.a, --CONH.sub.2, --NH.sub.2, unsubstituted
C.sub.1-8 aminoalkyl, substituted or unsubstituted C.sub.1-8 alkyl,
or substituted or unsubstituted C.sub.1-8 alkoxy; R.sup.a is H or
substituted or unsubstituted C.sub.1-8 alkyl; L is a bond; and Z is
selected from the group consisting of ##STR00164## wherein the Z
group is unsubstituted or substituted with 1 to 3 independently
selected R.sup.8 substituents; each R.sup.8 is independently
selected from the group consisting of H, halo, --CN, --OH, oxo,
substituted or unsubstituted C.sub.1-8 alkyl, substituted or
unsubstituted C.sub.1-8 alkoxy, --NR.sup.20R.sup.21, substituted or
unsubstituted aryl, substituted or unsubstituted heteroaryl, and
substituted or unsubstituted heterocyclyl; and R.sup.20 and
R.sup.21 are each independently H or substituted or unsubstituted
C.sub.1-8 alkyl.
9. The composition of claim 8, wherein R.sup.1 is selected from the
group consisting of: --CH.sub.2CH.sub.3, --CH(CH.sub.3).sub.2,
--C(CH.sub.3).sub.3, --C(CH.sub.3).sub.2CH.sub.2CH.sub.3,
--C(CH.sub.2CH.sub.2)CN, --C(OH)(CH.sub.3).sub.2, --OCH.sub.3,
--OCH.sub.2CH.sub.3, --OCH(CH.sub.3).sub.2, --OC(CH.sub.3).sub.3,
--OCH.sub.2CH(CH.sub.3).sub.2, --OCF.sub.3, and morpholino; R.sup.2
is H, F, or Cl; or R.sup.3 is H, --CH.sub.3, or --OCH.sub.3;
R.sup.4 is H or F; R.sup.5 is H; R.sup.6 is H, --CH.sub.3,
--CH.sub.2CH.sub.3, --CH(CH.sub.3).sub.2, --C.sub.3H.sub.7,
--CH.sub.2F, --CHF.sub.2, --CF.sub.2CH.sub.3, --CF.sub.3,
--CH.sub.2OCH.sub.3, --CH.sub.2OH, --CH.sub.2CN, --CN, or
--CONH.sub.2; and each R.sup.8 is independently selected from the
group consisting of H, F, Cl, Br, --CH.sub.3, --OH, --OCH.sub.3,
--OCH.sub.2CH.sub.3, --NH.sub.2, --N(CH.sub.3).sub.2, and --CN.
10. The composition of claim 8, wherein R.sup.1 is
--C(CH.sub.3).sub.3; R.sup.2 is H or F; R.sup.3 is H; R.sup.4 is H;
R.sup.5 is H; and R.sup.6 is --CH.sub.3, --CH.sub.2F, --CHF.sub.2,
or --CF.sub.3.
11. A method of modulating CCR(9) function in a cell, comprising
contacting the cell with a CCR(9) modulating amount of the compound
of claim 1 or salt thereof.
12. A method for treating a CCR(9)-mediated condition or disease
comprising administering to a subject an effective amount of a
compound or salt thereof of formula (I): ##STR00165## wherein:
R.sup.1 is selected from the group consisting of substituted or
unsubstituted C.sub.2-8 alkyl, substituted or unsubstituted
C.sub.1-8 alkoxy, unsubstituted C.sub.1-8 alkylamino, and
substituted or unsubstituted C.sub.3-10 heterocyclyl; and R.sup.2
is H, F, Cl, or substituted or unsubstituted C.sub.1-8 alkoxy; or
R.sup.1 and R.sup.2 together with the carbon atoms to which they
are attached form a non-aromatic carbocyclic ring or a heterocyclic
ring; R.sup.3 is H, substituted or unsubstituted C.sub.1-8 alkyl,
substituted or unsubstituted C.sub.1-8 alkoxy, or halo; R.sup.4 is
H or F; R.sup.5 is H, F, Cl, or --CH.sub.3; and R.sup.6 is H, halo,
--CN, --CO.sub.2R.sup.a, --CONH.sub.2, --NH.sub.2, substituted or
unsubstituted C.sub.1-8 alkyl, substituted or unsubstituted
C.sub.1-8 alkoxy, or unsubstituted C.sub.1-8 aminoalkyl, wherein
R.sup.a is H or substituted or unsubstituted C.sub.1-8 alkyl; or
R.sup.5 and R.sup.6 together with the carbon atoms to which they
are attached form a carbocyclic ring; L is a bond, --CH.sub.2--, or
--CH(CH.sub.3)--; each of A.sup.1, A.sup.2, A.sup.3, A.sup.4,
A.sup.5, A.sup.6, A.sup.7, and A.sup.8 are independently selected
from the group consisting of N, N--O, and --CR.sup.8--; wherein at
least one and not more than two of A.sup.1, A.sup.2, A.sup.3,
A.sup.4, A.sup.5, A.sup.6, A.sup.7, and A.sup.6 are N or N--O;
R.sup.8 is each independently selected from the group consisting of
H, halo, --CN, --OH, oxo, substituted or unsubstituted C.sub.1-8
alkyl, substituted or unsubstituted C.sub.1-8 alkoxy,
--NR.sup.20R.sup.21, substituted or unsubstituted aryl, substituted
or unsubstituted heteroaryl, and substituted or unsubstituted
heterocyclyl; R.sup.20 and R.sup.21 are each independently H or
substituted or unsubstituted C.sub.1-8 alkyl; and the compound is
not
3,4-dimethoxy-N-(3-methyl-1-(4,6,8-trimethylquinolin-2-yl)-1H-pyrazol-5-y-
l)benzenesulfonamide,
N-(1-(4,8-dimethylquinolin-2-yl)-3-methyl-1H-pyrazol-5-yl)-3,4-dimethoxyb-
enzenesulfonamide,
3,4-dimethoxy-N-(3-methyl-1-(4-methylquinolin-2-yl)-1H-pyrazol-5-yl)benze-
nesulfonamide,
3,4-dimethoxy-N-(3-methyl-1-(quinolin-2-yl)-1H-pyrazol-5-yl)benzenesulfon-
amide,
2,3-dihydro-N-[3-methyl-1-(4-methyl-2-quinolinyl)-1H-pyrazol-5-yl]--
2-oxo-6-benzoxazolesulfonamide,
2,3-dihydro-N-[3-methyl-1-(4,8-dimethyl-2-quinolinyl)-1H-pyrazol-5-yl]-2--
oxo-6-benzoxazolesulfonamide,
3,4-dimethoxy-N-(1-(8-methoxy-4-methylquinolin-2-yl)-3-methyl-1H-pyrazol--
5-yl)benzenesulfonamide,
2,3-dihydro-N-[3-methyl-1-(2-quinolinyl)-1H-pyrazol-5-yl]-2-oxo-6-benzoxa-
zolesulfonamide,
2,3-dihydro-N-[1-(8-methoxy-4-methyl-2-quinolinyl)-3-methyl-1H-pyrazol-5--
yl]-2-oxo-6-benzoxazolesulfonamide, or
2,3-dihydro-N-[3-methyl-1-(4,6,8-trimethyl-2-quinolinyl)-1H-pyrazol-5-yl]-
-2-oxo-6-benzoxazolesulfonamide.
13. The method of claim 12, wherein the compound or salt thereof is
of formula (II): ##STR00166## wherein: R.sup.1 is selected from the
group consisting of substituted or unsubstituted C.sub.2-8 alkyl,
substituted or unsubstituted C.sub.1-8 alkoxy, unsubstituted
C.sub.1-8 alkylamino, and substituted or unsubstituted C.sub.3-10
heterocyclyl; and R.sup.2 is H, F, Cl, or substituted or
unsubstituted C.sub.1-8 alkoxy; or R.sup.1 and R.sup.2 together
with the carbon atoms to which they are attached form a
non-aromatic carbocyclic ring or a heterocyclic ring; R.sup.3 is H,
substituted or unsubstituted C.sub.1-8 alkyl, substituted or
unsubstituted C.sub.1-8 alkoxy, or halo; R.sup.4 is H or F; R.sup.5
is H, F, Cl, or --CH.sub.3; R.sup.6 is H, halo, --CN,
--CO.sub.2R.sup.a, --CONH.sub.2, --NH.sub.2, unsubstituted
C.sub.1-8 aminoalkyl, substituted or unsubstituted C.sub.1-8 alkyl,
or substituted or unsubstituted C.sub.1-8 alkoxy; R.sup.a is H or
substituted or unsubstituted C.sub.1-8 alkyl; L is a bond; and Z is
selected from the group consisting of ##STR00167## wherein the Z
group is unsubstituted or substituted with 1 to 3 independently
selected R.sup.8 substituents; each R.sup.8 is independently
selected from the group consisting of H, halo, --CN, --OH, oxo,
substituted or unsubstituted C.sub.1-8 alkyl, substituted or
unsubstituted C.sub.1-8 alkoxy, --NR.sup.20R.sup.21, substituted or
unsubstituted aryl, substituted or unsubstituted heteroaryl, and
substituted or unsubstituted heterocyclyl; and R.sup.20 and
R.sup.21 are each independently H or substituted or unsubstituted
C.sub.1-8 alkyl.
14. The method of claim 12, wherein the subject is a human.
15. The method of claim 12, wherein the administering is oral,
parenteral, rectal, transdermal, sublingual, nasal or topical.
16. The method of claim 12, wherein the CCR(9)-mediated disease or
condition is an inflammatory bowel disease, an allergic disease,
psoriasis, atopic dermatitis, asthma, a fibrotic disease, graft
rejection, a graft-v-host disease, an immune mediated food allergy,
an autoimmune disease, Celiac disease, rheumatoid arthritis,
thymoma, thymic carcinoma, leukemia, solid tumor, acute lymphocytic
leukemia, melanoma, primary sclerosing cholangitis, hepatitis,
inflammatory hepatic disease, or post-operative ileus.
17. The method of claim 12, wherein the CCR(9)-mediated disease or
condition is an inflammatory bowel disease selected from Crohn's
disease or ulcerative colitis.
18. The method of claim 12, wherein the CCR(9)-mediated disease or
condition is asthma.
19. The method of claim 12, wherein the CCR(9)-mediated disease is
graft-v-host disease.
20. The method of claim 12, further comprising administering an
anti-inflammatory or analgesic agent.
Description
REFERENCE TO EARLIER FILED APPLICATIONS
[0001] The present application is a continuation of U.S. patent
application Ser. No. 16/170,752, filed Oct. 25, 2018, which is a
continuation of U.S. patent application Ser. No. 14/541,637, filed
Nov. 14, 2014, which is a continuation of U.S. patent application
Ser. No. 13/781,412, filed Feb. 28, 2013, which claims the benefit
under 35 U.S.C. .sctn. 119(e) of U.S. Provisional Patent
Application No. 61/604,998, filed Feb. 29, 2012, and titled
"AZA-ARYL 1H-PYRAZOL-1-7L ENZENE SULFONAMIDES," which are
incorporated, in their entirety, by this reference.
BACKGROUND
[0002] The present invention provides compounds and pharmaceutical
compositions containing one or more of those compounds or their
pharmaceutically acceptable salts, that are effective in inhibiting
the binding or function of various chemokines to chemokine
receptors. As antagonists or modulators of chemokine receptors, the
compounds and compositions have utility in treating various immune
disorder conditions and diseases.
[0003] Chemokines, also known as chemotactic cytokines, are a group
of small molecular-weight proteins that are released by a wide
variety of cells and have a variety of biological activities.
Chemokines attract various types of cells of the immune system,
such as macrophages, T cells, eosinophils, basophils and
neutrophils, and cause them to migrate from the blood to various
lymphoid and none-lymphoid tissues. They mediate infiltration of
inflammatory cells to sites of inflammation, and are responsible
for the initiation and perpetuation of many inflammation diseases
(reviewed in Schall, Cytokine, 3:165-183 (1991), Schall et al.,
Curr. Opin. Immunol., 6:865-873 (1994)).
[0004] In addition to stimulating chemotaxis, chemokines can induce
other changes in responsive cells, including changes in cell shape,
granule exocytosis, integrin up-regulation, formation of bioactive
lipids (e.g., leukotrienes), respiratory burst associated with
leukocyte activation, cell proliferation, resistance to induction
of apoptosis and angiogenesis. Thus, chemokines are early triggers
of the inflammatory response, causing inflammatory mediator
release, chemotaxis and extravasation to sites of infection or
inflammation. They are also stimulators of a multitude of cellular
processes that bear important physiological functions as well as
pathological consequences.
[0005] Chemokines exert their effects by activating chemokine
receptors expressed by responsive cells. Chemokine receptors are a
class of G-protein coupled receptors, also known as
seven-transmembrane receptors, found on the surface of a wide
variety of cell types such as leukocytes, endothelial cells, smooth
muscle cells and tumor cells.
[0006] Chemokines and chemokine receptors are expressed by
intrinsic renal cells and infiltrating cells during renal
inflammation (Segerer et al., J. Am. Soc. Nephrol., 11:152-76
(2000); Morii et al., J. Diabetes Complications, 17:11-5 (2003);
Lloyd et al. J. Exp. Med., 185:1371-80 (1997); Gonzalez-Cuadrado et
al. Clin. Exp. Immunol., 106:518-22 (1996); Eddy & Giachelli,
Kidney Int., 47:1546-57 (1995); Diamond et al., Am. J. Physiol.,
266:F926-33 (1994)).
[0007] Tlymphocyte (T cell) infiltration into the small intestine
and colon has been linked to the pathogenesis of Coeliac diseases,
food allergies, rheumatoid arthritis, human inflammatory bowel
diseases (IBD) which include Crohn's disease and ulcerative
colitis. Blocking trafficking of relevant T cell populations to the
intestine can lead to an effective approach to treat human IBD.
More recently, chemokine receptor-9 (CCR(9)) has been noted to be
expressed on gut-homing T cells in peripheral blood, elevated in
patients with small bowel inflammation such as Crohn's disease and
celiac disease. The only CCR(9) ligand identified to date, TECK
(thymus-expressed chemokine) is expressed in both the small and
large intestines and the ligand receptor pair is now thought to
play a pivotal role in the development of IBD. In particular, this
pair mediates the migration of disease causing inflammatory cells
to the intestine. See for example, Zaballos et al., J. Immunol.,
162(10):5671-5675 (1999); Kunkel et al., J. Exp. Med.,
192(5):761-768 (2000); Papadakis et al., J. Immunol.,
165(9):5069-5076 (2000); Papadakis et al., Gastroenterology,
121(2):246-254 (2001); Campbell et al., J. Exp. Med.,
195(1):135-141 (2002); Wurbel et al., Blood, 98(9):2626-2632
(2001); and Uehara et al., J. Immunol, 168(6):2811-2819 (2002);
Rivera-Nieves et al., Gastroenterology, 2006 November;
131(5):1518-29; and Kontoyiannis et al., J. Exp. Med., Vol. 196,
Number 12, Dec. 16, 2002. In addition CCR(9) bearing lymphocytes
have been show to mediate the pathology of filariasis (lymphatic
filarial disease) and inhibition of CCR(9) has been correlated with
reduction of the pathology associated with such conditions. See for
example Babu et al., Journal of Infectious Diseases, 191: 1018-26,
2005.
[0008] The identification of compounds that modulate the function
of CCR(9) represents an attractive new family of therapeutic agents
for the treatment of inflammatory and other conditions and diseases
associated with CCR(9) activation, such as inflammatory bowel
disease.
[0009] US 2011/0130426 discloses compounds of formula I and their
use in medical therapy such as modulating the glucocorticoid
receptor in warm blooded animals:
##STR00001##
[0010] WO 02/00651 discloses compounds of formula (Ia) as
inhibitors of trypsin-like serine protease enzymes, and methods of
using the same as anti-coagulant agents for treatment and
prevention of thromboembolic disorders:
##STR00002##
BRIEF SUMMARY
[0011] The present invention is directed to compounds and
pharmaceutically acceptable salts thereof, compositions, and
methods useful in modulating chemokine activity and chemokine
receptor activity. The compounds and salts thereof, compositions,
and methods described herein are useful in treating or preventing
chemokine-mediated conditions or diseases, including certain
inflammatory and immunoregulatory disorders and diseases.
[0012] The compounds of the present invention have been shown to
modulate one or more of CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7,
CCR8, CCR(9), CCR10, CCR11, CCR12, CXCR1, CXCR2, CXCR3, CXCR4,
CXCR5, CXCR6, CXCR7, CX3CR1, C5aR, chemR23, FPRL1, FPR1, and FPRL2.
In particular, various compounds of the present invention modulate
CCR(9) as shown in the examples.
[0013] In one embodiment, the present compounds may be represented
by formula (I) or salts thereof:
##STR00003##
where R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, L,
A.sup.1, A.sup.2, A.sup.3, A.sup.4, A.sup.5, A.sup.6, A.sup.7, and
A.sup.8 are as defined below.
[0014] In another aspect, the present invention provides
compositions useful in modulating chemokine activity. In one
embodiment, a composition according to the present invention
comprises a compound according to the invention and a
pharmaceutically acceptable carrier or excipient.
[0015] In yet another aspect, the present invention provides
methods of modulating chemokine function in a cell, comprising
contacting the cell with a therapeutically effective amount of a
compound or composition according to the invention.
[0016] In still another aspect, the present invention provides
methods for modulating chemokine function, comprising contacting a
chemokine receptor with a therapeutically effective amount of a
compound or composition according to the invention.
[0017] In still another aspect, the present invention provides
methods for treating a chemokine-mediated condition or disease,
comprising administering to a subject a safe and effective amount
of a compound or composition according to the invention.
[0018] The administering may be oral, parenteral, rectal,
transdermal, sublingual, nasal or topical. In some aspects the
compound may be administered in combination with an
anti-inflammatory or analgesic agent.
[0019] In addition to the compounds provided herein, the present
invention further provides pharmaceutical compositions containing
one or more of these compounds, as well as methods for the use of
these compounds in therapeutic methods, primarily to treat diseases
associated with chemokine signaling activity. The CCR(9) mediated
disease or condition is inflammatory bowel diseases, an allergic
disease, psoriasis, atopic dermatitis, asthma, fibrotic diseases,
graft rejection, immune mediated food allergies, autoimmune
diseases, Celiac disease, rheumatoid arthritis, thymoma, thymic
carcinoma, leukemia, solid tumor, acute lymphocytic leukemia,
melanoma, primary sclerosing cholangitis, hepatitis, inflammatory
hepatic disease, or post-operative ileus.
DETAILED DESCRIPTION
General
[0020] The present invention is directed to compounds and salts
thereof, compositions and methods useful in the modulation of
chemokine receptor function, particularly CCR(9) function.
Modulation of chemokine receptor activity, as used herein in its
various forms, is intended to encompass antagonism, agonism,
partial antagonism, inverse agonism and/or partial agonism of the
activity associated with a particular chemokine receptor,
preferably the CCR(9) receptor. Accordingly, the compounds of the
present invention are compounds which modulate at least one
function or characteristic of mammalian CCR(9), for example, a
human CCR(9) protein. The ability of a compound to modulate the
function of CCR(9), can be demonstrated in a binding assay (e.g.,
ligand binding or agonist binding), a chemotaxis (migration assay),
a signaling assay (e.g., activation of a mammalian G protein,
induction of rapid and transient increase in the concentration of
cytosolic free calcium), and/or cellular response assay (e.g.,
stimulation of chemotaxis, exocytosis or inflammatory mediator
release by leukocytes).
Abbreviations and Definitions
[0021] When describing the compounds, compositions, methods and
processes of this invention, the following terms have the following
meanings, unless otherwise indicated.
[0022] The term "alkyl" by itself or as part of another substituent
refers to a hydrocarbon group which may be linear, cyclic, or
branched or a combination thereof having the number of carbon atoms
designated (i.e., C.sub.1-8 means one to eight carbon atoms). The
term "cycloalkyl" by itself or as a part of another substituent
refers to a cyclic alkyl group having the number of carbons
designated and is a subset of the term "alkyl." Other subsets of
the term "alkyl" include "linear" and "branched" alkyl groups which
refer to two different types of acyclic alkyl groups. Examples of
alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl,
t-butyl, isobutyl, sec-butyl, cyclohexyl, cyclopentyl,
(cyclohexyl)methyl, cyclopropylmethyl, bicyclo[2.2.1]heptane,
bicyclo[2.2.2]octane, etc. In this list of examples, the methyl,
ethyl, n-propyl, and n-butyl alkyl examples are also examples of
"linear alkyl" groups. Similarly, isopropyl and t-butyl are also
examples of "branched alkyl" groups. Cyclopentyl, cyclohexyl,
(cyclohexyl)methyl, cyclopropylmethyl, bicyclo[2.2.1]heptane,
bicyclo[2.2.2]octane are examples of "cycloalkyl" groups. In some
embodiments, cyclopropyl may be used as a bridging group between
two other moieties and represented as --CH(CH.sub.2)CH--. Alkyl
groups can be substituted or unsubstituted, unless otherwise
indicated. Examples of substituted alkyl include haloalkyl,
thioalkyl, aminoalkyl, and the like. Additional examples of
suitable substitutions of alkyl include, but are not limited to,
hydroxy-isopropyl, --C(CH.sub.3).sub.2--OH, aminomethyl,
2-nitroethyl, 4-cyanobutyl, 2,3-dichloropentyl, and
3-hydroxy-5-carboxyhexyl, 2-aminoethyl, pentachloroethyl,
trifluoromethyl, 2-diethylaminoethyl, 2-dimethylaminopropyl,
ethoxycarbonylmethyl, methanylsulfanylmethyl, methoxymethyl,
3-hydroxypentyl, 2-carboxybutyl, 4-chlorobutyl, and
pentafluoroethyl.
[0023] "Alkoxy" refers to --O-alkyl. Examples of an alkoxy group
include methoxy, ethoxy, n-propoxy etc. The alkyl portion of alkoxy
may be alkyl of from 1 to 16 carbons, and in some embodiments of
from 1 to 8 carbons.
[0024] "Alkenyl" refers to an unsaturated hydrocarbon group which
may be linear, cyclic or branched or a combination thereof. Alkenyl
groups with 2-8 carbon atoms are preferred. The alkenyl group may
contain 1, 2 or 3 carbon-carbon double bonds. Examples of alkenyl
groups include ethenyl, n-propenyl, isopropenyl, n-but-2-enyl,
n-hex-3-enyl, cyclohexenyl, cyclopentenyl and the like. Alkenyl
groups can be substituted or unsubstituted, unless otherwise
indicated.
[0025] "Alkynyl" refers to an unsaturated hydrocarbon group which
may be linear, cyclic or branched or a combination thereof. Alkynyl
groups with 2-8 carbon atoms are preferred. The alkynyl group may
contain 1, 2 or 3 carbon-carbon triple bonds. Examples of alkynyl
groups include ethynyl, n-propynyl, n-but-2-ynyl, n-hex-3-ynyl and
the like. Alkynyl groups can be substituted or unsubstituted,
unless otherwise indicated.
[0026] "Alkylamino" refers to --N(alkyl).sub.2 or --NH(alkyl). When
the alkylamino group contains two alkyl groups, the alkyl groups
may be combined together to form a carbocyclic or heterocylic ring.
It is to be understood that the alkyl groups of the alkylamino
group may be substituted or unsubstituted. Examples of an
alkylamino group include methylamino, tert-butylamino,
dimethylamino, di-isopropylamino, morpholino, and the like.
[0027] "Aminoalkyl", as a substituted alkyl group, refers to a
monoaminoalkyl or polyaminoalkyl group, most typically substituted
with from 1-2 amino groups. Examples include aminomethyl,
2-aminoethyl, 2-diethylaminoethyl, and the like.
[0028] "Aryl" refers to a polyunsaturated, aromatic hydrocarbon
group having a single ring (monocyclic) or multiple rings
(bicyclic), which can be fused together or linked covalently. Aryl
groups with 6-10 carbon atoms are preferred, where this number of
carbon atoms can be designated by C.sub.6-10, for example. Examples
of aryl groups include phenyl and naphthalene-1-yl,
naphthalene-2-yl, biphenyl and the like. Aryl groups can be
substituted or unsubstituted, unless otherwise indicated.
Substituted aryl may be substituted with one or more substituents.
Suitable substituents for aryl include substituted or unsubstituted
C.sub.1-8 alkyl and those substituents as discussed above for
substituted alkyl.
[0029] "Halo" or "halogen", by itself or as part of a substituent
refers to a chlorine, bromine, iodine, or fluorine atom.
[0030] "Haloalkyl", as a substituted alkyl group, refers to a
monohaloalkyl or polyhaloalkyl group, most typically substituted
with from 1-3 halogen atoms. Examples include 1-chloroethyl,
3-bromopropyl, trifluoromethyl and the like.
[0031] "Heterocyclyl" refers to a saturated or unsaturated
non-aromatic ring containing at least one heteroatom (typically 1
to 5 heteroatoms) selected from nitrogen, oxygen or sulfur. The
heterocyclyl ring may be monocyclic or bicyclic. Preferably, these
groups contain 0-5 nitrogen atoms, 0-2 sulfur atoms and 0-2 oxygen
atoms with the caveat that at least one heteroatom is present. In
some embodiments, these groups contain 0-3 nitrogen atoms, 0-1
sulfur atoms and 0-1 oxygen atoms. Examples of heterocycle groups
include pyrrolidine, piperidine, imidazolidine, pyrazolidine,
butyrolactam, valerolactam, imidazolidinone, hydantoin, dioxolane,
phthalimide, piperidine, 1,4-dioxane, morpholine, thiomorpholine,
thiomorpholine-S-oxide, thiomorpholine-S,S-dioxide, piperazine,
pyran, pyridone, 3-pyrroline, thiopyran, pyrone, tetrahydrofuran,
tetrahydrothiophene, quinuclidine and the like. Preferred
heterocyclic groups are monocyclic, though they may be fused or
linked covalently to an aryl or heteroaryl ring system.
[0032] In the definitions above, suitable substituents for
substituted alkyl, alkeynyl, and alkynyl include: halogen, --CN,
--CO.sub.2R', --C(O)R', --C(O)NR'R'', oxo (.dbd.O or --O--), --OR',
--OC(O)R', --OC(O)NR'R''--NO.sub.2, --NR'C(O)R'',
--NR'''C(O)NR'R'', --NR'R'', --NR'CO.sub.2R'', --NR'S(O)R'',
--NR'S(O).sub.2R''', --NR'''S(O)NR'R'', --NR'''S(O).sub.2NR'R'',
--SR', --S(O)R', --S(O).sub.2R', --S(O).sub.2NR'R'',
--NR'--C(NHR'').dbd.NR''', --SiR'R''R''', --OSiR'R''R''',
--N.sub.3, substituted or unsubstituted C.sub.6-10 aryl,
substituted or unsubstituted 5- to 10-membered heteroaryl, and
substituted or unsubstituted 3- to 10-membered heterocyclyl. The
number of possible substituents range from zero to (2m'+1), where
m' is the total number of carbon atoms in such radical. With
respect to substituted alkyl, R', R'' and R''' each independently
refer to a variety of groups including hydrogen, substituted or
unsubstituted C.sub.1-8 alkyl, substituted or unsubstituted
C.sub.2-8 alkenyl, substituted or unsubstituted C.sub.2-8 alkynyl,
substituted or unsubstituted aryl, substituted or unsubstituted
heteroaryl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted arylalkyl, substituted or unsubstituted
aryloxyalkyl. When R' and R'' are attached to the same nitrogen
atom, they can be combined with the nitrogen atom to form a 3-, 4-,
5-, 6-, or 7-membered ring (for example, --NR'R'' includes
1-pyrrolidinyl and 4-morpholinyl). Furthermore, R' and R'', R'' and
R''', or R' and R''' may together with the atom(s) to which they
are attached, form a substituted or unsubstituted 5-, 6-, or
7-membered ring.
[0033] In one preferred embodiment, heterocyclic groups may be
represented by formula (AA) below:
##STR00004##
where formula (AA) is attached via a free valence on either M.sup.1
or M.sup.2; M.sup.1 represents O, NR.sup.e, or S(O).sub.i; M.sup.2
represents CR.sup.fR.sup.g, O, S(O).sub.j, or NR.sup.e; where it
may be necessary to omit one R.sup.f, R.sup.g, or R.sup.e to create
a free valence on M.sup.1 or M.sup.2 such as, for example CR.sup.f,
CR.sup.g, or N; I is 0, 1 or 2; j is 1, 2 or 3 and k is 1, 2 or 3,
with the proviso that j+k is 3, 4, or 5; and R.sup.a, R.sup.b,
R.sup.c, R.sup.d, R.sup.e, R.sup.f, and R.sup.g are independently
selected from the group consisting of hydrogen, halogen,
unsubstituted or substituted C.sub.1-8 alkyl, unsubstituted or
substituted C.sub.2-8 alkenyl, unsubstituted or substituted
C.sub.2-8 alkynyl, --COR.sup.h, --CO.sub.2R.sup.h,
--CONR.sup.hR.sup.i, --NR.sup.hCOR.sup.i, --SO.sub.2R.sup.h,
--SO.sub.2NR.sup.hR.sup.i, --NR.sup.hSO.sub.2R.sup.i,
--NR.sup.hR.sup.i, --OR.sup.h, --SiR.sup.hR.sup.iR.sup.j,
--OSiR.sup.hR.sup.iR.sup.j, -Q.sup.1COR.sup.h,
-Q.sup.1CO.sub.2R.sup.h, -Q.sup.1CONR.sup.hR.sup.i,
-Q.sup.1NR.sup.hCOR.sup.i, -Q.sup.1SO.sub.2R.sup.h,
-Q.sup.1SO.sub.2NR.sup.hR.sup.i, -Q.sup.1NR.sup.hSO.sub.2R.sup.i,
Q.sup.1NR.sup.hR.sup.i, -Q.sup.1OR.sup.h, wherein Q.sup.1 is a
member selected from the group consisting of C.sub.1-4 alkylene,
C.sub.2-4 alkenylene and C.sub.2-4 alkynylene, and R.sup.h, R.sup.i
and R.sup.j are independently selected from the group consisting of
hydrogen and C.sub.1-8 alkyl, and wherein the aliphatic portions of
each of the R.sup.a, R.sup.b, R.sup.c, R.sup.d, R.sup.e, R.sup.f,
R.sup.g, R.sup.h, R.sup.i and R substituents are optionally
substituted with from one to three members selected from the group
consisting of halogen, --OH, --OR.sup.n, --OC(O)NHR.sup.n,
--OC(O)NR.sup.nR.sup.o, --SH, --SR.sup.n, --S(O)R.sup.n,
--S(O).sub.2R.sup.n, --SO.sub.2NH.sub.2, --S(O).sub.2NHR.sup.n,
--S(O).sub.2NR.sup.nR.sup.o, --NHS(O).sub.2R.sup.n,
--NR.sup.nS(O).sub.2R.sup.o, --C(O)NH.sub.2, --C(O)NHR.sup.n,
--C(O)NR.sup.nR.sup.o, --C(O)R.sup.n, --NHC(O)R.sup.o,
--NR.sup.nC(O)R.sup.o, --NHC(O)NH.sub.2, --NR.sup.nC(O)NH.sub.2,
--NR.sup.nC(O)NHR.sup.o, --NHC(O)NHR.sup.n,
--NR.sup.nC(O)NR.sup.oR.sup.p, --NHC(O)NR.sup.nR.sup.o,
--CO.sub.2H, --CO.sub.2R.sup.n, --NHCO.sub.2R.sup.n,
--NR.sup.nCO.sub.2R.sup.o, --CN, --NO.sub.2, --NH.sub.2,
--NHR.sup.n, --NR.sup.nR.sup.o, --NR.sup.nS(O)NH.sub.2 and
--NR.sup.nS(O).sub.2NHR.sup.o, wherein R.sup.n, R.sup.o and R.sup.p
are independently an unsubstituted C.sub.1-8 alkyl. Additionally,
any two of R.sup.a, R.sup.b, R.sup.c, R.sup.d, R.sup.e, R.sup.f and
R.sup.g may be combined to form a bridged or spirocyclic ring
system.
[0034] In another preferred embodiment, the number of
R.sup.a+R.sup.b+R.sup.c+R.sup.d groups that are other than hydrogen
is 0, 1 or 2. In a more preferred embodiment, R.sup.a, R.sup.b,
R.sup.c, R.sup.d, R.sup.e, R.sup.f, and R.sup.g are independently
selected from the group consisting of hydrogen, halogen,
unsubstituted or substituted C.sub.1-8 alkyl, --COR.sup.h,
--CO.sub.2R.sup.h, --CONR.sup.hR.sup.h, --NR.sup.hCOR.sup.h,
--SO.sub.2R.sup.h, --SO.sub.2NR.sup.hR.sup.i,
--NSO.sub.2R.sup.hR.sup.i, --NR.sup.hR.sup.i, and --OR.sup.h,
wherein R.sup.h and R.sup.i are independently selected from the
group consisting of hydrogen and unsubstituted C.sub.1-8 alkyl and
wherein the aliphatic portions of each of the R.sup.a, R.sup.b,
R.sup.c, R.sup.d, R.sup.e, R.sup.f and R.sup.g substituents are
optionally substituted with from one to three members selected from
the group consisting of halogen, --OH, --OR.sup.n,
--OC(O)NHR.sup.n, --OC(O)NR.sup.nR.sup.o, --SH, --SR.sup.n,
--S(O)R.sup.o, --S(O).sub.2R.sup.n, --SO.sub.2NH.sub.2,
--S(O).sub.2NHR.sup.n, --S(O).sub.2NR.sup.nR.sup.o,
--NHS(O).sub.2R.sup.n, --NR.sup.nS(O).sub.2R.sup.o, --C(O)NH.sub.2,
--C(O)NHR.sup.n, --C(O)NR.sup.nR.sup.o, --C(O)R.sup.n,
--NHC(O)R.sup.n, --NR.sup.nC(O)R.sup.o, --NHC(O)NH.sub.2,
--NR.sup.nC(O)NH.sub.2, --NR.sup.nC(O)NHR.sup.o, --NHC(O)NHR.sup.n,
--NR.sup.nC(O)NR.sup.oR.sup.p, --NHC(O)NR.sup.nR.sup.o,
--CO.sub.2H, --CO.sub.2R.sup.n, --NHCO.sub.2R.sup.n,
--NR.sup.nCO.sub.2R.sup.o, --CN, --NO.sub.2, --NH.sub.2,
--NHR.sup.n, --NR.sup.nR.sup.o, --NR.sup.nS(O)NH.sub.2, and
--NR.sup.nS(O).sub.2NHR.sup.o, wherein R.sup.n, R.sup.o and R.sup.p
are independently an unsubstituted C.sub.1-8 alkyl.
[0035] In a more preferred embodiment, R.sup.a, R.sup.b, R.sup.c,
R.sup.d, R.sup.e, R.sup.f, and R.sup.g are independently hydrogen
or C.sub.1-4 alkyl. In another preferred embodiment, at least three
of R.sup.a, R.sup.b, R.sup.c, R.sup.d, R.sup.e, R.sup.f, and
R.sup.g are hydrogen.
[0036] "Heteroaryl" refers to an aromatic group containing at least
one heteroatom, where the heteroaryl group may be monocyclic or
bicyclic. Examples include pyridyl, pyridazinyl, pyrazinyl,
pyrimidinyl, triazinyl, quinolinyl, quinoxalinyl, quinazolinyl,
cinnolinyl, phthalazinyl, benzotriazinyl, purinyl, benzimidazolyl,
benzopyrazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuryl,
isoindolyl, indolizinyl, benzotriazinyl, thienopyridinyl,
thienopyrimidinyl, pyrazolopyrimidinyl, imidazopyridines,
benzothiazolyl, benzofuranyl, benzothienyl, indolyl, azaindolyl,
azaindazolyl, quinolyl, isoquinolyl, isothiazolyl, pyrazolyl,
indazolyl, pteridinyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl,
isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, thiazolyl, furyl
or thienyl. Preferred heteroaryl groups are those having at least
one aryl ring nitrogen atom, such as quinolinyl, quinoxalinyl,
purinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl,
benzothiazolyl, indolyl, quinolyl, isoquinolyl and the like.
Preferred 6-ring heteroaryl systems include pyridyl, pyridazinyl,
pyrazinyl, pyrimidinyl, triazinyl and the like. Preferred 5-ring
heteroaryl systems include isothiazolyl, pyrazolyl, imidazolyl,
thienyl, furyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl,
oxadiazolyl, thiadiazolyl, pyrrolyl, thiazolyl and the like.
[0037] Heterocyclyl and heteroaryl can be attached at any available
ring carbon or heteroatom. Each heterocyclyl and heteroaryl may
have one or more rings. When multiple rings are present, they can
be fused together or linked covalently. Each heterocyclyl and
heteroaryl must contain at least one heteroatom (typically 1 to 5
heteroatoms) selected from nitrogen, oxygen or sulfur. Preferably,
these groups contain 0-5 nitrogen atoms, 0-2 sulfur atoms and 0-2
oxygen atoms. More preferably, these groups contain 0-3 nitrogen
atoms, 0-1 sulfur atoms and 0-1 oxygen atoms.
[0038] Heterocyclyl and heteroaryl groups can be substituted or
unsubstituted, unless otherwise indicated. For substituted groups,
the substitution may be on a carbon or heteroatom. For example,
when the substitution is oxo (.dbd.O or --O--), the resulting group
may have either a carbonyl (--C(O)--) or a N-oxide
(--N.sup.+--O--).
[0039] Suitable substituents for substituted alkyl, substituted
alkenyl, and substituted alkynyl include halogen, --CN,
--CO.sub.2R', --C(O)R', --C(O)NR'R'', oxo (.dbd.O or --O--), --OR',
--OSiR'R''R''', --OC(O)R', --OC(O)NR'R''--NO.sub.2, --NR'C(O)R'',
--NR'''C(O)NR'R'', --NR'R'', --NR'CO.sub.2R'', --NR'S(O)R'',
--NR'S(O).sub.2R''', --NR'''S(O)NR'R'', --NR'''S(O).sub.2NR'R'',
--SR', --S(O)R', --S(O).sub.2R', --S(O).sub.2NR'R'',
--NR'--C(NHR'').dbd.NR''', --SiR'R''R''', --N.sub.3, substituted or
unsubstituted C.sub.6-10 aryl, substituted or unsubstituted 5- to
10-membered heteroaryl, and substituted or unsubstituted 3- to
10-membered heterocyclyl. The number of possible substituents range
from zero to (2m'+1), where m' is the total number of carbon atoms
in such radical.
[0040] Suitable substituents for substituted aryl, substituted
heteroaryl and substituted heterocyclyl include halogen, --CN,
--CO.sub.2R', --C(O)R', --C(O)NR'R'', oxo (.dbd.O or --O--), --OR',
--OSiR'R''R''', --OC(O)R', --OC(O)NR' R'', --NO.sub.2,
--NR'C(O)R'', --NR'''C(O)NR'R'', --NR'R'', --NR'CO.sub.2R'',
--NR'S(O)R'', --NR'S(O).sub.2R'', --NR'''S(O)NR'R'',
--NR'''S(O).sub.2NR'R'', --SR', --S(O)R', --S(O).sub.2R',
--S(O).sub.2NR'R'', --NR'--C(NHR'').dbd.NR''', --SiR'R''R''',
--N.sub.3, substituted or unsubstituted C.sub.1-8 alkyl,
substituted or unsubstituted C.sub.2-8 alkenyl, substituted or
unsubstituted C.sub.2-8 alkynyl, substituted or unsubstituted
C.sub.6-10 aryl, substituted or unsubstituted 5- to 10-membered
heteroaryl, and substituted or unsubstituted 3- to 10-membered
heterocyclyl. The number of possible substituents range from zero
to the total number of open valences on the aromatic ring
system.
[0041] As used above, R', R'' and R''' each independently refer to
a variety of groups including hydrogen, substituted or
unsubstituted C.sub.1-8 alkyl, substituted or unsubstituted
C.sub.2-8 alkenyl, substituted or unsubstituted C.sub.2-8 alkynyl,
substituted or unsubstituted aryl, substituted or unsubstituted
heteroaryl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted arylalkyl, substituted or unsubstituted
aryloxyalkyl. When R' and R'' are attached to the same nitrogen
atom, they can be combined with the nitrogen atom to form a 3-, 4-,
5-, 6-, or 7-membered ring (for example, --NR'R'' includes
1-pyrrolidinyl and 4-morpholinyl). Furthermore, R' and R'', R'' and
R''', or R' and R''' may together with the atom(s) to which they
are attached, form a substituted or unsubstituted 5-, 6-, or
7-membered ring.
[0042] Two of the substituents on adjacent atoms of an aryl or
heteroaryl ring may optionally be replaced with a substituent of
the formula -T-C(O)--(CH.sub.2).sub.q--U--, wherein T and U are
independently --NR''''--, --O--, --OH.sub.2-- or a single bond, and
q is an integer of from 0 to 2. Alternatively, two of the
substituents on adjacent atoms of the aryl or heteroaryl ring may
optionally be replaced with a substituent of the formula
-A'-(CH.sub.2).sub.r--B'--, wherein A' and B' are independently
--CH.sub.2--, --O--, --NR''''--, --S--, --S(O)--, --S(O).sub.2--,
--S(O).sub.2NR''''-- or a single bond, and r is an integer of from
1 to 3. One of the single bonds of the new ring so formed may
optionally be replaced with a double bond. Alternatively, two of
the substituents on adjacent atoms of the aryl or heteroaryl ring
may optionally be replaced with a substituent of the formula
--(CH.sub.2).sub.s--X--(CH.sub.2).sub.t--, where s and t are
independently integers of from 0 to 3, and XIV is --O--,
--NR''''--, --S--, --S(O)--, --S(O).sub.2--, or --S(O).sub.2NR'--.
R'''' in is selected from hydrogen or unsubstituted C.sub.1-8
alkyl.
[0043] "Heteroatom" is meant to include oxygen (O), nitrogen (N),
sulfur (S) and silicon (Si).
[0044] "Pharmaceutically acceptable" carrier, diluent, or excipient
is a carrier, diluent, or excipient compatible with the other
ingredients of the formulation and not deleterious to the recipient
thereof.
[0045] "Pharmaceutically-acceptable salt" refers to a salt which is
acceptable for administration to a patient, such as a mammal (e.g.,
salts having acceptable mammalian safety for a given dosage
regime). Such salts can be derived from pharmaceutically-acceptable
inorganic or organic bases and from pharmaceutically-acceptable
inorganic or organic acids, depending on the particular
substituents found on the compounds described herein. When
compounds of the present invention contain relatively acidic
functionalities, base addition salts can be obtained by contacting
the neutral form of such compounds with a sufficient amount of the
desired base, either neat or in a suitable inert solvent. Salts
derived from pharmaceutically-acceptable inorganic bases include
aluminum, ammonium, calcium, copper, ferric, ferrous, lithium,
magnesium, manganic, manganous, potassium, sodium, zinc and the
like. Salts derived from pharmaceutically-acceptable organic bases
include salts of primary, secondary, tertiary and quaternary
amines, including substituted amines, cyclic amines,
naturally-occurring amines and the like, such as arginine, betaine,
caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine,
2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine,
ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine,
glucosamine, histidine, hydrabamine, isopropylamine, lysine,
methylglucamine, morpholine, piperazine, piperidine, polyamine
resins, procaine, purines, theobromine, triethylamine,
trimethylamine, tripropylamine, tromethamine and the like. When
compounds of the present invention contain relatively basic
functionalities, acid addition salts can be obtained by contacting
the neutral form of such compounds with a sufficient amount of the
desired acid, either neat or in a suitable inert solvent. Salts
derived from pharmaceutically-acceptable acids include acetic,
ascorbic, benzenesulfonic, benzoic, camphosulfonic, citric,
ethanesulfonic, fumaric, gluconic, glucoronic, glutamic, hippuric,
hydrobromic, hydrochloric, isethionic, lactic, lactobionic, maleic,
malic, mandelic, methanesulfonic, mucic, naphthalenesulfonic,
nicotinic, nitric, pamoic, pantothenic, phosphoric, succinic,
sulfuric, tartaric, p-toluenesulfonic and the like. In some
embodiments, the compounds include a sodium addition salt.
[0046] Also included are salts of amino acids such as arginate and
the like, and salts of organic acids like glucuronic or
galactunoric acids and the like (see, for example, Berge, S. M. et
al, "Pharmaceutical Salts", J. Pharmaceutical Science, 1977,
66:1-19). Certain specific compounds of the present invention
contain both basic and acidic functionalities that allow the
compounds to be converted into either base or acid addition
salts.
[0047] The neutral forms of the compounds may be regenerated by
contacting the salt with a base or acid and isolating the parent
compound in the conventional manner. The parent form of the
compound differs from the various salt forms in certain physical
properties, such as solubility in polar solvents, but otherwise the
salts are equivalent to the parent form of the compound for the
purposes of the present invention.
[0048] "Salt thereof" refers to a compound formed when the hydrogen
of an acid is replaced by a cation, such as a metal cation or an
organic cation and the like.
[0049] Preferably, the salt is a pharmaceutically-acceptable salt,
although this is not required for salts of intermediate compounds
which are not intended for administration to a patient.
[0050] In addition to salt forms, the present invention provides
compounds which are in a prodrug form. Prodrugs are often useful
because, in some situations, they may be easier to administer than
the parent drug. They may, for instance, be bioavailable by oral
administration whereas the parent drug is not. The prodrug may also
have improved solubility in pharmaceutical compositions over the
parent drug. A wide variety of prodrug derivatives are known in the
art, such as those that rely on hydrolytic cleavage or oxidative
activation of the prodrug. An example, without limitation, of a
prodrug would be a compound of the present invention which is
administered as an ester (the "prodrug"), but then is metabolically
hydrolyzed to the carboxylic acid, the active entity. Additional
examples include peptidyl derivatives of a compound of the
invention.
[0051] Prodrugs of the compounds described herein are those
compounds that readily undergo chemical changes under physiological
conditions to provide the compounds of the present invention.
Additionally, prodrugs can be converted to the compounds of the
present invention by chemical or biochemical methods in an ex vivo
environment. For example, prodrugs can be slowly converted to the
compounds of the present invention when placed in a transdermal
patch reservoir with a suitable enzyme or chemical reagent.
[0052] Prodrugs may be prepared by modifying functional groups
present in the compounds in such a way that the modifications are
cleaved, either in routine manipulation or in vivo, to the parent
compounds. Prodrugs include compounds wherein hydroxyl, amino,
sulfhydryl, or carboxyl groups are bonded to any group that, when
administered to a mammalian subject, cleaves to form a free
hydroxyl, amino, sulfhydryl, or carboxyl group respectively.
Examples of prodrugs include, but are not limited to, acetate,
formate and benzoate derivatives of alcohol and amine functional
groups in the compounds of the invention. Preparation, selection,
and use of prodrugs is discussed in T. Higuchi and V. Stella,
"Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S.
Symposium Series; "Design of Prodrugs", ed. H. Bundgaard, Elsevier,
1985; and in Bioreversible Carriers in Drug Design, ed. Edward B.
Roche, American Pharmaceutical Association and Pergamon Press,
1987, each of which are hereby incorporated by reference in their
entirety.
[0053] The compounds of the invention may be present in the form of
pharmaceutically acceptable metabolites thereof. The term
"metabolite" means a pharmaceutically acceptable form of a
metabolic derivative of a compound of the invention (or a salt
thereof). In some aspects, the metabolite may be a functional
derivative of a compound that is readily convertible in vivo into
an active compound. In other aspects, the metabolite may be an
active compound.
[0054] The term "acid isosteres" means, unless otherwise stated, a
group which can replace a carboxylic acid, having an acidic
functionality and steric and electronic characteristics that
provide a level of activity (or other compound characteristic such
as solubility) similar to a carboxylic acid. Representative acid
isosteres include: hydroxamic acids, sulfonic acids, sulfinic
acids, sulfonamides, acyl-sulfonamides, phosphonic acids,
phosphinic acids, phosphoric acids, tetrazole, and
oxo-oxadiazoles.
[0055] "Therapeutically effective amount" refers to an amount
sufficient to effect treatment when administered to a patient in
need of treatment.
[0056] "Treating" or "treatment" as used herein refers to the
treating or treatment of a disease or medical condition (such as a
viral, bacterial or fungal infection or other infectious diseases,
as well as autoimmune or inflammatory conditions) in a patient,
such as a mammal (particularly a human or a companion animal) which
includes ameliorating the disease or medical condition, i.e.,
eliminating or causing regression of the disease or medical
condition in a patient; suppressing the disease or medical
condition, i.e., slowing or arresting the development of the
disease or medical condition in a patient; or alleviating the
symptoms of the disease or medical condition in a patient.
[0057] Certain compounds of the present invention can exist in
unsolvated forms as well as solvated forms, including hydrated
forms. In general, both solvated forms and unsolvated forms are
intended to be encompassed within the scope of the present
invention. Certain compounds of the present invention may exist in
multiple crystalline or amorphous forms (i.e., as polymorphs). In
general, all physical forms are equivalent for the uses
contemplated by the present invention and are intended to be within
the scope of the present invention.
[0058] It will be apparent to one skilled in the art that certain
compounds of the present invention may exist in tautomeric forms;
all such tautomeric forms of the compounds being within the scope
of the invention. For example, some compounds having heteroaryl may
be substituted with one or more hydroxyl groups. Tautomeric forms
would, therefore, include oxo substitutions. Certain compounds of
the present invention possess asymmetric carbon atoms (optical
centers) or double bonds; the racemates, diastereomers, geometric
isomers and individual isomers (e.g., separate enantiomers) are all
intended to be encompassed within the scope of the present
invention. The compounds of the present invention may also contain
unnatural proportions of atomic isotopes at one or more of the
atoms that constitute such compounds. For example, the compounds
may be radiolabeled with radioactive isotopes, such as for example
tritium (.sup.3H), iodine-125 (.sup.125I) or carbon-14 (.sup.14C).
All isotopic variations of the compounds of the present invention,
whether radioactive or not, are intended to be encompassed within
the scope of the present invention.
[0059] The compounds of the present invention may include a
detectable label. A detectable label is a group that is detectable
at low concentrations, usually less than micromolar, probably less
than nanomolar and possibly less than picomolar, and that can be
readily distinguished from other molecules, due to differences in a
molecular property (e.g. molecular weight, mass to charge ratio,
radioactivity, redox potential, luminescence, fluorescence,
electromagnetic properties, binding properties, and the like).
Detectable labels may be detected by spectroscopic, photochemical,
biochemical, immunochemical, electrical, magnetic, electromagnetic,
optical or chemical means and the like.
[0060] A wide variety of detectable labels are within the scope of
the present invention, including hapten labels (e.g. biotin, or
labels used in conjunction with detectable antibodies such as horse
radish peroxidase antibodies); mass tag labels (e.g. stable isotope
labels); radioisotopic labels (including .sup.3H, .sup.125I
.sup.35S, .sup.14C, or .sup.32P); metal chelate labels; luminescent
labels including fluorescent labels (such as fluorescein,
isothiocyanate, Texas red, rhodamine, green fluorescent protein,
and the like), phosphorescent labels, and chemiluminescent labels,
typically having quantum yield greater than 0.1; electroactive and
electron transfer labels; enzyme modulator labels including
coenzymes, organometallic catalysts horse radish peroxidase,
alkaline phosphatase and others commonly used in an ELISA;
photosensitizer labels; magnetic bead labels including Dynabeads;
colorimetric labels such as colloidal gold, silver, selenium, or
other metals and metal sol labels (see U.S. Pat. No. 5,120,643,
which is herein incorporated by reference in its entirety for all
purposes), or colored glass or plastic (e.g., polystyrene,
polypropylene, latex, etc.) bead labels; and carbon black labels.
Patents teaching the use of such detectable labels include U.S.
Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437;
4,275,149; 4,366,241; 6,312,914; 5,990,479; 6,207,392; 6,423,551;
6,251,303; 6,306,610; 6,322,901; 6,319,426; 6,326,144; and
6,444,143, which are herein incorporated by reference in their
entirety for all purposes.
[0061] Detectable labels are commercially available or may be
prepared as known to one skilled in the art. Detectable labels may
be covalently attached to the compounds using a reactive functional
group, which can be located at any appropriate position. Methods
for attaching a detectable label are known to one skilled in the
art. When the reactive group is attached to an alkyl, or
substituted alkyl chain tethered to an aryl nucleus, the reactive
group may be located at a terminal position of an alkyl chain.
Compounds
[0062] The present invention provides compounds that modulate the
activity of CCR(9). Chemokine receptors are integral membrane
proteins which interact with an extracellular ligand, such as a
chemokine, and mediate a cellular response to the ligand, e.g.,
chemotaxis, increased intracellular calcium ion concentration, etc.
Therefore, modulation of a chemokine receptor function, e.g.,
interference with a chemokine receptor ligand interaction, will
modulate a chemokine receptor mediated response, and treat or
prevent a chemokine receptor mediated condition or disease.
Modulation of a chemokine receptor function includes both
inducement and inhibition of the function. The type of modulation
accomplished will depend on the characteristics of the compound,
i.e., antagonist or full, partial or inverse agonist.
[0063] For example, compounds of this invention act as potent
CCR(9) antagonists, and this antagonistic activity has been further
confirmed in animal testing for inflammation, one of the hallmark
disease states for CCR(9). Accordingly, the compounds provided
herein are useful in pharmaceutical compositions, methods for the
treatment of CCR(9)-mediated diseases, and as controls in assays
for the identification of competitive CCR(9) antagonists.
[0064] In the formulae set forth below, when a variable appears
more than once in the same formula, it can be either the same or
different. For example, in formula (I), one R.sup.8 can be
--NH.sub.2 and the remainder can be hydrogen.
[0065] In one embodiment, the compounds of the present invention
are represented by formula (I), or salts thereof:
##STR00005##
where R.sup.1 is selected from the group consisting of substituted
or unsubstituted C.sub.2-8 alkyl, substituted or unsubstituted
C.sub.1-8 alkoxy, substituted or unsubstituted C.sub.1-8
alkylamino, and substituted or unsubstituted C.sub.3-10
heterocyclyl;
[0066] R.sup.2 is H, F, Cl, substituted or unsubstituted C.sub.1-8
alkoxy; or R.sup.1 and R.sup.2 together with the carbon atoms to
which they are attached form a non-aromatic carbocyclic ring or a
heterocyclic ring; R.sup.3 is H, substituted or unsubstituted
C.sub.1-8 alkyl, substituted or unsubstituted C.sub.1-8 alkoxy, or
halo; R.sup.4 is H or F; R.sup.5 is H, F, Cl, or --CH.sub.3;
R.sup.6 is H, halo, --CN, --CO.sub.2R.sup.a, --CONH.sub.2,
--NH.sub.2, substituted or unsubstituted C.sub.1-8 alkyl,
substituted or unsubstituted C.sub.1-8 alkoxy, or substituted or
unsubstituted C.sub.1-8 aminoalkyl; R.sup.a is H or substituted or
unsubstituted C.sub.1-8 alkyl; where R.sup.5 and R.sup.6 may
together form a carbocyclic ring; L is a bond or --CH.sub.2--, or
--CH(CH.sub.3)--; each of A.sup.1, A.sup.2, A.sup.3, A.sup.4,
A.sup.5, A.sup.6, A.sup.7, and A.sup.8 are independently selected
from the group consisting of N, N--O, and --CR.sup.8--; where at
least one and not more than two of A.sup.1, A.sup.2, A.sup.3,
A.sup.4, A.sup.5, A.sup.6, A.sup.7 and A.sup.8 are N or N--O;
R.sup.8 is each independently selected from the group consisting of
H, halo, --CN, --OH, oxo, substituted or unsubstituted C.sub.1-8
alkyl, substituted or unsubstituted C.sub.1-8 alkoxy, and
--NR.sup.20R.sup.21, substituted or unsubstituted aryl, substituted
or unsubstituted heteroaryl, and substituted or unsubstituted
heterocyclyl; and R.sup.20 and R.sup.21 are each independently H,
or substituted or unsubstituted C.sub.1-8 alkyl.
[0067] In one embodiment of formula (I), R.sup.1 is substituted or
unsubstituted C.sub.2-8 alkyl; preferably R.sup.1 is t-butyl;
R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are H; R.sup.6 is substituted
or unsubstituted C.sub.1-8 alkyl, substituted or unsubstituted
C.sub.1-8 alkoxy, --CN, --CONH.sub.2, --NH.sub.2, or C.sub.1-8
aminoalkyl; preferably R.sup.6 is unsubstituted C.sub.1-8 alkyl, or
C.sub.1-8 haloalkyl; more preferably R.sup.6 is --CH.sub.3,
--CH.sub.2F, --CHF.sub.2, or --CF.sub.3; L is a bond; and A.sup.1,
A.sup.2, A.sup.3, A.sup.4, A.sup.5, A.sup.6, A.sup.7, A.sup.8, and
R.sup.8 are as defined formula (I).
[0068] In another embodiment of formula (I), R.sup.1 is substituted
or unsubstituted C.sub.2-8 alkyl; preferably R.sup.1 is t-butyl;
R.sup.2 is F; R.sup.3, R.sup.4 and R.sup.5 are H; R.sup.6 is
substituted or unsubstituted C.sub.1-8 alkyl, substituted or
unsubstituted C.sub.1-8 alkoxy, --CN, --CONH.sub.2, --NH.sub.2, or
substituted or unsubstituted C.sub.1-8 aminoalkyl; preferably
R.sup.6 is unsubstituted C.sub.1-8 alkyl, or C.sub.1-8 haloalkyl;
more preferably R.sup.6 is --CH.sub.3, --CH.sub.2F, --CHF.sub.2, or
--CF.sub.3; L is a bond; and A.sup.1, A.sup.2, A.sup.3, A.sup.4,
A.sup.5, A.sup.6, A.sup.7, A.sup.8, and R.sup.8 are as defined
formula (I).
[0069] In one embodiment, the compounds of formula (I) of the
present invention are represented by formula (II), or salts
thereof:
##STR00006##
where R.sup.1 is selected from the group consisting of substituted
or unsubstituted C.sub.2-8 alkyl, substituted or unsubstituted
C.sub.1-8 alkoxy, substituted or unsubstituted C.sub.1-8
alkylamino, and substituted or unsubstituted C.sub.3-10
heterocyclyl; R.sup.2 is H, F, Cl, or substituted or unsubstituted
C.sub.1-8 alkoxy; or R.sup.1 and R.sup.2 together with the carbon
atoms to which they are attached form a non-aromatic carbocyclic
ring or a heterocyclic ring; R.sup.3 is H, substituted or
unsubstituted C.sub.1-8 alkyl, substituted or unsubstituted
C.sub.1-8 alkoxy, or halo; R.sup.4 is H or F; R.sup.5 is H, F, Cl,
or --CH.sub.3; R.sup.6 is H, halo, --CN, --CO.sub.2R.sup.a,
--CONH.sub.2, --NH.sub.2, substituted or unsubstituted C.sub.1-8
aminoalkyl, substituted or unsubstituted C-s alkyl, or substituted
or unsubstituted C.sub.1-8 alkoxy; R.sup.a is H or substituted or
unsubstituted C.sub.1-8 alkyl; where R.sup.5 and R.sup.6 may
together form a carbocyclic ring; L is a bond, --CH.sub.2--, or
--CH(CH.sub.3)--; Z is selected from the group consisting of
##STR00007##
and N-oxides thereof; where the Z group may be unsubstituted or
substituted with 1 to 3 independently selected R.sup.8
substituents; each R.sup.8 is independently selected from the group
consisting of H, halo, --CN, --OH, oxo, substituted or
unsubstituted C.sub.1-8 alkyl, substituted or unsubstituted
C.sub.1-8 alkoxy, --NR.sup.20R.sup.21, substituted or unsubstituted
aryl, substituted or unsubstituted heteroaryl, and substituted or
unsubstituted heterocyclyl; and R.sup.20 and R.sup.21 are each
independently H, or substituted or unsubstituted C.sub.1-8
alkyl.
[0070] In one embodiment of formula II, Z is selected from the
group consisting of: substituted or unsubstituted quinolinyl,
substituted or unsubstituted isoquinolinyl, substituted or
unsubstituted 1,6-naphthyridinyl, substituted or unsubstituted
cinnolinyl, substituted or unsubstituted phthalazinyl, substituted
or unsubstituted quinazolinyl.
[0071] In one embodiment of formula (II), R.sup.1 is substituted or
unsubstituted C.sub.2-8 alkyl; preferably R.sup.1 is t-butyl;
R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are H; and R.sup.6 is
substituted or unsubstituted C.sub.1-8 alkyl, substituted or
unsubstituted C.sub.1-8 alkoxy, --CN, --CONH.sub.2, --NH.sub.2, or
substituted or unsubstituted C.sub.1-8 aminoalkyl; preferably
R.sup.6 is unsubstituted C.sub.1-8 alkyl, or C.sub.1-8 haloalkyl;
more preferably R.sup.6 is --CH.sub.3, --CH.sub.2F, --CHF.sub.2, or
--CF.sub.3.
[0072] In another embodiment of formula (II), R.sup.1 is
substituted or unsubstituted C.sub.2-8 alkyl; preferably R.sup.1 is
t-butyl; R.sup.2 is F; R.sup.3, R.sup.4 and R.sup.5 are H; and
R.sup.6 is substituted or unsubstituted C.sub.1-8 alkyl,
substituted or unsubstituted C.sub.1-8 alkoxy, --CN, --CONH.sub.2,
--NH.sub.2, or substituted or unsubstituted C.sub.1-8 aminoalkyl;
preferably R.sup.6 is unsubstituted C.sub.1-8 alkyl, or C.sub.1-8
haloalkyl; more preferably R.sup.6 is --CH.sub.3, --CH.sub.2F,
--CHF.sub.2, or --CF.sub.3.
[0073] In one embodiment, the compounds of formula (I) of the
present invention are represented by formula (IIIa) or (IIIb), or
salts thereof:
##STR00008##
where R.sup.1 is selected from the group consisting of substituted
or unsubstituted C.sub.2-8 alkyl, substituted or unsubstituted
C.sub.1-8 alkoxy, substituted or unsubstituted C.sub.1-8
alkylamino, and substituted or unsubstituted C.sub.3-10
heterocyclyl; preferably substituted or unsubstituted C.sub.2-8
alkyl; more preferably t-butyl; R.sup.2 is H, F, Cl, or substituted
or unsubstituted C.sub.1-8 alkoxy; preferably H or F; more
preferably H; or R.sup.1 and R.sup.2 together with the carbon atoms
to which they are attached form a non-aromatic carbocyclic ring or
a heterocyclic ring; R.sup.3 is H, substituted or unsubstituted
C.sub.1-8 alkyl, substituted or unsubstituted C.sub.1-8 alkoxy, or
halo; preferably H or halo; more preferably H; R.sup.4 is H or F;
preferably H; R.sup.5 is H, F, Cl, or --CH.sub.3; preferably H;
R.sup.6 is H, halo, --CN, --CO.sub.2R.sup.a, --CONH.sub.2,
--NH.sub.2, substituted or unsubstituted C.sub.1-8 aminoalkyl,
substituted or unsubstituted C.sub.1-8 alkyl, or substituted or
unsubstituted C.sub.1-8 alkoxy; preferably unsubstituted C.sub.1-8
alkyl, or C.sub.1-8 haloalkyl; more preferably --CH.sub.3,
--CH.sub.2F, --CHF.sub.2, or --CF.sub.3; R.sup.a is H or
substituted or unsubstituted C.sub.1-8 alkyl; or where R.sup.5 and
R.sup.6 together with the carbon atoms to which they are attached
form a carbocyclic ring; each R.sup.8 is independently selected
from the group consisting of H, halo, --CN, --OH, oxo, substituted
or unsubstituted C.sub.1-8 alkyl, substituted or unsubstituted
C.sub.1-8 alkoxy, and --NR.sup.20R.sup.21, substituted or
unsubstituted aryl, substituted or unsubstituted heteroaryl, and
substituted or unsubstituted heterocyclyl; R.sup.20 and R.sup.21
are each independently H, or substituted or unsubstituted C.sub.1-8
alkyl; and n is 0, 1, 2, or 3.
[0074] In one embodiment of formula (IIIa) or (IIIb), R.sup.1 is
substituted or unsubstituted C.sub.2-8 alkyl; preferably R.sup.1 is
t-butyl; R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are H; R.sup.6 is
substituted or unsubstituted C.sub.1-8 alkyl, substituted or
unsubstituted C.sub.1-8 alkoxy, --CN, --CONH.sub.2, --NH.sub.2, or
substituted or unsubstituted C.sub.1-8 aminoalkyl; preferably
R.sup.6 is unsubstituted C.sub.1-8 alkyl, or C.sub.1-8 haloalkyl;
more preferably R.sup.6 is --CH.sub.3, --CH.sub.2F, --CHF.sub.2, or
--CF.sub.3; L is a bond; and A.sup.1, A.sup.2, A.sup.3, A.sup.4,
A.sup.5, A.sup.6, A.sup.7, A.sup.8, and R.sup.8 are as defined
formula (I).
[0075] In one embodiment of formula (IIIa) or (IIIb), R.sup.1 is
substituted or unsubstituted C.sub.2-8 alkyl; preferably R.sup.1 is
t-butyl; R.sup.2 is F; R.sup.3, R.sup.4 and R.sup.5 are H; R.sup.6
is substituted or unsubstituted C.sub.1-8 alkyl, substituted or
unsubstituted C.sub.1-8 alkoxy, --CN, --CONH.sub.2, --NH.sub.2, or
substituted or unsubstituted C.sub.1-8 aminoalkyl; preferably
R.sup.6 is unsubstituted C.sub.1-8 alkyl, or C.sub.1-8 haloalkyl;
more preferably R.sup.6 is --CH.sub.3, --CH.sub.2F, --CHF.sub.2, or
--CF.sub.3; L is a bond; and A.sup.1, A.sup.2, A.sup.3, A.sup.4,
A.sup.5, A.sup.6, A.sup.7, A.sup.8, and R.sup.8 are as defined
formula (I).
[0076] In one embodiment of formula (IIIa) or (IIIb), R.sup.1 is
selected from the group consisting of --CH.sub.2CH.sub.3,
--CH(CH.sub.3).sub.2, --C(CH.sub.3).sub.3,
--C(CH.sub.3).sub.2CH.sub.2CH.sub.3, C(CH.sub.2CH.sub.2)CN,
--C(OH)(CH.sub.3).sub.2, --OCH.sub.3, --OCH.sub.2CH.sub.3,
--OCH(CH.sub.3).sub.2, --OC(CH.sub.3).sub.3,
--OCH.sub.2CH(CH.sub.3).sub.2, --OCF.sub.3, and morpholino;
preferably R.sup.1 is --C(CH.sub.3).sub.3; R.sup.2 is H, F, or Cl;
preferably R.sup.2 is H or F; R.sup.1 and R.sup.2 may together form
--OC(CH.sub.3).sub.2CH.sub.2-- or
--C(CH.sub.3).sub.2CH.sub.2CH.sub.2--; R.sup.3 is H, --CH.sub.3, or
--OCH.sub.3; preferably R.sup.3 is H; R.sup.4 is H or F; preferably
R.sup.4 is H; R.sup.5 is H; R.sup.6 is H, --CH.sub.3,
--CH.sub.2CH.sub.3, --CH(CH.sub.3).sub.2, C.sub.3H.sub.7,
--CH.sub.2F, --CHF.sub.2, --CF.sub.2CH.sub.3, --OF.sub.3,
--CH.sub.2OCH.sub.3, --CH.sub.2OH, --CH.sub.2CN, --CN, or
--CONH.sub.2; preferably R.sup.6 is --CH.sub.3, --CH.sub.2F,
--CHF.sub.2, or --CF.sub.3; and R.sup.8 is each independently
selected from the group consisting of H, F, Cl, Br, --CH.sub.3,
--OH, --OCH.sub.3, --OCH.sub.2CH.sub.3, --NH.sub.2,
--N(CH.sub.3).sub.2, and --CN; preferably R.sup.8 is H or
--NH.sub.2.
[0077] In some embodiments, R.sup.2 is H. In some embodiments,
R.sup.2 is F.
[0078] In one embodiment, the compounds of formula (IIIa) or
(IIIb), or salts thereof are selected from the group consisting
of:
##STR00009## ##STR00010## ##STR00011## ##STR00012##
Preferred R.sup.1 Substituents
[0079] In formulae (I, II, IIIa, and IIIb), R.sup.1 is selected
from the group consisting of substituted or unsubstituted C.sub.2-8
alkyl, substituted or unsubstituted C.sub.1-8 alkoxy, substituted
or unsubstituted C.sub.1-8 alkylamino, and substituted or
unsubstituted C.sub.3-10 heterocyclyl. When R.sup.1 is substituted
alkyl, the alkyl group is preferably substituted with halo or
hydroxy. When R.sup.1 is substituted alkoxy, the alkoxy group is
preferably substituted with halo. Preferably R.sup.1 is
unsubstituted C.sub.2-8 alkyl, including C.sub.3-8 cycloalkyl,
C.sub.2-8 haloalkyl, C.sub.1-8 hydroxyalkyl, unsubstituted
C.sub.1-8 alkoxy, C.sub.1-8 haloalkoxy, and C.sub.1-8 alkylamino;
more preferably unsubstituted C.sub.2-8 alkyl, C.sub.2-8 haloalkyl,
unsubstituted C.sub.1-8 alkoxy, and C.sub.1-8 alkylamino; even more
preferably unsubstituted C.sub.2-8 alkyl, unsubstituted C.sub.1-8
alkoxy, and morpholino; still more preferably unsubstituted
C.sub.2-8; and most preferably t-butyl.
Preferred R.sup.6 Substituents
[0080] In formulae (I, II, IIIa, and IIIb), R.sup.6 is H, halo,
--CN, --CO.sub.2R.sup.a, --CONH.sub.2, --NH.sub.2, substituted or
unsubstituted C.sub.1-8 alkyl, substituted or unsubstituted
C.sub.1-8 alkoxy, or substituted or unsubstituted C.sub.1-8
aminoalkyl. When R.sup.6 is substituted alkyl, the alkyl group is
preferably substituted with halo, hydroxy, alkoxy, or cyano.
Preferably R.sup.6 is --CN, --CONH.sub.2, --NH.sub.2, unsubstituted
C.sub.1-8 alkyl, unsubstituted C.sub.1-8 haloalkyl, and
unsubstituted C.sub.1-8 alkoxy; more preferably unsubstituted
C.sub.1-8 alkyl, or unsubstituted C.sub.1-8 haloalkyl, even more
preferably unsubstituted C.sub.1-8 alkyl; most preferably
methyl.
Compositions that Modulate Chemokine Activity
[0081] In another aspect, the present invention provides
compositions that modulate chemokine activity, specifically CCR(9)
activity. Generally, the compositions for modulating chemokine
receptor activity in humans and animals will comprise a
pharmaceutically acceptable excipient or diluent and a compound
having any of the formulae I-Ill.
[0082] The term "composition" as used herein is intended to
encompass a product comprising the specified ingredients in the
specified amounts, as well as any product which results, directly
or indirectly, from combination of the specified ingredients in the
specified amounts. By "pharmaceutically acceptable" it is meant the
carrier, diluent or excipient must be compatible with the other
ingredients of the formulation and not deleterious to the recipient
thereof.
[0083] The pharmaceutical compositions for the administration of
the compounds of this invention may conveniently be presented in
unit dosage form and may be prepared by any of the methods well
known in the art of pharmacy. All methods include the step of
bringing the active ingredient into association with the carrier
which constitutes one or more accessory ingredients. In general,
the pharmaceutical compositions are prepared by uniformly and
intimately bringing the active ingredient into association with a
liquid carrier or a finely divided solid carrier or both, and then,
if necessary, shaping the product into the desired formulation. In
the pharmaceutical composition the active object compound is
included in an amount sufficient to produce the desired effect upon
the process or condition of diseases.
[0084] The pharmaceutical compositions containing the active
ingredient may be in a form suitable for oral use, for example, as
tablets, troches, lozenges, aqueous or oily suspensions,
dispersible powders or granules, emulsions and self-emulsifications
as described in U.S. Pat. No. 6,451,339, hard or soft capsules, or
syrups or elixirs. Compositions intended for oral use may be
prepared according to any method known to the art for the
manufacture of pharmaceutical compositions. Such compositions may
contain one or more agents selected from sweetening agents,
flavoring agents, coloring agents and preserving agents in order to
provide pharmaceutically elegant and palatable preparations.
Tablets contain the active ingredient in admixture with other
non-toxic pharmaceutically acceptable excipients which are suitable
for the manufacture of tablets. These excipients may be, for
example, inert diluents such as cellulose, silicon dioxide,
aluminum oxide, calcium carbonate, sodium carbonate, glucose,
mannitol, sorbitol, lactose, calcium phosphate or sodium phosphate;
granulating and disintegrating agents, for example, corn starch, or
alginic acid; binding agents, for example PVP, cellulose, PEG,
starch, gelatin or acacia, and lubricating agents, for example
magnesium stearate, stearic acid or talc. The tablets may be
uncoated or they may be coated enterically or otherwise by known
techniques to delay disintegration and absorption in the
gastrointestinal tract and thereby provide a sustained action over
a longer period. For example, a time delay material such as
glyceryl monostearate or glyceryl distearate may be employed. They
may also be coated by the techniques described in the U.S. Pat.
Nos. 4,256,108; 4,166,452; and U.S. Pat. No. 4,265,874 to form
osmotic therapeutic tablets for control release.
[0085] Formulations for oral use may also be presented as hard
gelatin capsules wherein the active ingredient is mixed with an
inert solid diluent, for example, calcium carbonate, calcium
phosphate or kaolin, or as soft gelatin capsules wherein the active
ingredient is mixed with water or an oil medium, for example peanut
oil, liquid paraffin, or olive oil. Additionally, emulsions can be
prepared with a non-water miscible ingredient such as oils and
stabilized with surfactants such as mono-diglycerides, PEG esters
and the like.
[0086] Aqueous suspensions contain the active materials in
admixture with excipients suitable for the manufacture of aqueous
suspensions. Such excipients are suspending agents, for example
sodium carboxymethylcellulose, methylcellulose,
hydroxypropylmethylcellulose, sodium alginate,
polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or
wetting agents may be a naturally-occurring phosphatide, for
example lecithin, or condensation products of an alkylene oxide
with fatty acids, for example polyoxyethylene stearate, or
condensation products of ethylene oxide with long chain aliphatic
alcohols, for example heptadecaethyleneoxycetanol, or condensation
products of ethylene oxide with partial esters derived from fatty
acids and a hexitol such as polyoxyethylene sorbitol monooleate, or
condensation products of ethylene oxide with partial esters derived
from fatty acids and hexitol anhydrides, for example polyethylene
sorbitan monooleate. The aqueous suspensions may also contain one
or more preservatives, for example ethyl, or n-propyl,
p-hydroxybenzoate, one or more coloring agents, one or more
flavoring agents, and one or more sweetening agents, such as
sucrose or saccharin.
[0087] Oily suspensions may be formulated by suspending the active
ingredient in a vegetable oil, for example arachis oil, olive oil,
sesame oil or coconut oil, or in a mineral oil such as liquid
paraffin. The oily suspensions may contain a thickening agent, for
example beeswax, hard paraffin or cetyl alcohol. Sweetening agents
such as those set forth above, and flavoring agents may be added to
provide a palatable oral preparation. These compositions may be
preserved by the addition of an anti-oxidant such as ascorbic
acid.
[0088] Dispersible powders and granules suitable for preparation of
an aqueous suspension by the addition of water provide the active
ingredient in admixture with a dispersing or wetting agent,
suspending agent and one or more preservatives. Suitable dispersing
or wetting agents and suspending agents are exemplified by those
already mentioned above. Additional excipients, for example
sweetening, flavoring and coloring agents, may also be present.
[0089] The pharmaceutical compositions of the invention may also be
in the form of oil in water emulsions. The oily phase may be a
vegetable oil, for example olive oil or arachis oil, or a mineral
oil, for example liquid paraffin or mixtures of these. Suitable
emulsifying agents may be naturally-occurring gums, for example gum
acacia or gum tragacanth, naturally-occurring phosphatides, for
example soy bean, lecithin, and esters or partial esters derived
from fatty acids and hexitol anhydrides, for example sorbitan
monooleate, and condensation products of the said partial esters
with ethylene oxide, for example polyoxyethylene sorbitan
monooleate. The emulsions may also contain sweetening and flavoring
agents.
[0090] Syrups and elixirs may be formulated with sweetening agents,
for example glycerol, propylene glycol, sorbitol or sucrose. Such
formulations may also contain a demulcent, a preservative, and
flavoring and coloring agents. Oral solutions can be prepared in
combination with, for example, cyclodextrin, PEG and
surfactants.
[0091] The pharmaceutical compositions may be in the form of a
sterile injectable aqueous or oleaginous suspension. This
suspension may be formulated according to the known art using those
suitable dispersing or wetting agents and suspending agents which
have been mentioned above. The sterile injectable preparation may
also be a sterile injectable solution or suspension in a non-toxic
parenterally acceptable diluent or solvent, for example as a
solution in 1,3-butane diol. Among the acceptable vehicles and
solvents that may be employed are water, Ringer's solution and
isotonic sodium chloride solution. In addition, sterile, axed oils
are conventionally employed as a solvent or suspending medium. For
this purpose any bland fixed oil may be employed including
synthetic mono- or diglycerides. In addition, fatty acids such as
oleic acid find use in the preparation of injectables.
[0092] The compounds of the present invention may also be
administered in the form of suppositories for rectal administration
of the drug. These compositions can be prepared by mixing the drug
with a suitable non-irritating excipient which is solid at ordinary
temperatures but liquid at the rectal temperature and will
therefore melt in the rectum to release the drug. Such materials
are cocoa butter and polyethylene glycols. Additionally, the
compounds can be administered via ocular delivery by means of
solutions or ointments. Still further, transdermal delivery of the
subject compounds can be accomplished by means of iontophoretic
patches and the like.
[0093] For topical use, creams, ointments, jellies, solutions or
suspensions containing the compounds of the present invention are
employed. As used herein, topical application is also meant to
include the use of mouth washes and gargles.
[0094] The pharmaceutical compositions and methods of the present
invention may further comprise other therapeutically active
compounds as noted herein, such as those applied in the treatment
of the above mentioned pathological conditions.
[0095] In one embodiment, the present invention provides a
composition consisting of a pharmaceutically acceptable carrier and
a compound of the invention.
Methods of Treatment
[0096] Depending on the disease to be treated and the subject's
condition, the compounds and compositions of the present invention
may be administered by oral, parenteral (e.g., intramuscular,
intraperitoneal, intravenous, ICV, intracisternal injection or
infusion, subcutaneous injection, or implant), inhalation, nasal,
vaginal, rectal, sublingual, or topical routes of administration
and may be formulated, alone or together, in suitable dosage unit
formulations containing conventional non-toxic pharmaceutically
acceptable carriers, adjuvants and vehicles appropriate for each
route of administration. The present invention also contemplates
administration of the compounds and compositions of the present
invention in a depot formulation.
[0097] In the treatment or prevention of conditions which require
chemokine receptor modulation an appropriate dosage level will
generally be about 0.001 to 100 mg per kg patient body weight per
day which can be administered in single or multiple doses.
Preferably, the dosage level will be about 0.01 to about 25 mg/kg
per day; more preferably about 0.05 to about 10 mg/kg per day. A
suitable dosage level may be about 0.01 to 25 mg/kg per day, about
0.05 to 10 mg/kg per day, or about 0.1 to 5 mg/kg per day. Within
this range the dosage may be 0.005 to 0.05, 0.05 to 0.5, 0.5 to
5.0, or 5.0 to 50 mg/kg per day. For oral administration, the
compositions are preferably provided in the form of tablets
containing 1.0 to 1000 milligrams of the active ingredient,
particularly 1.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0,
150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0,
900.0, and 1000.0 milligrams of the active ingredient for the
symptomatic adjustment of the dosage to the patient to be treated.
The compounds may be administered on a regimen of 1 to 4 times per
day, preferably once or twice per day.
[0098] It will be understood, however, that the specific dose level
and frequency of dosage for any particular patient may be varied
and will depend upon a variety of factors including the activity of
the specific compound employed, the metabolic stability and length
of action of that compound, the age, body weight, hereditary
characteristics, general health, sex, diet, mode and time of
administration, rate of excretion, drug combination, the severity
of the particular condition, and the host undergoing therapy.
[0099] In some embodiments, compounds of the present invention are
administered as part of a combination therapy. For instance an
amount of a chemotherapeutic agent or radiation is administered to
the subject prior to, subsequent to or in combination with the
compounds of the present invention. In some embodiments, the amount
is sub-therapeutic when the chemotherapeutic agent or radiation is
administered alone. Those of skill in the art will appreciate that
"combinations" can involve combinations in treatments (i.e., two or
more drugs can be administered as a mixture, or at least
concurrently or at least introduced into a subject at different
times but such that both are in the bloodstream of a subject at the
same time). Additionally, compositions of the current invention may
be administered prior to or subsequent to a second therapeutic
regimen, for instance prior to or subsequent to a dose of
chemotherapy or irradiation.
[0100] In still other embodiments, the present methods are directed
to the treatment of allergic diseases, wherein a compound or
composition of the invention is administered either alone or in
combination with a second therapeutic agent, wherein said second
therapeutic agent is an antihistamine or an anti-inflammatory. When
used in combination, the practitioner can administer a combination
of the compound or composition of the present invention and a
second therapeutic agent. Also, the compound or composition and the
second therapeutic agent can be administered sequentially, in any
order.
[0101] The compounds and compositions of the present invention can
be combined with other compounds and compositions having related
utilities to prevent and treat the condition or disease of
interest, such as inflammatory conditions and diseases, including
inflammatory bowel disease (including Crohn's disease and
ulcerative colitis), allergic diseases, psoriasis, atopic
dermatitis and asthma, and those pathologies noted above. Selection
of the appropriate agents for use in combination therapies can be
made one of ordinary skill in the art. The combination of
therapeutic agents may act synergistically to effect the treatment
or prevention of the various disorders. Using this approach, one
may be able to achieve therapeutic efficacy with lower dosages of
each agent, thus reducing the potential for adverse side
effects.
[0102] In treating, preventing, ameliorating, controlling or
reducing the risk of inflammation, the compounds of the present
invention may be used in conjunction with an antiinflammatory or
analgesic agent such as an opiate agonist, a lipoxygenase
inhibitor, such as an inhibitor of 5-lipoxygenase, a cyclooxygenase
inhibitor, such as a cyclooxygenase-2 inhibitor, an interleukin
inhibitor, such as an interleukin-1 inhibitor, an NMDA antagonist,
an inhibitor of nitric oxide or an inhibitor of the synthesis of
nitric oxide, aminosalicylates, corticosteroids and other
immunosuppressive drugs, a non-steroidal antiinflammatory agent, or
a cytokine-suppressing antiinflammatory agent, for example with a
compound such as acetaminophen, aspirin, codeine, biological TNF
sequestrants, biological agents which target .alpha.4.beta.7, ACE2
inhibitors, protein linase C inhibitors, fentanyl, ibuprofen,
indomethacin, ketorolac, morphine, naproxen, phenacetin, piroxicam,
a steroidal analgesic, sufentanyl, sunlindac, tenidap, and the
like.
[0103] Similarly, the compounds of the present invention may be
administered with a pain reliever; a potentiator such as caffeine,
an H2-antagonist, simethicone, aluminum or magnesium hydroxide; a
decongestant such as pseudophedrine; an antitussive such as
codeine; a diuretic; a sedating or non-sedating antihistamine; a
very late antigen (VLA-4) antagonist; an immunosuppressant such as
cyclosporin, tacrolimus, rapamycin, EDG receptor agonists, or other
FK-506 type immunosuppressants; a steroid; a non-steroidal
anti-asthmatic agent such as a 32-agonist, leukotriene antagonist,
or leukotriene biosynthesis inhibitor; an inhibitor of
phosphodiesterase type IV (PDE-IV); a cholesterol lowering agent
such as a HMG-CoA reductase inhibitor, sequestrant, or cholesterol
absorption inhibitor; and an anti-diabetic agent such as insulin,
.alpha.-glucosidase inhibitors or glitazones.
[0104] The weight ratio of the compound of the present invention to
the second active ingredient may be varied and will depend upon the
effective dose of each ingredient. Generally, an effective dose of
each will be used. Thus, for example, when a compound of the
present invention is combined with an NSAID the weight ratio of the
compound of the present invention to the NSAID will generally range
from about 1000:1 to about 1:1000, preferably about 200:1 to about
1:200. Combinations of a compound of the present invention and
other active ingredients will generally also be within the
aforementioned range, but in each case, an effective dose of each
active ingredient should be used.
Methods of Treating or Preventing CCR(9)-mediated Conditions or
Diseases
[0105] In yet another aspect, the present invention provides
methods of treating or preventing a CCR(9)-mediated condition or
disease by administering to a subject having such a condition or
disease a therapeutically effective amount of any compound of
formulae above. Compounds for use in the present methods include
those compounds according to the above formulae, those provided
above as embodiments, those specifically exemplified in the
Examples below, and those provided with specific structures herein.
The "subject" is defined herein to include animals such as mammals,
including, but not limited to, primates (e.g., humans), cows,
sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like.
In preferred embodiments, the subject is a human.
[0106] As used herein, the phrase "CCR(9)-mediated condition or
disease" and related phrases and terms refer to a condition or
disease characterized by inappropriate, i.e., less than or greater
than normal, CCR(9) functional activity. Inappropriate CCR(9)
functional activity might arise as the result of CCR(9) expression
in cells which normally do not express CCR(9), increased CCR(9)
expression (leading to, e.g., inflammatory and immunoregulatory
disorders and diseases) or decreased CCR(9) expression.
Inappropriate CCR(9) functional activity might also arise as the
result of TECK secretion by cells which normally do not secrete
TECK, increased TECK expression (leading to, e.g., inflammatory and
immunoregulatory disorders and diseases) or decreased TECK
expression. A CCR(9)-mediated condition or disease may be
completely or partially mediated by inappropriate CCR(9) functional
activity. However, a CCR(9)-mediated condition or disease is one in
which modulation of CCR(9) results in some effect on the underlying
condition or disease (e.g., a CCR(9) antagonist results in some
improvement in patient well-being in at least some patients).
[0107] The term "therapeutically effective amount" means the amount
of the subject compound that will elicit the biological or medical
response of a cell, tissue, system, or animal, such as a human,
that is being sought by the researcher, veterinarian, medical
doctor or other treatment provider.
[0108] Diseases and conditions associated with inflammation, immune
disorders, infection and cancer can be treated or prevented with
the present compounds, compositions, and methods. In one group of
embodiments, diseases or conditions, including chronic diseases, of
humans or other species can be treated with inhibitors of CCR(9)
function. These diseases or conditions include: (1) allergic
diseases such as systemic anaphylaxis or hypersensitivity
responses, drug allergies, insect sting allergies and food
allergies, (2) inflammatory bowel diseases, such as Crohn's
disease, ulcerative colitis, microscopic colitis, ileitis and
enteritis, and postoperative ileus, (3) vaginitis, (4) psoriasis
and inflammatory dermatoses such as dermatitis, eczema, atopic
dermatitis, allergic contact dermatitis, urticaria and pruritus,
(5) vasculitis, (6) spondyloarthropathies, (7) scleroderma, (8)
asthma and respiratory allergic diseases such as allergic asthma,
allergic rhinitis, hypersensitivity lung diseases and the like, (9)
autoimmune diseases, such as fibromyalagia, ankylosing spondylitis,
juvenile RA, Still's disease, polyarticular juvenile RA,
pauciarticular juvenile RA, polymyalgia rheumatica, rheumatoid
arthritis, psoriatic arthritis, osteoarthritis, polyarticular
arthritis, multiple sclerosis, systemic lupus erythematosus, type I
diabetes, type II diabetes, glomerulonephritis, and the like, (10)
graft rejection (including allograft rejection), (11) graft-v-host
disease (including both acute and chronic), (12) other diseases in
which undesired inflammatory responses are to be inhibited, such as
atherosclerosis, myositis, neurodegenerative diseases (e.g.,
Alzheimer's disease), encephalitis, meningitis, hepatitis,
nephritis, sepsis, sarcoidosis, allergic conjunctivitis, otitis,
chronic obstructive pulmonary disease, sinusitis, Behcet's syndrome
and gout, (13) immune mediated food allergies such as Coeliac
(Celiac) disease (14) pulmonary fibrosis and other fibrotic
diseases, (15) irritable bowel syndrome, (16) primary sclerosing
cholangitis, (17) cancer (including both primary and metastatic),
(18) bacterial associated syndromes such as hemorrhagic colitis and
hemolytic uremic syndrome (19) melanoma, (20) primary sclerosing
cholangitis, (21) post-operative ileus, (22) hepatitis, and (23)
inflammatory hepatic diseases.
[0109] In another group of embodiments, diseases or conditions can
be treated with modulators and agonists of CCR(9) function.
Examples of diseases to be treated by modulating CCR(9) function
include cancers, cardiovascular diseases, diseases in which
angiogenesis or neovascularization play a role (neoplastic
diseases, retinopathy and macular degeneration), infectious
diseases (viral infections, e.g., HIV infection, and bacterial
infections) and immunosuppressive diseases such as organ transplant
conditions and skin transplant conditions. The term "organ
transplant conditions" is means to include bone marrow transplant
conditions and solid organ (e.g., kidney, liver, lung, heart,
pancreas or combination thereof) transplant conditions.
[0110] Preferably, the present methods are directed to the
treatment of diseases or conditions selected from inflammatory
bowel disease including Crohn's disease and Ulcerative Colitis,
allergic diseases, psoriasis, atopic dermatitis and asthma,
autoimmune disease such as rheumatoid arthritis and immune-mediated
food allergies such as Coelaic disease.
[0111] In yet other embodiments, the present methods are directed
to the treatment of psoriasis where a compound or composition of
the invention is used alone or in combination with a second
therapeutic agent such as a corticosteroid, a lubricant, a
keratolytic agent, a vitamin D.sub.3 derivative, PUVA and
anthralin.
[0112] In other embodiments, the present methods are directed to
the treatment of atopic dermatitis using a compound or composition
of the invention either alone or in combination with a second
therapeutic agent such as a lubricant and a corticosteroid.
[0113] In further embodiments, the present methods are directed to
the treatment of asthma using a compound or composition of the
invention either alone or in combination with a second therapeutic
agent such as a .beta.2-agonist and a corticosteroid.
Preparation of Modulators
[0114] The following examples are offered to illustrate, but not to
limit, the claimed invention.
[0115] Additionally, those skilled in the art will recognize that
the molecules claimed in this patent may be synthesized using a
variety of standard organic chemistry transformations.
[0116] Certain general reaction types employed widely to synthesize
target compounds in this invention are summarized in the examples.
Specifically, generic procedures for sulfonamide formation and
aza-aryl N-oxide formation are described within and were employed
routinely.
[0117] While not intended to be exhaustive, representative
synthetic organic transformations which can be used to prepare
compounds of the invention are included below.
[0118] These representative transformations include; standard
functional group manipulations; reductions such as nitro to amino;
oxidations of functional groups including alcohols and aza-aryls;
aryl substitutions via IPSO or other mechanisms for the
introduction of a variety of groups including nitrile, methyl and
halogen; protecting group introductions and removals; Grignard
formation and reaction with an electrophile; metal-mediated cross
couplings including but not limited to Buckwald, Suzuki and
Sonigashira reactions; halogenations and other electrophilic
aromatic substitution reactions; diazonium salt formations and
reactions of these species; etherifications; cyclative
condensations, dehydrations, oxidations and reductions leading to
heteroaryl groups; aryl metallations and transmetallations and
reaction of the ensuing aryl-metal species with an electrophile
such as an acid chloride or Weinreb amide; amidations;
esterifications; nucleophilic substitution reactions; alkylations;
acylations; sulfonamide formation; chlorosulfonylations; ester and
related hydrolyses, and the like.
[0119] Certain molecules claimed in this patent can exist in
different enantiomeric and diastereomeric forms and all such
variants of these compounds are within the scope of the invention.
In particular, when R.sup.8 is OH and ortho to a nitrogen, although
illustrated by formula as --N.dbd.C(OH)-- it is to be understood
that the tautomeric form --NH--C(O)-- is also within the scope of
the formula.
[0120] In the descriptions of the syntheses that follow, some
precursors were obtained from commercial sources. These commercial
sources include Aldrich Chemical Co., Acros Organics, Ryan
Scientific Incorporated, Oakwood Products Incorporated, Lancaster
Chemicals, Sigma Chemical Co., Lancaster Chemical Co., TCI-America,
Alfa Aesar, Davos Chemicals, and GFS Chemicals.
[0121] Compounds of the invention, including those listed in the
table of activities, can be made by the methods and approaches
described in the following experimental section, and by the use of
standard organic chemistry transformations that are well known to
those skilled in the art.
Examples
[0122] Exemplary compounds used in the method of the invention and
in pharmaceutical compositions of the invention include but are not
limited to the compounds listed in the following table.
Pharmaceutically acceptable salts of the compounds listed in this
table are also useful in the method of the invention and in
pharmaceutical compositions of the invention. These compounds are
within the scope of this invention and were tested for CCR(9)
activity as described below.
[0123] Compounds of the invention were assayed for activity in the
chemotaxis assay described herein under the section below titled
"Example of in vitro assay" where the "chemotaxis assay" is
described. All compounds listed in Table 1 has IC.sub.50 of
<1000 nM in the chemotaxis assay.
TABLE-US-00001 TABLE 1 Exemplary compounds with CCR(9) activity in
calcium mobilization assay. Compounds having an IC.sub.50 value of
less than 100 nM are labeled (+++); from 100-1000 nM are labeled
(++); and above 1000 nM are labeled (+). CCR(9) Chemical Structure
Ca.sup.2+ ##STR00013## + ##STR00014## +++ ##STR00015## +++
##STR00016## +++ ##STR00017## +++ ##STR00018## +++ ##STR00019## +++
##STR00020## +++ ##STR00021## ++ ##STR00022## +++ ##STR00023## +++
##STR00024## +++ ##STR00025## +++ ##STR00026## +++ ##STR00027## +++
##STR00028## ++ ##STR00029## +++ ##STR00030## ++ ##STR00031## +++
##STR00032## + ##STR00033## +++ ##STR00034## +++ ##STR00035## +++
##STR00036## +++ ##STR00037## +++ ##STR00038## ++ ##STR00039## +++
##STR00040## +++ ##STR00041## ++ ##STR00042## +++ ##STR00043## ++
##STR00044## +++ ##STR00045## +++ ##STR00046## +++ ##STR00047## +++
##STR00048## ++ ##STR00049## +++ ##STR00050## +++ ##STR00051## +++
##STR00052## +++ ##STR00053## +++ ##STR00054## +++ ##STR00055## +++
##STR00056## ++ ##STR00057## +++ ##STR00058## +++
TABLE-US-00002 TABLE 2 Exemplary compounds with CCR(9) activity in
serum migration assay. Compounds having an IC.sub.50 value of less
than 500 nM are labeled (+++); from 501-2500 nM are labeled (++);
and above 2501 nM are labeled (+). Chemical Structure A2
##STR00059## ++ ##STR00060## + ##STR00061## ++ ##STR00062## ++
##STR00063## +++ ##STR00064## ++ ##STR00065## ++ ##STR00066## ++
##STR00067## ++ ##STR00068## ++ ##STR00069## +++ ##STR00070## +
##STR00071## ++ ##STR00072## ++ ##STR00073## +++ ##STR00074## ++
##STR00075## ++ ##STR00076## +++ ##STR00077## ++ ##STR00078## +++
##STR00079## +++ ##STR00080## +++ ##STR00081## ++ ##STR00082## ++
##STR00083## +++ ##STR00084## ++ ##STR00085## ++ ##STR00086## ++
##STR00087## ++ ##STR00088## ++ ##STR00089## ++ ##STR00090## +
##STR00091## ++ ##STR00092## ++ ##STR00093## ++ ##STR00094## ++
##STR00095## ++ ##STR00096## ++ ##STR00097## ++ ##STR00098## +++
##STR00099## + ##STR00100## ++ ##STR00101## ++ ##STR00102## ++
##STR00103## ++ ##STR00104## +++ ##STR00105## +++ ##STR00106## ++
##STR00107## ++ ##STR00108## ++ ##STR00109## + ##STR00110## +++
##STR00111## ++ ##STR00112## +++ ##STR00113## +++ ##STR00114## ++
##STR00115## ++ ##STR00116## ++ ##STR00117## +++ ##STR00118## +++
##STR00119## +++ ##STR00120## ++
[0124] Reagents and solvents used below can be obtained from
commercial sources such as Aldrich Chemical Co. (Milwaukee, Wis.,
USA). .sup.1H-NMR were recorded on a Varian Mercury 400 MHz NMR
spectrometer. Significant peaks are tabulated in the order:
multiplicity (br, broad; s, singlet; d, doublet; t, triplet; q,
quartet; m, multiplet) and number of protons. Mass spectrometry
results are reported as the ratio of mass over charge, followed by
the relative abundance of each ion (in parenthesis). In tables, a
single m/e value is reported for the M+H (or, as noted, M-H, M+Na,
etc.) ion containing the most common atomic isotopes. Isotope
patterns correspond to the expected formula in all cases.
Electrospray ionization (ESI) mass spectrometry analysis was
conducted on a Hewlett-Packard MSD electrospray mass spectrometer
using the HP1100 HPLC for sample delivery. Normally the analyte was
dissolved in methanol at 0.1 mg/mL and 1 microliter was infused
with the delivery solvent into the mass spectrometer, which scanned
from 100 to 1500 daltons. All compounds could be analyzed in the
positive ESI mode, using acetonitrile/water with 1% formic acid as
the delivery solvent. The compounds provided below could also be
analyzed in the negative ESI mode, using 2 mM NH.sub.4OAc in
acetonitrile/water as delivery system.
[0125] Compounds of the present invention may be synthesized by
General Synthesis A shown below. Treatment of an aryl sulfonyl
chloride of formula A with the pyrazole amine B in the presence of
a base such as pyridine at a suitable temperature, for example
80.degree. C., affords the aryl sulfonamides of formula C. The
pyrazole amines, B, may be synthesized treatment of hydrazine D
with nitrile C at a suitable elevated temperature in a solvent such
as ethanol. One skilled in the art will understand that the
substituents, including, for example, R.sup.1, R.sup.2, R.sup.3,
R.sup.4, and R.sup.6 may need to be protected as known to one
skilled in the art with standard protecting groups during the
synthesis depending upon their reactivity to the reaction
conditions.
General Synthesis A
##STR00121##
[0126] Example 1: Synthesis of
4-t-butyl-N-(3-methyl-1-(quinazolin-4-yl)-1H-pyrazol-5-yl)benzenesulfonam-
ide
##STR00122##
[0128] a) To a stirring solution of 4-hydrazinoquinazoline (0.16 g,
1.0 mmol) and 3-oxo-butyronitrile (0.083 g, 1.0 mmol) in ethanol
(10 mL) was heated at 60.degree. C. for 18 h. After cooling to room
temperature, the reaction mixture was concentrated in vacuo. The
crude residue was purified by flash chromatography (SiO.sub.2, 30%
ethyl acetate in hexanes) to give the desired compound (0.20 g,
0.089 mmol, 89%).
[0129] b) To a mixture of 4-t-butylbenzenesulfonyl chloride (0.084
g, 0.36 mmol) and 3-methyl-1-(quinazolin-4-yl)-1H-pyrazol-5-amine
(0.067 g, 0.30 mmol) in pyridine (0.6 mL) was heated at 80.degree.
C. for 15 h with stirring. After cooling to room temperature,
dichloromethane was added to the reaction mixture and washed with 1
M aqueous sodium hydrogen sulfate (1 mL). The aqueous layer was
further extracted with dichloromethane (2.times.5 mL), and the
combined organic layers were dried (Na.sub.2SO.sub.4), filtered,
and concentrated in vacuo. The crude residue was purified by flash
chromatography (SiO.sub.2, 5-60% ethyl acetate in hexanes) to give
the title compound as a white solid (0.30 g, 0.071 mmol, 24%).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.92 (s, 1H), 9.27 (dd,
J=1.2, 8.8 Hz, 1H), 9.98 (s, 1H), 7.99 (dd, J=0.8, 8.4 Hz, 1H),
7.89 (ddd, J=1.2, 6.8, 8.4 Hz, 1H), 7.66-7.61 (m, 2H), 7.28-7.25
(m, 2H), 6.34 (s, 1H), 2.37 (s, 3H), 1.13 (s, 9H); MS: (ES) m/z
calculated for C.sub.22H.sub.24F.sub.3N.sub.5O.sub.2S [M+H].sup.+
422.2, found 422.3.
Example 2: Synthesis of
4-t-butyl-N-(1-(isoquinolin-4-yl)-3-methyl-1H-pyrazol-5-yl)benzenesulfona-
mide
##STR00123##
[0131] a) To a stirring solution of 4-aminoisoquinoline (1.4 g,
10.0 mmol) in 5 N aqueous hydrochloric acid (12 mL) at 0.degree. C.
was added a solution of sodium nitrite (NaNO.sub.2, 0.069 g, 10.0
mmol) in deionized water (1 mL), while maintaining the internal
temperature below 0.degree. C. The reaction mixture was stirred at
0.degree. C. for 30 min and a solution of tin(II) chloride
dihydrate (SnCl.sub.2.2H.sub.2O, 5.6 g, 25.0 mmol) dissolved in
concentrated hydrochloric acid (5 mL) was added dropwise. The
mixture was stirred at room temperature for 2 h and the solution
was adjusted to pH .about.12-14 with 20% aqueous sodium hydroxide.
The mixture was extracted with 2:1 CHCl.sub.3/iPrOH. The organic
layer was dried (Na.sub.2SO.sub.4), filtered, and concentrated in
vacuo. The resulting crude product was purified by flash
chromatography (SiO.sub.2, 50% ethyl acetate in hexanes) to give
the desired compound (0.84 g, 5.3 mmol, 53%).
[0132] b) To a stirring suspension of 4-hydrazinylisoquinoline
(0.32 g, 2.0 mmol) and 3-oxo-butyronitrile (0.16 g, 0.19 mmol) in
ethanol (10 mL) was heated at 80.degree. C. for 3 h. After cooling
to room temperature, 20% aqueous sodium hydroxide (1 mL) was added
to the reaction mixture and was further heated at 80.degree. C. for
1 h. The reaction mixture was cooled to room temperature and
concentrated in vacuo. The crude residue was dissolved in 1:1
dichloromethane/methanol (40 mL) and the phases were separated. The
organic layer was dried (Na.sub.2SO.sub.4), and filtered through a
pad of Celite. The filtrate was concentrated in vacuo and the crude
residue was purified by flash chromatography (SiO.sub.2, 50-100%
ethyl acetate in hexanes) to give the desired product (0.36 g, 1.6
mmol, 81%).
[0133] c) A mixture of 4-t-butylbenzenesulfonyl chloride (0.10 g,
0.43 mmol) and 1-(isoquinolin-4-yl)-3-methyl-1H-pyrazol-5-amine
(0.080 g, 0.36 mmol) in pyridine (5 mL) was heated at 80.degree. C.
for 15 h with stirring. After cooling to room temperature, the
reaction mixture was concentrated in vacuo. The crude residue was
purified by flash chromatography (SiO.sub.2, 50-100% ethyl acetate
in hexanes) to give the title compound as a white solid (0.18 g,
0.12 mmol, 27%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.89 (s,
1H), 8.02 (s, 1H), 8.87 (dd, J=1.6, 6.8 Hz, 1H), 7.58-7.53 (m, 2H),
7.58 (s, 1H), 7.56 (s, 1H), 7.39-7.35 (m, 3H), 6.25 (s, 1H), 2.34
(s, 3H), 1.32 (s, 9H); MS: (ES) m/z calculated for
C.sub.23H.sub.25N.sub.4O.sub.2S [M+H].sup.+421.2, found 422.2.
Example 3: Synthesis of
4-t-butyl-N-(1-(8-fluoroquinolin-4-yl)-3-methyl-1H-pyrazol-5-yl)benzenesu-
lfonamide
##STR00124##
[0135] a) To a stirring solution of 8-fluoroquinolin-4-amine (1.0
g, 6.2 mmol) in concentrated hydrochloric acid (6.2 mL) and
deionized water (6.0 mL) at 0.degree. C. was added a solution of
NaNO.sub.2 (0.51 g, 7.4 mmol) in deionized water (3 mL). The
reaction mixture was stirred at 0.degree. C. for 30 min and a
solution of SnCl.sub.2.2H.sub.2O (2.8 g, 12.4 mmol) dissolved in
deionized water (3 mL) was then added dropwise. The mixture was
stirred at room temperature for 2 h and the suspension was basified
with aqueous sodium bicarbonate. The mixture was extracted with 2:1
CHCl.sub.3/iPrOH. The organic layer was washed with 1 M aqueous
sodium bisulfate, dried (Na.sub.2SO.sub.4), filtered, and
concentrated in vacuo. The resulting crude product was used
directly without further purification (0.34 g, 1.9 mmol, 31%).
[0136] b) To a solution of crude 4-chloro-8-fluoroquinoline (0.27
g, 1.5 mmol) and NH.sub.2NH.sub.2.H.sub.2O (1.5 mL, 16.6 mmol) in
ethanol (1.6 mL) was heated at 160.degree. C. in microwave for 1 h
with stirring. After cooling the mixture to room temperature,
aqueous saturated sodium bicarbonate was added to the reaction
mixture and the aqueous layer was extracted with 2:1
CHCl.sub.3/iPrOH (2.times.5 mL). The combine organic layers were
washed with water, dried (Na.sub.2SO.sub.4), filtered, and
concentrated in vacuo. The crude residue was used directly without
further purification (0.27 g, 1.5 mmol, 100%).
[0137] c) To a stirring solution of crude
8-fluoro-4-hydrazinylquinoline (0.27 g, 1.5 mmol) and
3-oxo-butyronitrile (0.15 g, 0.19 mmol) in pyridine (3 mL) was
heated at 80.degree. C. for 15 h. After cooling to room
temperature, aqueous saturated sodium bicarbonate was added to the
reaction mixture and extracted with dichloromethane (3.times.10
mL). The combined organic layers were dried (Na.sub.2SO.sub.4),
filtered, and concentrated in vacuo. The crude residue was used
directly without further purification (0.14 g, 0.76 mmol, 50%).
[0138] d) A mixture of 4-t-butylbenzenesulfonyl chloride (0.13 g,
0.55 mmol) and crude
1-(8-fluoroquinolin-4-yl)-3-methyl-1H-pyrazol-5-amine (0.14 g, 0.55
mmol) in pyridine (1 mL) was heated at 80.degree. C. for 15 h with
stirring. After cooling to room temperature, dichloromethane was
added to the reaction mixture and washed with 1 M aqueous sodium
hydrogen sulfate (1 mL). The aqueous layer was further extracted
with dichloromethane (2.times.5 mL), and the combined organic
layers were dried (Na.sub.2SO.sub.4), filtered, and concentrated in
vacuo. The crude residue was purified by reverse phase HPLC (C18
column, acetonitrile-H.sub.2O with 0.1% TFA as eluent) to give the
title compound as a white solid (0.005 g, 0.011 mmol, 2%). .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 8.80 (d, J=4.8 Hz, 1H), 7.61 (d,
J=1.6 Hz, 1H), 7.59 (d, J=2.0 Hz, 1H), 7.47-7.41 (m, 5H), 7.13 (d,
J=4.8 Hz, 1H), 6.20 (s, 1H), 2.35 (s, 3H), 1.35 (s, 9H); MS: (ES)
m/z calculated for C.sub.23H.sub.24FN.sub.4O.sub.2S [M+H].sup.+
439.5, found 439.3.
Example 4: Synthesis of
4-t-butyl-N-(3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)benzenesulfonamid-
e
##STR00125##
[0140] a) A solution of 5-aminoquinoline (0.75 g, 5.2 mmol) in
concentrated hydrochloric acid (3.8 mL) was stirred at 0.degree. C.
for 10 min. A solution of sodium nitrite (0.43 g, 6.2 mmol) in
deionized water (0.5 mL) was added to the cold reaction mixture
over 10 min and stirred at 0.degree. C. for 1 h to form a
heterogeneous mixture. L-ascorbic acid (0.95 g, 5.4 mmol) was then
added to the reaction mixture over 10 min. The reaction mixture was
warmed to room temperature and stirred for 45 min. The reaction
slurry was then heated at 80.degree. C. for 20 min and deionized
water (4 mL) was added. The suspension was re-cooled to 0.degree.
C. and stirred for 2 h. The solid was collected by filtration and
washed with methanol to give the desired product (0.45 g, 2.8 mmol,
54%).
[0141] b) To a stirring suspension of quinolin-5-yl-hydrazine (0.25
g, 1.6 mmol) in 3:1 ethanol/deionized water (2.5 mL) was added
3-oxo-butyronitrile (0.13 g, 1.6 mmol). The reaction mixture was
then heated at 60.degree. C. for 2 h. After cooling to room
temperature, the reaction mixture was concentrated in vacuo and the
resulting crude product was used directly without further
purification (0.21 g, 1.5 mmol, 94%)
[0142] c) A mixture of 4-t-butylbenzenesulfonyl chloride (0.59 g,
2.5 mmol) and crude 3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-amine
(0.47 g, 2.1 mmol) in pyridine (0.6 mL) was heated at 80.degree. C.
for 15 h with stirring. After cooling to room temperature,
dichloromethane was added to the reaction mixture and washed with 1
M aqueous sodium hydrogen sulfate (1 mL). The aqueous layer was
further extracted with dichloromethane (2.times.5 mL), and the
combined organic layers were dried (Na.sub.2SO.sub.4), filtered,
and concentrated in vacuo. The crude residue was purified by flash
chromatography (SiO.sub.2, 1-10% methanol containing 10% ammonium
hydroxide in dichloromethane) to give the title compound as a white
solid (0.18 g, 0.12 mmol, 6%). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.87 (dd, J=1.2, 4.0 Hz, 1H), 8.11 (d, J=8.4 Hz, 1H),
7.58-7.53 (m, 4H), 7.42 (s, 1H), 7.40 (s, 1H), 7.29-7.23 (m, 1H),
6.94 (d, J=7.2 Hz, 1H), 6.28 (s, 1H), 2.34 (s, 3H), 1.36 (s, 9H);
MS: (ES) m/z calculated for C.sub.23H.sub.25N.sub.4O.sub.2S
[M+H].sup.+ 421.2, found 421.3.
Example 5: Synthesis of
N-(3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)-4-(trifluoromethoxy)benzen-
esulfonamide
##STR00126##
[0144] To a stirring mixture of
4-(trifluoromethoxy)benzene-1-sulfonyl chloride (0.060 g, 0.23
mmol) and 3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-amine (prepared
from Example 4 step b, 0.050 g, 0.22 mmol) in pyridine (1.0 mL) was
heated at 80.degree. C. for 1 h. After cooling to room temperature,
dichloromethane was added to the reaction mixture and washed with 1
M aqueous sodium hydrogen sulfate (1 mL). The aqueous layer was
further extracted with dichloromethane (2.times.5 mL), and the
combined organic layers were dried (Na.sub.2SO.sub.4), filtered,
and concentrated in vacuo. The crude residue was purified by flash
chromatography (SiO.sub.2, 2-10% methanol in dichloromethane) and
purification by reverse phase HPLC (C18 column,
acetonitrile-H.sub.2O with 0.1% TFA as eluent) to give the title
compound as a white solid (0.010 g, 0.022 mmol, 10%). .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 8.75 (d, J=4.0 Hz, 1H), 8.01 (d,
J=8.8 Hz, 1H), 7.71 (s, 1H), 7.69 (s, 1H), 7.56 (t, J=8.4 Hz, 1H),
7.49 (d, J=8.4 Hz, 1H), 7.21-7.17 (m, 4H), 6.12 (s, 1H), 2.34 (s,
3H); MS: (ES) m/z calculated for
C.sub.20H.sub.16F.sub.3N.sub.4O.sub.3S [M+H].sup.+ 449.1, found
449.7.
Example 6: Synthesis of
4-ethyl-N-(3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)benzenesulfonamide
##STR00127##
[0146] A mixture of 4-ethylbenzenesulfonyl chloride (0.033 g, 0.16
mmol) and 3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-amine (prepared
from Example 4 step b, 0.030 g, 0.13 mmol) in pyridine (1.0 mL) was
heated at 80.degree. C. for 2 h with stirring. After cooling to
room temperature, dichloromethane was added to the reaction mixture
and washed with 1 M aqueous sodium hydrogen sulfate (1 mL). The
aqueous layer was further extracted with dichloromethane (2.times.5
mL), and the combined organic layers were dried (Na.sub.2SO.sub.4),
filtered, and concentrated in vacuo. The crude residue was purified
by reverse phase HPLC (C18 column, acetonitrile-H.sub.2O with 0.1%
TFA as eluent) to give the title compound as a white solid (0.019
g, 0.049 mmol, 38%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.86
(dd, J=2.0, 4.0 Hz, 1H), 8.12 (d, J=8.8 Hz, 1H), 7.60 (dd, J=7.2,
8.4 Hz, 1H), 7.51-7.46 (m, 3H), 7.27-7.23 (m, 1H), 7.15 (s, 1H),
7.13 (s, 1H), 7.06 (d, J=7.6 Hz, 1H), 6.27 (s, 1H), 2.68 (q, J=7.6
Hz, 2H), 2.34 (s, 3H), 1.27 (t, J=7.6 Hz, 3H); MS: (ES) m/z
calculated for C.sub.21H.sub.21N.sub.4O.sub.2S [M+H].sup.+ 393.2,
found 393.2
Example 7: Synthesis of
4-isopropyl-N-(3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)benzenesulfonam-
ide
##STR00128##
[0148] A mixture of 4-t-pentylbenzenesulfonyl chloride (0.028 g,
0.13 mmol) and 3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-amine
(prepared from Example 4 step b, 0.023 g, 0.10 mmol) in pyridine
(1.0 mL) was heated at 80.degree. C. for 18 h with stirring. After
cooling to room temperature, dichloromethane was added to the
reaction mixture and washed with 1 M aqueous sodium hydrogen
sulfate (1 mL). The aqueous layer was further extracted with
dichloromethane (2.times.5 mL), and the combined organic layers
were dried (Na.sub.2SO.sub.4), filtered, and concentrated in vacuo.
The crude residue was purified by reverse phase HPLC (C18 column,
acetonitrile-H.sub.2O with 0.1% TFA as eluent) to give the title
compound as a white solid (0.020 g, 0.05 mmol, 50%). .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 9.02 (d, J=4.4 Hz, 1H), 8.43 (d,
J=8.8 Hz, 1H), 8.30 (d, J=8.4 Hz, 1H), 7.87-7.33 (m, 2H), 7.72-7.70
(m, 3H), 7.35 (s, 1H), 7.33 (s, 1H), 5.94 (s, 1H), 3.04-2.98 (m,
1H), 2.32 (s, 3H), 1.29 (s, 6H); MS: (ES) m/z calculated for
C.sub.22H.sub.23N.sub.4O.sub.2S [M+H].sup.+ 407.2, found 407.0.
Example 8: Synthesis of
4-isopropoxy-N-(3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)benzenesulfona-
mide
##STR00129##
[0150] A stirred mixture of 4-isopropoxybenzene-1-sulfonyl chloride
(0.10 g, 0.52 mmol) and
3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-amine (prepared from
Example 4 step b, 0.10 g, 0.44 mmol) in pyridine (2 mL) was heated
at 80.degree. C. for 1 h. After cooling to room temperature,
aqueous saturated sodium bicarbonate was added to the reaction
mixture and extracted with dichloromethane. The organic layer was
dried (Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The
crude residue was purified by flash chromatography (SiO.sub.2,
2-10% methanol in dichloromethane), followed by reverse phase HPLC
(C18 column, acetonitrile-H.sub.2O with 0.1% TFA as eluent) to give
the title compound as a white solid (0.015 g, 0.036 mmol, 8%).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.58 (dd, J=2.0, 4.0 Hz,
1H), 8.09 (d, J=8.4 Hz, 1H), 7.61 (dd, J=7.6, 8.4 Hz, 1H), 7.50 (d,
J=2.0 Hz, 1H), 7.48 (d, J=1.6 Hz, 1H), 7.25-7.21 (m, 2H), 7.14 (dd,
J=0.8, 7.2 Hz, 1H), 6.74 (d, J=2.4 Hz, 1H), 6.72 (d, J=2.0 Hz, 1H),
6.25 (s, 1H), 4.57 (hept, J=6.0 Hz, 1H), 2.33 (s, 3H), 1.39 (d,
J=6.4 Hz, 6H); MS: (ES) m/z calculated for
C.sub.23H.sub.23N.sub.4O.sub.3S [M+H].sup.+ 423.2, found 423.0.
Example 9: Synthesis of
4-isobutoxy-N-(3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)benzenesulfonam-
ide
##STR00130##
[0152] a) To a stirring solution of isobutoxybenzene (0.60 g, 4.0
mmol) in dichloromethane (5 mL) at -45.degree. C. was added
chlorosulfonic acid (0.6 mL, 9.1 mmol) dropwise, and the reaction
mixture was stirred at -45.degree. C. for 1 h. The reaction mixture
was then warmed to 0.degree. C. and additional chlorosulfonic acid
(0.6 mL, 9.1 mmol) was added dropwise. The reaction mixture was
then stirred at 0.degree. C. for 1 h and poured into ice. The
aqueous layer was extracted with ethyl acetate and the organic
layer was dried (Na.sub.2SO.sub.4), filtered, and concentrated in
vacuo. The crude residue was purified by flash chromatography
(SiO.sub.2, 5-10% ethyl acetate in hexanes) to give
4-isobutoxybenzene-1-sulfonyl chloride (0.32 g, 1.1 mmol, 28%).
[0153] b) A stirred mixture of 4-isobutoxybenzene-1-sulfonyl
chloride (0.060 g, 0.24 mmol),
3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-amine (prepared from
Example 4 step b, 0.050 g, 0.22 mmol), and
4-(dimethylamino)pyridine (DMAP, 0.025 g, 0.20 mmol) in pyridine (2
mL) was heated at 80.degree. C. for 2 h. After cooling to room
temperature, aqueous saturated sodium bicarbonate was added to the
reaction mixture and extracted with dichloromethane. The organic
layer was dried (Na.sub.2SO.sub.4), filtered, and concentrated in
vacuo. The crude residue was purified by flash chromatography
(SiO.sub.2, 2-5% methanol in dichloromethane), followed by reverse
phase HPLC (C18 column, acetonitrile-H.sub.2O with 0.1% TFA as
eluent) to give the title compound as a white solid (0.041 g, 0.094
mmol, 43%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.84 (d,
J=4.0 Hz, 1H), 8.11 (d, J=8.0 Hz, 1H), 7.63 (t, J=8.0 Hz, 1H),
7.48-7.44 (m, 2H), 7.23 (d, J=4.0, Hz, 1H), 7.21 (d, J=4.0, Hz,
1H), 7.15 (dd, J=1.2, 7.2 Hz, 1H), 6.72 (d, J=2.4 Hz, 1H), 6.70 (d,
J=2.4 Hz, 1H), 6.25 (s, 1H), 3.72 (dd, J=2.0, 6.4 Hz, 2H), 2.33 (s,
3H), 2.13 (hept, J=6.4 Hz, 1H), 1.08 (dd, J=2.4, 6.4 Hz, 6H); MS:
(ES) m/z calculated for C.sub.23H.sub.25N.sub.4O.sub.2S [M+H].sup.+
437.2, found 437.0.
Example 10: Synthesis of
N-(3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)-4-t-pentylbenzenesulfonami-
de
##STR00131##
[0155] A mixture of 4-t-pentylbenzenesulfonyl chloride (0.13 g,
0.53 mmol) and 3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-amine
(prepared from Example 4 step b, 0.10 g, 0.44 mmol) in pyridine
(1.0 mL) was heated at 80.degree. C. for 3 h with stirring. After
cooling to room temperature, dichloromethane was added to the
reaction mixture and washed with 1 M aqueous sodium hydrogen
sulfate (1 mL). The aqueous layer was further extracted with
dichloromethane (2.times.5 mL), and the combined organic layers
were dried (Na.sub.2SO.sub.4), filtered, and concentrated in vacuo.
The crude residue was purified by reverse phase HPLC (C18 column,
acetonitrile-H.sub.2O with 0.1% TFA as eluent) to give the title
compound as a white solid (0.11 g, 0.24 mmol, 55%). .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 8.96 (dd, J=1.6, 4.8 Hz, 1H), 8.20
(d, J=8.8 Hz, 1H), 8.13 (d, J=8.4 Hz, 1H), 7.75 (d, J=7.6 Hz, 1H),
7.71 (s, 1H), 7.69 (s, 1H), 7.54 (dd, J=4.8, 8.4 Hz, 1H), 7.46-7.43
(m, 3H), 6.02 (s, 1H), 2.32 (s, 3H), 1.70 (q, J=7.2 Hz, 2H), 1.34
(s, 6H), 0.70 (t, J=7.2 Hz, 3H); MS: (ES) m/z calculated for
C.sub.24H.sub.27N.sub.4O.sub.2S [M+H].sup.+435.2, found 435.1.
Example 11: Synthesis of
4-(2-hydroxypropan-2-yl)-N-(3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)be-
nzenesulfonamide
##STR00132##
[0157] a) A mixture of 4-acetylbenzene-1-sulfonyl chloride (0.050
g, 0.22 mmol), 3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-amine
(prepared from Example 4 step b, 0.060 g, 0.27 mmol), and DMAP
(0.027 g, 0.22 mmol) in pyridine (2 mL) was heated at 80.degree. C.
for 2.5 h with stirring. After cooling to room temperature, 1 M
aqueous lithium hydroxide (2 mL) was added to the reaction mixture
and stirred for 2 h. The solution was added 4:1
dichloromethane/methanol and washed with 1 M aqueous ammonium
chloride (5 mL). The solution was adjusted to pH .about.8-9 with
ammonium hydroxide and the phases were separated. The organic layer
was dried (Na.sub.2SO.sub.4), filtered, and concentrated in vacuo.
The crude residue was purified by flash chromatography (SiO.sub.2,
2-5% methanol in dichloromethane). The product was then
recrystallized in minimal amount of 4:1 dichloromethane/methanol
and the solid was collected by filtration to give the desired solid
(0.059 g, 0.15 mmol, 66%).
[0158] b) A solution of methyl magnesium bromide (1.4 M solution in
3:1 toluene/THF, 1.4 mL, 2.0 mmol) was added to a flask containing
4-acetyl-N-(3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)benzenesulfonamide
(0.059 g, 0.15 mmol) in THF (6 mL) at -45.degree. C. with stirring.
The reaction mixture was slowly warmed to .about.10.degree. C. over
1 h and 4:1 dichloromethane/methanol was added (2 mL). The organic
layer was washed with aqueous saturated ammonium chloride, dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The crude
residue was purified by reverse phase HPLC (C18 column,
acetonitrile-H.sub.2O with 0.1% TFA as eluent) to give the title
compound as a white solid (0.020 g, 0.047 mmol, 32%). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.81 (d, J=4.4 Hz, 1H), 8.05 (d,
J=8.8 Hz, 1H), 7.54 (t, J=8.0 Hz, 1H), 7.69 (d, J=8.0 Hz, 1H), 7.67
(s, 1H), 7.65 (s, 1H), 7.51-7.47 (m, 3H), 7.36 (dd, J=4.4, 8.4 Hz,
1H), 5.73 (s, 1H), 2.15 (s, 3H), 1.56 (s, 6H); MS: (ES) m/z
calculated for C.sub.22H.sub.23N.sub.4O.sub.3S [M+H].sup.+433.2,
found 433.0.
Example 12: Synthesis of
2,2-dimethyl-N-(3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)-2,3-dihydrobe-
nzofuran-5-sulfonamide
##STR00133##
[0160] A stirring mixture of
2,2-dimethyl-2,3-dihydro-1-benzofuran-5-sulfonyl chloride (0.10 g,
0.41 mmol) and 3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-amine
(prepared from Example 4 step b, 0.11 g, 0.49 mmol) in pyridine
(0.41 mL) was heated at 80.degree. C. for 1 h. After cooling to
room temperature, the reaction mixture was concentrated in vacuo.
The crude residue was purified by flash chromatography (SiO.sub.2,
0-20% ethyl acetate in hexanes), followed by reverse phase HPLC
(C18 column, acetonitrile-H.sub.2O with 0.1% TFA as eluent) to give
the title compound as a white solid (0.070 g, 0.16 mmol, 40%).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.82 (s, 1H), 8.06 (d,
J=8.0 Hz, 1H), 7.60 (t, J=7.6 Hz, 1H), 7.54 (d, J=8.0 Hz, 1H), 7.42
(d, J=8.4 Hz, 1H), 7.31 (s, 1H), 7.24 (d, J=3.2 Hz, 1H), 7.19 (d,
J=6.8 Hz, 1H), 6.61 (d, J=8.8 Hz, 1H), 6.24 (s, 1H), 2.89 (s, 2H),
2.34 (s, 3H), 1.51 (s, 6H); MS: (ES) m/z calculated for
C.sub.23H.sub.23N.sub.4O.sub.3S [M+H].sup.+435.2, found 435.3.
Example 13: Synthesis of
2,2-dimethyl-N-(3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)chroman-6-sulf-
onamide
##STR00134##
[0162] A stirring mixture of 2,2-dimethylchroman-6-sulfonyl
chloride (0.050 g, 0.22 mmol) and
3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-amine (prepared from
Example 4 step b, 0.068 g, 0.26 mmol) in pyridine (1.0 mL) was
heated at 80.degree. C. for 15 h. After cooling to room
temperature, dichloromethane was added to the reaction mixture and
washed with 1 M aqueous saturated bisulfate (1 mL). The aqueous
layer was further extracted with dichloromethane (2.times.5 mL),
and the combined organic layers were dried (Na.sub.2SO.sub.4),
filtered, and concentrated in vacuo. The resulting crude residue
was purified by flash chromatography (SiO.sub.2, 0-20% ethyl
acetate in hexanes), followed by reverse phase HPLC (C18 column,
acetonitrile-H.sub.2O with 0.1% TFA as eluent) to give the title
compound as a white solid (0.010 g, 0.022 mmol, 10%). .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 9.09 (d, J=4.8 Hz, 1H), 8.38 (d,
J=8.4 Hz, 1H), 8.29 (d, J=8.4 Hz, 1H), 7.87 (t, J=7.6 Hz, 1H), 7.66
(dd, J=4.8, 8.8 Hz, 1H), 7.61 (d, J=7.6 Hz, 1H), 7.40-7.38 (m, 2H),
6.72 (d, J=9.2 Hz, 1H), 6.09 (s, 1H), 2.71 (t, J=6.4 Hz, 2H), 2.34
(s, 3H), 1.83 (t, J=6.4 Hz, 2H), 1.36 (s, 6H); MS: (ES) m/z
calculated for C.sub.24H.sub.25N.sub.4O.sub.3S [M+H].sup.+ 449.2,
found 449.1
Example 14: Synthesis of
1,1-dimethyl-N-(3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)-2,3-dihydro-1-
H-indene-5-sulfonamide
##STR00135##
[0164] a) To a stirring solution of 3,3-dimethyl-1-indanone (0.10
g, 0.64 mmol) in sulfuric acid (0.63 mL) at 0.degree. C. was added
potassium nitrate (KNO.sub.3, 0.063 g, 0.63 mmol) in sulfuric acid
(0.2 mL). The reaction mixture was stirred at 0.degree. C. for 1 h,
then warmed to room temperature and stirred for 15 h. The reaction
mixture was quenched with ice and the aqueous layer was extracted
with ethyl acetate. The organic layer was dried (Na.sub.2SO.sub.4),
filtered, and concentrated in vacuo. The crude residue was purified
by flash chromatography (SiO.sub.2, 20% ethyl acetate in hexanes)
to give the desired product (0.096 g, 0.47 mmol, 73%).
[0165] b) In a Parr shaker flask containing
3,3-dimethyl-6-nitro-1-indanone (1.0 g, 4.8 mmol) and palladium
hydroxide on carbon (Pd(OH).sub.2, 20% by weight, 0.52 g) in
methanol (2 mL) and methane sulfonic acid (MeSO.sub.3H, 0.4 mL, 6.2
mmol) was hydrogenated at 50 psi for 1.5 h. The reaction mixture
was diluted with methanol and filtered through a pad of Celite. The
filtrate was concentrated in vacuo and the resulting crude residue
was purified by flash chromatography (SiO.sub.2, 100% ethyl
acetate) to give the desired product (0.34 g, 2.1 mmol, 44%).
[0166] c) To a solution of glacial acetic acid (8 mL) at 0.degree.
C. was bubbled in sulfur dioxide gas (SO.sub.2) for 30 min.
Copper(II) chloride (CuCl.sub.2, 0.29 g, 2.16 mmol) was added to
the reaction mixture and stirred for 30 min at 0.degree. C. to give
a blue/green solution. To another flask containing
1,1-dimethylindan-5-amine (0.34 g, 2.13 mmol) in concentrated
hydrochloric acid (4.2 mL) at 0.degree. C. was added NaNO.sub.2
(0.22 g, 3.2 mmol) and stirred for 30 min. This diazonium solution
was then slowly added to the prepared copper solution and stirred
at 0.degree. C. for 30 min. The reaction mixture was then slowly
heated to 70.degree. C. over 2 h. After cooling to room
temperature, the reaction mixture was quenched with deionized water
and the aqueous layer was extracted with ethyl acetate (2.times.10
mL). The combined organic layers were dried (Na.sub.2SO.sub.4),
filtered, and concentrated in vacuo. The crude residue was purified
by flash chromatography (SiO.sub.2, 0-10% ethyl acetate in hexanes)
to afford the desired product (0.067 g, 0.27 mmol, 13%).
[0167] d) A mixture of 1,1-dimethylindan-5-sulfonyl chloride (0.030
g, 0.13 mmol) and 3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-amine
(prepared from Example 4 step b, 0.028 g, 0.12 mmol) in pyridine
(0.12 mL) was heated at 80.degree. C. for 1 h with stirring. After
cooling to room temperature, the reaction mixture was concentrated
in vacuo. The resulting crude residue was purified by flash
chromatography (SiO.sub.2, 20% ethyl acetate in hexanes), followed
by reverse phase HPLC (C18 column, acetonitrile-H.sub.2O with 0.1%
TFA as eluent) to give the title compound as a white solid (0.015
g, 0.036 mmol, 28%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
10.30 (s, 1H), 8.90 (d, J=3.2 Hz, 1H), 8.06 (d, J=8.4 Hz, 1H), 7.73
(t, J=8.0 Hz, 1H), 7.57 (d, J=9.2 Hz, 1H), 7.46 (dd, J=4.0, 8.4 Hz,
1H), 7.30-7.26 (m, 2H), 7.18 (s, 1H), 7.11 (d, J=8.0 Hz, 1H), 6.05
(s, 1H), 2.71 (d, J=7.6 Hz, 2H), 2.20 (s, 3H), 1.84 (d, J=7.2 Hz,
2H), 1.18 (s, 6H); MS: (ES) m/z calculated for
C.sub.24H.sub.25N.sub.4O.sub.2S [M+H].sup.+ 433.2, found 433.1.
Example 15: Synthesis of
3-fluoro-N-(3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)-4-morpholinobenze-
nesulfonamide
##STR00136##
[0169] a) A mixture of 4-bromo-3-fluorobenzene-1-sulfonyl chloride
(1.4 g, 5.2 mmol) and 3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-amine
(prepared from Example 4 step b, 0.90 g, 4.0 mmol) in pyridine (10
mL) was stirred at room temperature for 2 h, then heated at
80.degree. C. for 2 h. After cooling to room temperature, 1 N
aqueous hydrochloric acid (1 mL) was added to the reaction mixture
and extracted with dichloromethane (2.times.5 mL). The combined
organic layers were dried (Na2SO4), filtered, and concentrated in
vacuo. The crude residue was purified by flash chromatography
(SiO2, 0-10% methanol in ethyl acetate to give the desired product
(0.20 g, 0.43 mmol, 11%).
[0170] b) A stirring mixture of
4-bromo-3-fluoro-N-(3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)benzenesul-
fonamide (0.07 g, 0.15 mmol), morpholine (0.066 g, 0.75 mmol),
tris(dibenzylideneacetone)dipalladium(0) (Pd.sub.2(dba).sub.3,
0.007 g, 0.008 mmol), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl
(BINAP, 0.014 g, 0.023 mmol), and potassium phosphate monobasic
(K.sub.3PO.sub.4.H.sub.2O, 0.21 g, 0.90 mmol) in anhydrous
N,N-dimethylformamide (DMF, 6 mL) was purged with nitrogen for 5
min. The reaction mixture was heated at 90.degree. C. for 4 h.
After cooling to room temperature, ethyl acetate (10 mL) was added
to the reaction mixture and washed with aqueous saturated sodium
bicarbonate. The organic layer was dried (Na.sub.2SO.sub.4),
filtered, and concentrated in vacuo. The resulting crude material
was purified by reverse phase HPLC (C18 column,
acetonitrile-H.sub.2O with 0.1% TFA as eluent) to give the title
compound as a white solid (0.049 g, 0.11 mmol, 70%). .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 9.06 (dd, J=1.6, 4.8 Hz, 1H), 8.36
(d, J=8.4 Hz, 1H), 8.31 (d, J=8.0 Hz, 1H), 7.88 (dd, J=8.4, 9.6 Hz,
1H), 7.68 (d, J=4.8 Hz, 1H), 7.66 (d, J=6.4 Hz, 1H), 7.37 (dd,
J=1.6, 8.4 Hz, 1H), 7.31 (dd, J=2.4, 12.4 Hz, 1H), 6.80 (t, J=6.8
Hz, 1H), 6.09 (s, 1H), 3.90-3.86 (m, 4H), 3.21-3.18 (m, 4H), 2.35
(s, 3H); MS: (ES) m/z calculated for
C.sub.23H.sub.23FN.sub.5O.sub.3S [M+H+468.2, found 468.2.
Example 16: Synthesis of
4-t-butyl-N-(1-(quinolin-5-yl)-1H-pyrazol-5-yl)benzenesulfonamide
##STR00137##
[0172] a) To a stirring solution of (ethoxymethylene)malononitrile
(0.38 g, 3.2 mmol) and quinolin-5-yl-hydrazine (prepared from
Example 4 step a, 0.5 g, 3.2 mmol) in ethanol (5 mL) was heated at
80.degree. C. for 15 h. After cooling to room temperature, the
reaction mixture was concentrated in vacuo and the crude solid was
used directly without further purification (0.70 g, 3.0 mmol,
95%).
[0173] b) To a solution of crude
5-amino-1-(quinolin-5-yl)-1H-pyrazole-4-carbonitrile (0.40 g, 1.7
mmol) in concentrated hydrochloric acid (5 mL) was heated at
100.degree. C. for 15 h with stirring. The reaction mixture was
cooled to room temperature and basified with aqueous saturated
sodium bicarbonate. The aqueous layer was extracted with 2:1
chloroform/iPrOH and the organic layer was dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The crude
residue was used directly without further purification (0.36 g, 1.7
mmol, 100%).
[0174] c) A stirred mixture of crude
1-(quinolin-5-yl)-1H-pyrazol-5-amine (0.080 g, 0.38 mmol),
4-t-butylbenzenesulfonyl chloride (0.13 g, 0.57 mmol), and DMAP
(0.068 g, 0.57 mmol) in pyridine (1.5 mL) was heated at 80.degree.
C. for 2 h. After cooling to room temperature, aqueous saturated
sodium bicarbonate was added to the reaction mixture and extracted
with 2:1 chloroform/iPrOH. The organic layer was dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The crude
residue was purified by reverse phase HPLC (C18 column,
acetonitrile-H.sub.2O with 0.1% TFA as eluent) to give the title
compound as a white solid (0.010 g, 0.025 mmol, 7%). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.87 (dd, J=2.0, 4.4 Hz, 1H), 8.13
(d, J=8.4 Hz, 1H), 7.76 (dd, J=7.2, 8.8 Hz, 1H), 7.69 (d, J=2.4 Hz,
1H), 7.65-7.62 (m, 1H), 7.52-7.42 (m, 3H), 7.51 (d, J=8.8 Hz, 1H),
7.43 (d, J=8.8 Hz, 1H), 7.28 (dd, J=1.2, 7.2 Hz, 1H), 6.25 (s, 1H),
1.35 (s, 9H); MS: (ES) m/z calculated for
C.sub.22H.sub.23N.sub.4O.sub.2S [M+H].sup.+ 407.2, found 407.0.
Example 17: Synthesis of
4-t-butyl-N-(3-ethyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)benzenesulfonamide
##STR00138##
[0176] a) To a solution of 3-oxopentanenitrile (0.74 g, 7.6 mmol)
and quinolin-5-yl-hydrazine (prepared from Example 4 step a, 1.0 g,
6.3 mmol) in ethanol (5 mL) was heated at 80.degree. C. for 3 h
with stirring. After cooling to room temperature, 20% aqueous
sodium hydroxide (1.5 mL) was added to the reaction mixture and
then heated at 70.degree. C. for 3 h. The reaction mixture was
cooled to room temperature and concentrated in vacuo. The crude
residue was dissolved in 1:1 dichloromethane/methanol (40 mL) and
the phases were separated. The organic layer was dried
(Na.sub.2SO.sub.4), and filtered through a pad of Celite. The
filtrate was concentrated in vacuo and the crude residue was
purified by flash chromatography (SiO.sub.2, 1-10% methanol
containing 10% ammonium hydroxide in dichloromethane) to give the
desired product (0.83 g, 3.5 mmol, 55%).
[0177] b) A mixture of 4-t-butylbenzenesulfonyl chloride (0.064 g,
0.27 mmol) and 3-ethyl-1-(quinolin-5-yl)-1H-pyrazol-5-amine (0.05
g, 0.21 mmol) in pyridine (0.5 mL) was heated at 80.degree. C. for
15 h with stirring. After cooling to room temperature,
dichloromethane was added to the reaction mixture and washed with 1
M aqueous sodium hydrogen sulfate (1 mL). The aqueous layer was
further extracted with dichloromethane (2.times.5 mL), and the
combined organic layers were dried (Na.sub.2SO.sub.4), filtered,
and concentrated in vacuo. The crude residue was dissolved in
methanol (3 mL) and 1 M aqueous sodium hydroxide (1.0 mL, 1.0
mmol). The reaction mixture was stirred at room temperature for 1 h
and the solvent was removed in vacuo. The resulting residue was
partitioned between dichloromethane (3 mL) and 1 M aqueous sodium
hydrogen sulfate (3 mL) and the phases were separated. The aqueous
layer was extracted with dichloromethane (2.times.5 mL), and the
combined organic layers were dried (Na.sub.2SO.sub.4), filtered,
and concentrated in vacuo. The crude residue was purified by
reverse phase HPLC (C18 column, acetonitrile-H.sub.2O with 0.1% TFA
as eluent) to give the title compound as a white solid (0.053 g,
0.12 mmol, 58%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.00 (d,
J=3.6 Hz, 1H), 8.23 (d, J=8.8 Hz, 1H), 8.19 (d, J=8.0 Hz, 1H), 7.79
(dd, J=8.0, 8.4 Hz, 1H), 7.69-7.65 (m, 2H), 7.59 (dd, J=4.4, 8.8
Hz, 1H), 7.51-7.47 (m, 3H), 6.05 (s, 1H), 2.69 (q, J=7.6 Hz, 2H),
1.37 (s, 9H), 1.29 (t, J=7.6 Hz, 3H); MS: (ES) m/z calculated for
C.sub.24H.sub.27N.sub.4O.sub.2S [M+H].sup.+ 435.2, found 435.2.
Example 18: Synthesis of
4-t-butyl-N-(3-cyclopropyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)benzenesulfo-
namide
##STR00139##
[0179] a) To a solution of 3-cyclopropyl-3-oxopropanenitrile (0.74
g, 7.6 mmol) and quinolin-5-yl-hydrazine (prepared from Example 4
step a, 1.0 g, 6.3 mmol) in ethanol (5 mL) was heated at 80.degree.
C. for 3 h with stirring. After cooling to room temperature, 20%
aqueous sodium hydroxide (1.5 mL) was added to the reaction mixture
and heated at 70.degree. C. for 3 h. The mixture was cooled to room
temperature and concentrated in vacuo. The crude residue was
dissolved in 1:1 dichloromethane/methanol (40 mL) and the phases
were separated. The organic layer was dried (Na.sub.2SO.sub.4), and
filtered through a pad of Celite. The filtrate was concentrated in
vacuo and the crude material was purified by flash chromatography
(SiO.sub.2, 1-10% methanol containing 10% ammonium hydroxide in
dichloromethane) to give the desired product (0.80 g, 3.2 mmol,
50%).
[0180] b) A mixture of 4-t-butylbenzenesulfonyl chloride (0.061 g,
0.26 mmol) and 3-cyclopropyl-1-(quinolin-5-yl)-1H-pyrazol-5-amine
(0.05 g, 0.20 mmol) in pyridine (1 mL) was heated at 80.degree. C.
for 15 h with stirring. After cooling to room temperature,
dichloromethane was added to the reaction mixture and washed with 1
M aqueous sodium hydrogen sulfate (1 mL). The aqueous layer was
further extracted with dichloromethane (2.times.5 mL), and the
combined organic layers were dried (Na.sub.2SO.sub.4), filtered,
and concentrated in vacuo. The resulting crude residue was
dissolved in methanol (3 mL) and 1 M aqueous sodium hydroxide (1.0
mL, 1.0 mmol) and stirred at room temperature for 1 h. The reaction
mixture was concentrated in vacuo and the resulting residue was
partitioned between dichloromethane (3 mL) and 1 M aqueous sodium
hydrogen sulfate (3 mL). The phases were separated and the aqueous
layer was extracted with dichloromethane (2.times.5 mL). The
combined organic layers were dried (Na.sub.2SO.sub.4), filtered,
and concentrated in vacuo. The crude residue was purified by
reverse phase HPLC (C18 column, acetonitrile-H.sub.2O with 0.1% TFA
as eluent) to give the title compound as a white solid (0.031 g,
0.070 mmol, 35%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.84
(d, J=4.0 Hz, 1H), 8.08 (d, J=8.0 Hz, 1H), 7.55-7.51 (m, 5H), 7.41
(s, 1H), 7.39 (s, 1H), 6.94 (d, J=7.2 Hz, 1H), 6.12 (s, 1H),
1.99-1.93 (m, 1H), 1.36 (s, 9H), 1.01-0.92 (m, 2H), 0.84-0.79 (m,
2H); MS: (ES) m/z calculated for C.sub.25H.sub.27N.sub.4O.sub.2S
[M+H].sup.+ 447.2, found 447.2.
Example 19: Synthesis of
4-t-butyl-N-(3-(cyanomethyl)-1-(quinolin-5-yl)-1H-pyrazol-5-yl)benzenesul-
fonamide
##STR00140## ##STR00141##
[0182] a) To a stirring solution of quinolin-5-yl-hydrazine
(prepared from Example 4 step a, 0.62 g, 3.9 mmol) in ethanol (4
mL) was added malononitrile (0.51 g, 7.7 mmol). The reaction
mixture was heated at 80.degree. C. for 15 h. After cooling to room
temperature, aqueous saturated ammonium chloride (1.5 mL) was added
to the reaction mixture and extracted with 2:1 chloroform/iPrOH.
The organic layer was washed with brine, dried (Na.sub.2SO.sub.4),
filtered, and concentrated in vacuo. The crude residue was purified
by flash chromatography (SiO.sub.2, 0-5% methanol in
dichloromethane) to give the desired product as a light-brown solid
(0.60 g, 2.2 mmol, 56%).
[0183] b) To a solution of
5-amino-3-(cyanomethyl)-1-(quinolin-5-yl)-1H-pyrazole-4-carbonitrile
(0.60 g, 2.2 mmol) in concentrated hydrochloric acid (50 mL) was
heated at 105.degree. C. for 22 h with stirring. The reaction
mixture was cooled to room temperature and the solution was
concentrated in vacuo. Methanol (50 mL) and concentrated
hydrochloric acid (0.5 mL) were added to the resulting residue, and
the reaction mixture was refluxed for 3 h. After cooling to room
temperature, the reaction mixture was basified with aqueous
saturated sodium bicarbonate. The aqueous layer was extracted with
2:1 chloroform/iPrOH and the organic layer was extracted with
aqueous saturated ammonium chloride, dried (Na.sub.2SO.sub.4),
filtered, and concentrated in vacuo. The crude residue was used
directly without further purification (0.40 g, 1.7 mmol, 65%).
[0184] c) A mixture of crude methyl
2-(5-amino-1-(quinolin-5-yl)-1H-pyrazol-3-yl)acetate (0.55 g, 2.0
mmol), 4-t-butylbenzenesulfonyl chloride (0.30 g, 1.3 mmol), and
DMAP (0.12 g, 1.0 mmol) in pyridine (5 mL) was heated at 80.degree.
C. for 2 h with stirring. After cooling to room temperature,
dichloromethane was added to the reaction mixture and washed with 1
M aqueous sodium hydrogen sulfate (1 mL). The aqueous layer was
further extracted with dichloromethane (2.times.5 mL), and the
combined organic layers were dried (Na.sub.2SO.sub.4), filtered,
and concentrated in vacuo. The crude residue was purified by
reverse phase HPLC (C18 column, acetonitrile-H.sub.2O with 0.1% TFA
as eluent) to give a white solid (0.075 g, 0.16 mmol, 12%).
[0185] d) To a suspension of methyl
2-(5-(4-t-butylphenylsulfonamido)-1-(quinolin-5-yl)-1H-pyrazol-3-yl)aceta-
te (0.066 g, 0.14 mmol) in THF (1 mL) and methanol (1 mL) was added
a solution of lithium hydroxide (0.05 g, 2.1 mmol) in deionized
water (0.5 mL). The reaction mixture was stirred at room
temperature for 1 h and the resulting solution was adjusted to pH-5
with 5 N aqueous hydrochloric acid. The aqueous layer was extracted
with 2:1 chloroform/iPrOH and the organic layer was washed with
brine, dried (Na.sub.2SO.sub.4), filtered, and concentrated in
vacuo. The crude material was used directly without further
purification (0.065 g, 0.14 mmol, 100%).
[0186] e) To a stirred solution of crude
2-(5-(4-t-butylphenylsulfonamido)-1-(quinolin-5-yl)-1H-pyrazol-3-yl)aceti-
c acid (0.065 g, 0.14 mmol) and
N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium
hexafluorophosphate (HATU, 0.11 g, 0.28 mmol) in DMF (1.5 mL) was
added a solution of saturated ammonia in dichloromethane (0.5 mL).
The reaction mixture was stirred at room temperature for 1 h and
brine was added. The aqueous layer was extracted with 2:1
chloroform/iPrOH and the organic layer was washed with brine, dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The crude
material was used directly without further purification (0.060 g,
0.14 mmol, 92%).
[0187] f) To a stirring solution of crude
2-(5-(4-t-butylphenylsulfonamido)-1-(quinolin-5-yl)-1H-pyrazol-3-yl)aceta-
mide (0.03 g, 0.07 mmol) and phosphorus(V) oxide chloride
(POCl.sub.3, 0.5 mL, 5.4 mmol) was heated at 100.degree. C. for 30
min. After cooling to room temperature, the reaction mixture was
concentrated in vacuo. Aqueous saturated sodium bicarbonate was
added to the resulting residue and extracted with 2:1
chloroform/iPrOH. The organic layer was dried (Na.sub.2SO.sub.4),
filtered, and concentrated in vacuo. The crude product was purified
by reverse phase HPLC (C18 column, acetonitrile-H.sub.2O with 0.1%
TFA as eluent) to give the title compound as a white solid (0.006
g, 0.013 mmol, 19%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.86
(dd, J=2.0, 4.4 Hz, 1H), 8.12 (d, J=8.4 Hz, 1H), 7.77 (dd, J=7.2,
8.4 Hz, 1H), 7.68 (d, J=8.4 Hz, 1H), 7.55-7.53 (m, 2H), 7.45-7.42
(m, 3H), 7.34 (dd, J=1.2, 7.2 Hz, 1H), 6.21 (s, 1H), 3.88 (s, 2H),
1.35 (s, 9H); MS: (ES) m/z calculated for
C.sub.24H.sub.24N.sub.5O.sub.2S [M+H].sup.+ 446.2, found 446.3.
Example 20: Synthesis of
4-t-butyl-N-(1-(quinolin-5-yl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)benzen-
esulfonamide
##STR00142##
[0189] a) To a stirring solution of
4,4,4-trifluoro-3-oxobutanenitrile (0.40 g, 2.9 mmol) and
quinolin-5-yl-hydrazine (prepared from Example 4 step a, 0.46 g,
2.9 mmol) in ethanol (3 mL) was heated at 140.degree. C. in
microwave for 40 min. After cooling to room temperature, the
reaction mixture was concentrated in vacuo. The resulting crude
residue was purified by flash chromatography (SiO.sub.2, 5-60%
ethyl acetate in hexanes) to give the desired product as a
light-brown solid (0.087 g, 0.31 mmol, 11%).
[0190] b) To a mixture of 4-t-butylbenzenesulfonyl chloride (0.067
g, 0.29 mmol) and
1-(quinolin-5-yl)-3-(trifluoromethyl)-1H-pyrazol-5-amine (0.011 g,
0.04 mmol) in pyridine (0.5 mL) was heated at 80.degree. C. for 2 h
with stirring. After cooling to room temperature, dichloromethane
was added to the reaction mixture and washed with 1 M aqueous
sodium hydrogen sulfate (1 mL). The aqueous layer was further
extracted with dichloromethane (2.times.5 mL), and the combined
organic layers were dried (Na.sub.2SO.sub.4), filtered, and
concentrated in vacuo. The crude residue was dissolved in methanol
(3 mL) and 1 M aqueous sodium hydroxide (1.0 mL, 1.0 mmol), and
stirred at room temperature for 1 h. The reaction mixture was
concentrated in vacuo and partitioned between dichloromethane (3
mL) and 1 M aqueous sodium hydrogen sulfate (3 mL). The phases were
separated and the aqueous layer was further extracted with
dichloromethane (2.times.5 mL). The combined organic layers were
dried (Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The
crude residue was purified by reverse phase HPLC (C18 column,
acetonitrile-H.sub.2O with 0.1% TFA as eluent) to give the title
compound as a white solid (0.006 g, 0.013 mmol, 32%). .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 8.78 (dd, J=1.6, 4.4 Hz, 1H), 8.07
(d, J=8.4 Hz, 1H), 7.66 (s, 1H), 7.63 (s, 1H), 7.55 (t, J=8.4 Hz,
1H), 7.45 (s, 1H), 7.48 (s, 1H), 7.43 (d, J=6.0 Hz, 1H), 7.27-7.24
(m, 1H), 7.09 (d, J=6.0 Hz, 1H), 6.70 (s, 1H), 1.38 (s, 9H); MS:
(ES) m/z calculated for C.sub.23H.sub.22F.sub.3N.sub.4O.sub.2S
[M+H].sup.+ 475.2, found 475.3.
Example 21: Synthesis of
4-isopropoxy-N-(1-(quinolin-5-yl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)ben-
zenesulfonamide
##STR00143##
[0192] To a mixture of 4-isopropoxybenzenesulfonyl chloride (0.080
g, 0.35 mmol) and
1-(quinolin-5-yl)-3-(trifluoromethyl)-1H-pyrazol-5-amine (prepared
from Example 21 step a, 0.032 g, 0.11 mmol) in pyridine (0.5 mL)
was heated at 80.degree. C. for 4 h with stirring. After cooling to
room temperature, the reaction mixture was concentrated in vacuo
and the crude residue was purified by reverse phase HPLC (C18
column, acetonitrile-H.sub.2O with 0.1% TFA as eluent) to give the
title compound as a white solid (0.025 g, 0.052 mmol, 47%). .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 8.94 (dd, J=1.6, 4.0 Hz, 1H),
8.19 (d, J=8.4 Hz, 1H), 7.82 (t, J=8.4 Hz, 1H), 7.50-7.46 (m, 2H),
7.40 (s, 1H), 7.38 (s, 1H), 7.35 (d, J=8.4 Hz, 1H), 6.83 (s, 1H),
6.81 (s, 1H), 6.64 (s, 1H), 4.63 (pent, J=6.0 Hz, 1H), 1.28 (d,
J=6.0 Hz, 6H); MS: (ES) m/z calculated for
C.sub.27H.sub.20F.sub.3N.sub.4O.sub.2S [M+H].sup.+ 477.2, found
477.3.
Example 22: Synthesis of
4-t-butyl-N-(3-(1,1-difluoroethyl)-1-(quinolin-5-yl)-1H-pyrazol-5-yl)benz-
enesulfonamide
##STR00144##
[0194] a) To a stirring solution of potassium t-butoxide (KOtBu,
1.7 M solution in THF, 32 mL, 54.4 mmol) in THF (10 mL) at
0.degree. C. was added ethyl 2,2-difluoropropanoate (5.0 g, 36.2
mmol) and acetonitrile (2.8 mL, 54.3 mmol). The reaction mixture
was warmed to room temperature and stirred for 18 h. Aqueous
saturated potassium bisulfate was added to the reaction mixture and
the pH was adjusted below 2. The aqueous layer was extracted with
ethyl acetate (2.times.50 mL), and the combined organic layers were
dried (Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The
resulting brown crude oil was used directly without further
purification (3.2 g, 24.1 mmol, 66%).
[0195] b) To a stirring solution of 5-hydrazinylquinoline (prepared
from Example 4 step a, 0.90 g, 5.6 mmol) in ethanol (10 mL) was
added crude 4,4-difluoro-3-oxopentanenitrile (0.75 g, 5.6 mmol) and
heated at 85.degree. C. for 6 h. After cooling to room temperature,
ethyl acetate was added to the reaction mixture and washed with 5 M
aqueous sodium hydroxide and brine. The organic layer was dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The crude
residue was purified by flash chromatography (SiO.sub.2, 50-100%
ethyl acetate in hexanes) to give the desired product (0.20 g, 0.73
mmol, 13%).
[0196] c) A mixture of 4-t-butylbenzene-1-sulfonyl chloride (0.080
g, 0.34 mmol),
3-(1,1-difluoroethyl)-1-(quinolin-5-yl)-1H-pyrazol-5-amine (0.045
g, 0.16 mmol), and DMAP (0.020 g, 0.16 mmol) in pyridine (1 mL) was
heated at 85.degree. C. for 5 h with stirring. After cooling to
room temperature, 1 M aqueous lithium hydroxide (1 mL) and 1 M
aqueous sodium hydroxide (1 mL) were added to the reaction mixture.
The resulting mixture was heated at 75.degree. C. for 1.5 h. After
cooling to room temperature, the reaction mixture was neutralized
with 1 N aqueous hydrochloric acid. The aqueous layer was extracted
with ethyl acetate (2.times.10 mL). The combined organic layers
were washed with aqueous saturated sodium bicarbonate, dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The crude
residue was purified by reverse phase HPLC (C18 column,
acetonitrile-H.sub.2O with 0.1% TFA as eluent) to give the title
compound as a white solid (0.040 g, 0.085 mmol, 53%). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 10.70 (s, 1H), 8.88 (dd, J=1.6, 4.4
Hz, 1H), 8.14 (dd, J=1.2, 8.4 Hz, 1H), 7.77 (dd, J=7.2, 8.8 Hz,
1H), 7.64-7.61 (m, 2H), 7.52-7.42 (m, 5H), 7.31 (dd, J=1.2, 7.2 Hz,
1H), 1.96 (t, J=15.4 Hz, 3H), 1.35 (s, 9H); MS: (ES) m/z calculated
for C.sub.24H.sub.25F.sub.2N.sub.4O.sub.2S [M+H].sup.+ 471.2, found
471.2.
Example 23: Synthesis of
4-t-butyl-N-(3-(difluoromethyl)-1-(quinolin-5-yl)-1H-pyrazol-5-yl)benzene-
sulfonamide
##STR00145##
[0198] a) To a stirring solution of KOtBu (1.0 M solution in THF,
121 mL, 121 mmol) at 0.degree. C. was added ethyl
2,2-difluoroacetate (10.0 g, 80.6 mmol) and acetonitrile (6.3 mL,
121 mmol). The reaction mixture was warmed to room temperature and
stirred for 18 h. Aqueous saturated potassium bisulfate was added
to the reaction mixture and the pH was adjusted below 2. The
aqueous layer was extracted with ethyl acetate (2.times.50 mL), and
he combined organic layers were dried (Na.sub.2SO.sub.4), filtered,
and concentrated in vacuo. The brown crude oil was used directly
without further purification (9.0 g, 75 mmol, 94%).
[0199] b) To a stirring solution of crude
4,4-difluoro-3-oxobutanenitrile (0.65 g, 4.0 mmol) and
5-hydrazinylquinoline (prepared from Example 4 step a, 0.50 g, 4.2
mmol) in ethanol (8 mL) was heated at 85.degree. C. for 6 h. After
cooling to room temperature, ethyl acetate was added to the
reaction mixture and washed with aqueous saturated sodium
bicarbonate and brine. The organic layer was dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The crude
residue was purified by flash chromatography (SiO.sub.2, 2-10%
methanol in ethyl acetate) to give the desired product (0.095 g,
0.36 mmol, 9%).
[0200] c) A mixture of 4-t-butylbenzene-1-sulfonyl chloride (0.070
g, 0.30 mmol),
3-(difluoromethyl)-1-(quinolin-5-yl)-1H-pyrazol-5-amine (0.045 g,
0.17 mmol), and DMAP (0.020 g, 0.17 mmol) in pyridine (2 mL) was
heated at 80.degree. C. for 5 h with stirring. After cooling to
room temperature, the reaction mixture was concentrated in vacuo.
The crude residue was purified by flash chromatography (SiO.sub.2,
5% methanol in ethyl acetate), followed by reverse phase HPLC (C18
column, acetonitrile-H.sub.2O with 0.1% TFA as eluent) to give the
title compound as a white solid (0.040 g, 0.085 mmol, 53%). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.88 (dd, J=2.0, 4.0 Hz, 1H),
8.15 (d, J=8.0 Hz, 1H), 7.77 (dd, J=7.2, 8.4 Hz, 1H), 7.63 (dddd,
J=0.8, 1.6, 1.2, 7.2 Hz, 1H), 7.53-7.43 (m, 5H), 7.31 (dd, J=0.8,
7.2 Hz, 1H), 6.71 (t, J=54.8 Hz, 1H), 6.42 (s, 1H), 1.35 (s, 9H);
MS: (ES) m/z calculated for C.sub.23H.sub.23F.sub.2N.sub.4O.sub.2S
[M+H].sup.+ 457.2, found 457.2.
Example 24: Synthesis of
4-t-butyl-N-(2-(isoquinolin-5-yl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol--
3-yl)benzenesulfonamide
##STR00146##
[0202] a) To a round bottom flask equipped with a stir bar
containing isoquinolin-5-amine (15.4 g, 10.0 mmol) was slowly added
concentrated hydrochloric acid (90 mL). The reaction slurry was
stirred at 0.degree. C. for 30 min and a solution of NaNO.sub.2
(7.3 g, 105.8 mmol) in minimal amount of deionized water was added
dropwise. The reaction mixture was stirred at 0.degree. C. for 30
min and then at room temperature for 30 min to form a deep red
solution. The reaction mixture was re-cooled to 0.degree. C., and a
solution of SnCl.sub.2.2H.sub.2O (47.4, 210.0 mmol) dissolved in
minimal amount of concentrated hydrochloric acid was added then
dropwise. The thick, brown mixture was stirred at 0.degree. C. for
30 min and then at room temperature for 4 h. The solid was
collected by filtration and washed with cold ethanol (200 mL). The
yellow solid was suspended in 2:1 CHCl.sub.3iPrOH (300 mL) and the
solution was adjusted to pH .about.12-14 with 2 M aqueous sodium
hydroxide (300 mL). The phases were separated and the aqueous layer
was further extracted with CHCl.sub.3/iPrOH (2.times.300 mL). The
combined organic layers were dried with anhydrous magnesium sulfate
(MgSO.sub.4), filtered, and concentrated in vacuo. The resulting
crude product was used directly without further purification (12.7
g, 79.8 mmol, 75%).
[0203] b) To a stirring suspension of crude
5-hydrazinylisoquinoline (0.45 g, 2.2 mmol) and
2-oxocyclopentanecarbonitrile (prepared as in Fleming, et al. J.
Org. Chem., 2007, 72, 1431-1436, 0.24 g, 2.2 mmol) in ethanol (10
mL) was heated at 70.degree. C. for 2 h. After cooling to room
temperature, 3 M aqueous sodium hydroxide (0.5 mL) was added to the
reaction mixture and stirred at room temperature for 1 h. The
mixture was then concentrated in vacuo and the resulting residue
was extracted with ethyl acetate. The organic layer was dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The crude
residue was purified by flash chromatography (SiO.sub.2, 5-10%
ethyl acetate in hexanes) to give the desired product (0.48 g, 1.6
mmol, 73%).
[0204] c) A mixture of 4-t-butylbenzenesulfonyl chloride (0.075 g,
0.32 mmol) and
2-(isoquinolin-5-yl)-2,4,5,6-tetrahydrocyclopentapyrazol-3-amin- e
(0.050 g, 0.20 mmol) in pyridine (1 mL) was stirred at room
temperature for 1 h. The reaction mixture was added 1 N aqueous
hydrochloric acid and extracted with in 2:1 CH.sub.2Cl.sub.2/iPrOH
(2.times.10 mL). The combine organic layers were dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The
resulting material was purified by reverse phase HPLC (C18 column,
acetonitrile-H.sub.2O with 0.1% TFA as eluent) to give the title
compound as a white solid (0.025 g, 0.056 mmol, 28%). .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 10.10 (s, 1H), 9.35 (s, 1H), 8.42
(d, J=6.0 Hz, 1H), 8.17 (d, J=8.8 Hz, 1H), 7.68 (t, J=8.0 Hz, 1H),
7.49 (d, J=7.2 Hz, 1H), 7.41-7.37 (m, 3H), 7.18 (d, J=4.8 Hz, 1H),
2.64 (t, J=7.2 Hz, 2H), 2.21 (pent, J=7.2 Hz, 2H), 2.06 (t, J=7.5
Hz, 2H), 1.25 (s, 9H); MS: (ES) m/z calculated for
C.sub.25H.sub.27N.sub.4O.sub.2S [M+H].sup.+ 447.2, found 447.1.
Example 25: Synthesis of
N-(1-(1-aminoisoquinolin-5-yl)-3-methyl-1H-pyrazol-5-yl)-4-t-butylbenzene-
sulfonamide
##STR00147## ##STR00148##
[0206] a) To a stirring suspension of 5-hydrazinylisoquinoline
(prepared from Example 25 step a, 0.60 g, 3.8 mmol) and
3-oxobutanenitrile (0.31 g, 3.8 mmol) in ethanol (3 mL) was heated
at 80.degree. C. for 2 h. After cooling to room temperature, the
reaction mixture was in vacuo and the resulting crude residue was
purified by flash chromatography (SiO.sub.2, 0-20% methanol in
ethyl acetate) to give the desired product (0.067 g, 2.8 mmol,
73%).
[0207] b) To a solution of
1-(isoquinolin-5-yl)-3-methyl-1H-pyrazol-5-amine (0.45 g, 2.0 mmol)
in dichloromethane (10 mL) was added DMAP (0.30 g, 2.5 mmol) and
di-t-butyl dicarbonate (Boc.sub.2O, 1.2 g, 5.5 mmol). The reaction
mixture was stirred at room temperature for 15 h and ethyl acetate
was added. The resulting solution was washed with 2 N aqueous
sodium hydroxide, 2 N aqueous hydrochloric acid, and brine. The
organic layer was dried (Na.sub.2SO.sub.4), filtered, and
concentrated in vacuo. The crude product was purified by flash
chromatography (SiO.sub.2, 20-50% ethyl acetate in hexanes) to
afford the desired product (0.76 g, 1.8 mmol, 90%).
[0208] c) To a stirring solution of di-t-butyl
1-(isoquinolin-5-yl)-3-methyl-1H-pyrazol-5-yliminodicarbonate (0.15
g, 0.35 mmol) in dichloromethane (10 mL) at 0.degree. C. was added
3-chloroperbenzoic acid (mCPBA, 0.2 g, 0.90 mmol). The reaction
mixture was slowly warmed to room temperature and stirred at the
same temperature for 4 h. A solution of 15% iPrOH in
dichloromethane was added to the reaction mixture and washed with
aqueous saturated sodium bicarbonate. The organic layer was dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The crude
product was purified by flash chromatography (SiO.sub.2, 5-10%
methanol in dichloromethane) to afford the desired product (0.12 g,
0.27 mmol, 78%).
[0209] d) A stirring mixture of
5-(5-(bis(t-butoxycarbonyl)amino)-3-methyl-1H-pyrazol-1-yl)isoquinoline
2-oxide (0.12 g, 0.27 mmol) in toluene (3 mL) and dichloromethane
(3 mL) at 0.degree. C. was added t-butylamine (0.3 mL, 2.86 mmol)
and p-toluenesulfonic anhydride (Ts.sub.2O, 0.30 g, 0.93 mmol) in
three portions. The reaction mixture was slowly warmed to room
temperature over 2 h and ethyl acetate was added. The organic layer
was washed with aqueous saturated sodium bicarbonate, 1 N aqueous
hydrochloric acid, and brine. The organic layer was dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The
resulting crude product was then dissolved in dichloromethane (5
mL) and a solution of hydrochloric acid in p-dioxane (4.0 N
solution in p-dioxane, 5.0 mL, 20 mmol) was added. The reaction
mixture was stirred at room temperature for 2 h and ethyl acetate
was added. The organic layer was washed with aqueous saturated
sodium bicarbonate, dried (Na.sub.2SO.sub.4), filtered, and
concentrated in vacuo. The crude product was used directly without
further purification (0.026 g, 0.090 mmol, 33%)
[0210] e) A mixture of crude
5-(5-amino-3-methyl-1H-pyrazol-1-yl)-N-t-butylisoquinolin-1-amine
(0.055 g, 0.30 mmol), 4-acetylbenzene-1-sulfonyl chloride (0.090 g,
0.39 mmol), and DMAP (0.037 g, 0.30 mmol) in pyridine (2 mL) was
heated at 85.degree. C. for 1 h with stirring. After cooling to
room temperature, 1 M aqueous lithium hydroxide (1 mL) and 1 M
aqueous sodium hydroxide (1 mL) were added to the reaction mixture.
The resulting mixture was heated at 75.degree. C. for 30 min. After
cooling to room temperature, the reaction mixture was neutralized
with 1 N aqueous hydrochloric acid. The aqueous layer was extracted
with ethyl acetate and the organic layer was washed with aqueous
saturated sodium bicarbonate, dried (Na.sub.2SO.sub.4), filtered,
and concentrated in vacuo. The crude material was used directly to
the next step.
[0211] f) The crude residue was dissolved in TFA (8 mL) and heated
at 80.degree. C. for 1.5 h with stirring. The reaction mixture was
cooled to room temperature and concentrated in vacuo. The crude
product was then dissolved in 15% methanol in dichloromethane and
washed with aqueous saturated sodium bicarbonate. The organic layer
was dried (Na.sub.2SO.sub.4), filtered, and concentrated in vacuo.
The resulting crude product was purified by reverse phase HPLC (C18
column, acetonitrile-H.sub.2O with 0.1% TFA as eluent) to give the
title compound as a white solid (0.035 g, 0.080 mmol, 42% for 2
steps). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.23 (dd, J=0.8,
8.8 Hz, 1H), 7.60-7.54 (m, 3H), 7.50-7.42 (m, 4H), 6.31 (dd, J=0.8,
6.4 Hz, 1H), 5.93 (s, 1H), 2.22 (s, 3H), 1.36 (s, 9H); MS: (ES) m/z
calculated for C.sub.23H.sub.26N.sub.5O.sub.2S [M+H].sup.+ 436.2,
found 436.1.
Example 26: Synthesis of
4-t-butyl-3-fluoro-N-(3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)benzenes-
ulfonamide
##STR00149##
[0213] a) To a stirred suspension of nitrosyl tetrafluoroborate
(8.4 g, 71.9 mmol) in dichloromethane at 0.degree. C. was added
quinolin-5-yl-hydrazine (prepared as in Laali, et al. J. Fluorine
Chem., 2001, 107, 31-34, 12.0 g, 61.8 mmol) in small portions over
5 min. After the addition is complete, the reaction mixture was
stirred at 0.degree. C. for 1 h and slowly warmed to room
temperature over 1 h to form a fine suspension. To this suspension,
1-ethyl-3-methyl-imidazolium tetrafluoroborate (ionic liquid, 50 g,
252.6 mmol) was slowly added, and the resulting mixture was heated
at 75.degree. C. for 2 h. The organic volatile was removed by
distillation via a Dean-Stark condenser. After cooling the mixture
to room temperature, diisopropyl ethylamine (iPr.sub.2NEt, 10 mL)
was added to the reaction mixture and stirred for 10 min. Diethyl
ether (300 mL) was added to the reaction mixture and washed with 1
N aqueous hydrochloric acid, and brine, dried (Na.sub.2SO.sub.4),
filtered, and concentrated in vacuo. The crude product was used
directly without further purification (10.0 g, 50.8 mmol, 82%).
[0214] b) In a Parr shaker flask containing crude
1-t-butyl-2-fluoro-4-nitrobenzene (1.0 g, 5.1 mmol) and Pd/C (10%
by weight, 0.040 g) in methanol (60 mL) was hydrogenated at 60 psi
for 2 h. The reaction mixture was diluted with methanol and
filtered through a pad of Celite. The filtrate was concentrated in
vacuo and the resulting residue was used directly without further
purification (0.80 g, 4.8 mmol, 94%).
[0215] c) To a flask containing glacial acetic acid (2 mL) at
0.degree. C. was bubbled in sulfur dioxide gas (SO.sub.2) for 30
min. Copper(I) chloride (CuCl, 0.10 g, 1.0 mmol) was added to the
reaction mixture and stirred 30 min at 0.degree. C. to give a
blue-green solution. To a separate flask, a solution of crude
4-t-butyl-3-fluro aniline (0.20 g, 1.2 mmol) in concentrated
hydrochloric acid (3 mL) at -15.degree. C. was added a solution of
NaNO.sub.2 (0.12 g, 1.7 mmol) in deionized water (1 mL). The
reaction mixture was stirred at the same temperature for 30 min.
This diazonium solution was slowly added to the prepared copper
solution and the resulting solution was bubbled with SO.sub.2 for
another 5 min. The reaction mixture was stirred at -15.degree. C.
for 1 h and warmed to 0.degree. C. over 1 h. Diethyl ether was then
added to the reaction mixture and the content was poured over ice.
The resulting mixture was extracted with diethyl ether and the
organic layer was further washed with ice water, dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The dark
crude oil was purified by flash chromatography (SiO.sub.2, 1-3%
ethyl acetate in hexanes) to afford the desired product (0.075 g,
0.30 mmol, 25%).
[0216] d) A mixture of 4-t-butyl-3-fluorobenzene-1-sulfonyl
chloride (0.075 g, 0.30 mmol),
3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-amine (prepared from
Example 4 step b, 0.050 g, 0.22 mmol), and DMAP (0.027 g, 0.22
mmol) in pyridine (1 mL) was heated at 85.degree. C. for 2.5 h with
stirring. After cooling to room temperature, 1 M aqueous lithium
hydroxide (1 mL) and 1 M aqueous sodium hydroxide (1 mL) were added
to the reaction mixture. The resulting mixture was stirred at room
temperature for 15 h and neutralized with 1 N aqueous hydrochloric
acid. The aqueous layer was extracted with ethyl acetate and the
organic layer was washed with aqueous saturated sodium bicarbonate,
dried (Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The
resulting crude residue was purified by reverse phase HPLC (C18
column, acetonitrile-H.sub.2O with 0.1% TFA as eluent) to give the
title compound as a white solid (0.006 g, 0.014 mmol, 6%). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.83 (dd, J=1.6, 4.4 Hz, 1H),
8.08 (dd, J=1.2, 8.4 Hz, 1H), 7.79 (dd, J=7.2, 8.4 Hz, 1H), 7.69
(ddd, J=0.8, 1.6, 7.6 Hz, 1H), 7.44 (dd, J=1.2, 7.2 Hz, 1H),
7.40-7.31 (m, 3H), 7.20 (dd, J=1.6, 7.2 Hz, 1H), 5.88 (s, 1H), 2.21
(s, 3H), 1.39 (s, 9H); MS: (ES) m/z calculated for
C.sub.23H.sub.24FN.sub.4O.sub.2S [M+H].sup.+ 439.2, found
439.2.
Example 27: Synthesis
N-(1-(2-aminoquinolin-5-yl)-3-methyl-1H-pyrazol-5-yl)-4-t-butyl-3-fluorob-
enzenesulfonamide
##STR00150## ##STR00151##
[0218] a) To a solution of
3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-amine (prepared from
Example 4 step b, 4.0 g, 17.9 mmol) in dichloromethane (50 mL) was
added DMAP (2.2 g, 17.9 mmol) and Boc.sub.2O (7.8 g, 35.9 mmol).
The reaction mixture was stirred at room temperature for 3 h and
ethyl acetate was added. The organic layer was washed with 1 N
aqueous hydrochloric acid, aqueous saturated sodium bicarbonate,
and brine. The organic layer was dried (Na.sub.2SO.sub.4),
filtered, and concentrated in vacuo and the crude product was used
directly without further purification (3.5 g, 8.3 mmol, 46%).
[0219] b) To a stirring solution of crude di-t-butyl
3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-yliminodicarbonate (3.5 g,
8.3 mmol) in dichloromethane (50 mL) at 0.degree. C. was slowly
added mCPBA (4.0 g, 17.8 mmol). The reaction mixture was slowly
warmed to room temperature and stirred for 2 h. A solution of 15%
iPrOH in dichloromethane was added to the reaction mixture and
washed with aqueous saturated sodium bicarbonate. The organic layer
was dried (Na.sub.2SO.sub.4), filtered, and concentrated in vacuo.
The crude product was purified by flash chromatography (SiO.sub.2,
2-5% methanol in dichloromethane) to afford the desired product
(3.0 g, 6.8 mmol, 82%).
[0220] c) A stirring mixture of
5-(5-(bis(t-butoxycarbonyl)amino)-3-methyl-1H-pyrazol-1-yl)quinoline
1-oxide (3.0 g, 6.8 mmol) in toluene (40 mL) and dichloromethane
(40 mL) at 0.degree. C. was added t-butylamine (5.5 mL, 52.3 mmol)
and Ts.sub.2O (5.0 g, 15.3 mmol) in two portions. The reaction
mixture was slowly warmed to room temperature over 2 h and ethyl
acetate was added. The organic layer was washed with aqueous
saturated sodium bicarbonate, 1 N aqueous hydrochloric acid, and
brine. The organic layer was dried (Na.sub.2SO.sub.4), filtered,
and concentrated in vacuo. The crude product was then dissolved in
dichloromethane (10 mL) and a solution of hydrochloric acid in
p-dioxane (4.0 N solution in p-dioxane, 20 mL, 80 mmol) was added.
The reaction mixture was stirred at room temperature for 2 h and
ethyl acetate was added. The organic layer was washed with aqueous
saturated sodium bicarbonate, dried (Na.sub.2SO.sub.4), filtered,
and concentrated in vacuo. The crude product was used directly
without further purification (0.45 g, 1.52 mmol, 22%)
[0221] d) A mixture of crude
5-(5-amino-3-methyl-1H-pyrazol-1-yl)-N-t-butylquinolin-2-amine
(0.075 g, 0.25 mmol), 4-t-butyl-3-fluorobenzene-1-sulfonyl chloride
(prepared from Example 27 step c, 0.11 g, 0.44 mmol), and DMAP
(0.031 g, 0.25 mmol) in pyridine (2 mL) was heated at 80.degree. C.
for 2 h with stirring. After cooling to room temperature, 1 M
aqueous lithium hydroxide (1 mL) and 1 M aqueous sodium hydroxide
(1 mL) were added to the reaction mixture and heated at 70.degree.
C. for 30 min. After cooling to room temperature, the reaction
mixture was neutralized with 1 N aqueous hydrochloric acid. The
aqueous layer was extracted with ethyl acetate and the organic
layer was washed with aqueous saturated sodium bicarbonate, dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The crude
material was used directly to the next step.
[0222] e) The crude residue was dissolved in TFA (6 mL) and heated
at 75.degree. C. for 2 h with stirring. After cooling to room
temperature, the reaction mixture was concentrated in vacuo. The
crude product was then dissolved in 10% methanol in dichloromethane
and washed with aqueous saturated sodium bicarbonate. The organic
layer was dried (Na.sub.2SO.sub.4), filtered, and concentrated in
vacuo. The resulting crude product was purified by reverse phase
HPLC (C18 column, acetonitrile-H.sub.2O with 0.1% TFA as eluent) to
give the title compound as a white solid (0.011 g, 0.024 mmol, 10%
for 2 steps). .sup.1H NMR (400 MHz, DMSO-d.sub.6) 11.01 (br s, 1H),
7.47 (m, 2H), 7.31 (d, J=8.0 Hz, 1H), 7.27 (d, J=8.0 Hz, 1H), 7.25
(dd, J=2.0, 8.0 Hz, 1H), 7.16 (dd, J=2.0, 8.0 Hz, 1H), 6.91 (m,
3H), 5.86 (s, 1H), 2.14 (s, 3H), 1.32 (s, 9H); MS: (ES) m/z
calculated for C.sub.23H.sub.25FN.sub.5O.sub.2S [M+H].sup.+ 454.2,
found 454.1.
Example 28: Synthesis of
4-t-butyl-3-chloro-N-(3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)benzenes-
ulfonamide
##STR00152##
[0224] a) To a stirring solution of quinolin-5-yl-hydrazine
(prepared as in Laali, et al. J. Fluorine Chem., 2001, 107, 31-34,
0.25 g, 1.29 mmol) in concentrated hydrochloric acid (1.3 mL) at
0.degree. C. was added a solution of NaNO.sub.2 (0.13 g, 1.9 mmol)
in deionized water (0.64 mL). The reaction mixture was stirred for
30 min at 0.degree. C. and heated at 70.degree. C. for 30 min.
Copper(II) chloride (0.22 g, 1.6 mmol) was added to the hot mixture
and stirred at 70.degree. C. for 30 min. After cooling the reaction
mixture to room temperature, a precipitate was formed and the solid
was collected by filtration. The solid was rinsed with cold
deionized water and dried under vacuum to give the desired product
(0.13 g, 0.61 mmol, 47%).
[0225] b) Concentrated hydrochloric acid (0.25 mL) was added slowly
to a solution of 1-t-butyl-2-chloro-4-nitrobenzene (0.13 g, 0.61
mmol) and iron powder (0.17 g, 3.0 mmol) in ethanol (1.2 mL). The
reaction mixture was stirred at room temperature for 1 h and the
slurry was diluted with ethanol. The resulting mixture was then
filtered through a pad of Celite and rinsed with additional ethanol
(30 mL). The filtrate was concentrated in vacuo and the resulting
crude material was purified by flash chromatography (SiO.sub.2,
0-80% ethyl acetate in hexanes) to afford the desired product (0.10
g, 0.55 mmol, 90%).
[0226] c) To a solution of glacial acetic acid (2 mL) at 0.degree.
C. was bubbled in sulfur dioxide gas (SO.sub.2) for 30 min.
Copper(II) chloride (0.073 g, 0.54 mmol) was added to the reaction
mixture and stirred for an additional 30 min at 0.degree. C. To
another flask containing of 4-t-butyl-3-chloroaniline (0.10 g, 0.54
mmol) in concentrated hydrochloric acid (0.5 mL) was added a
solution of NaNO.sub.2 (0.06 g, 0.87 mmol) in deionized water (0.1
mL) at 0.degree. C. with stirring. This diazonium solution was
slowly added to the prepared copper solution and stirred at
0.degree. C. for 30 min. Diethyl ether was added to the reaction
mixture and the phases were separated. The aqueous layer was
further extracted with ethyl acetate (2.times.10 mL), and the
combined organic layers were dried (Na.sub.2SO.sub.4), filtered,
and concentrated in vacuo. The crude residue was purified by flash
chromatography (SiO.sub.2, 0-20% ethyl acetate in hexanes) to
afford the desired product (0.061 g, 0.23 mmol, 42%).
[0227] d) A mixture of 4-t-butyl-3-chlorobenzene-1-sulfonyl
chloride (0.050 g, 0.19 mmol) and
3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-amine (prepared from
Example 4 step b, 0.042 g, 0.095 mmol) in pyridine (0.2 mL) was
heated at 80.degree. C. for 1 h with stirring. After cooling to
room temperature, the reaction mixture was concentrated in vacuo
and the crude residue was purified by flash chromatography
(SiO.sub.2, 20% ethyl acetate in hexanes) to give the title
compound as a white solid (0.066 g, 0.16 mmol, 83%). .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 8.86 (dd, J=2.0, 4.0 Hz, 1H), 7.98
(d, J=8.4 Hz, 1H), 7.76 (t, J=8.4 Hz, 1H), 7.70 (d, J=8.4 Hz, 1H),
7.44 (s, 3H), 7.40 (d, J=7.6 Hz, 1H), 7.34 (dd, J=4.0, 8.0 Hz, 1H),
5.48 (s, 1H), 2.02 (s, 3H), 1.44 (s, 9H); MS: (ES) m/z calculated
for C.sub.23H.sub.24ClN.sub.4O.sub.2S [M+H].sup.+ 455.2, found
455.2.
Example 29: Synthesis of
3-fluoro-4-isopropoxy-N-(3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-yl)benze-
nesulfonamide
##STR00153##
[0229] a) To a stirring solution of 2-fluoro-4-nitrophenol (1.6 g,
10.2 mmol) and potassium carbonate (K.sub.2CO.sub.3, 2.5 g, 18.1
mmol) in DMF (10 mL) was stirred at room temperature for 5 min.
Isopropyl iodide (iPrI, 2 mL, 20.0 mmol) was then added to the
reaction and the resulting mixture was stirred at room temperature
for 2 h, and then heated at 45.degree. C. for 6 h. The reaction
mixture was cooled to room temperature and diethyl ether was added.
The mixture was washed with deionized water and aqueous saturated
sodium bicarbonate. The organic layer was dried (Na.sub.2SO.sub.4),
filtered, and concentrated in vacuo. The crude product was used
directly without further purification (2.0 g, 10.1 mmol, 99%).
[0230] b) To a Parr shaker flask containing crude
2-fluoro-1-isopropoxy-4-nitrobenzene (2.0 g, 10.1 mmol) and Pd/C
(10% by weight, 0.50 g) in methanol (100 mL) was hydrogenated at 35
psi for 1 h. The reaction mixture was diluted with methanol and
filtered through a pad of Celite. The filtrate was concentrated in
vacuo and the resulting residue was used directly without further
purification (1.7 g, 10.1 mmol, 100%).
[0231] c) To a solution of glacial acetic acid (40 mL) was bubbled
in SO.sub.2. After 15 min, copper (I) chloride (0.50 g, 5.1 mmol)
was added and the bubbling of SO.sub.2 gas continued until the
solution maintained a green/blue color. To another flask containing
of crude 3-fluoro-4-isopropoxyaniline (1.5 g, 8.9 mmol) in 1:1
glacial acetic acid and concentrated hydrochloric acid (10 mL) at
-15.degree. C. was added a solution of NaNO.sub.2 (0.75 g, 10.8
mmol) in deionized water (3 mL) and stirred at -15.degree. C. for
30 min. This diazonium solution was then slowly added to the
prepared copper solution and stirred at -15.degree. C. for 30 min.
Diethyl ether (30 mL) was added to the reaction mixture and stirred
at -15.degree. C. for 1 h. The reaction mixture was poured into ice
and additional diethyl ether (30 mL) was added. The phases were
separated and the aqueous layer was further extracted with ethyl
acetate (2.times.10 mL). The combined organic layers were dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The crude
residue was purified by flash chromatography (SiO.sub.2, 5-10%
ethyl acetate in hexanes) to afford the desired product (0.20 g,
0.79 mmol, 9%).
[0232] d) A mixture of 3-fluoro-4-isopropoxybenzene-1-sulfonyl
chloride (0.050 g, 0.19 mmol),
3-methyl-1-(quinolin-5-yl)-1H-pyrazol-5-amine (prepared from
Example 4 step b, 0.025 g, 0.11 mmol), and DMAP (0.020 g, 0.16
mmol) in pyridine (2 mL) was heated at 85.degree. C. for 2 h with
stirring. After cooling to room temperature, the reaction mixture
was concentrated in vacuo and the crude residue was purified by
reverse phase HPLC (C18 column, acetonitrile-H.sub.2O with 0.1% TFA
as eluent) to give the title compound as a white solid (0.015 g,
0.034 mmol, 31%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.85
(d, J=4.4 Hz, 1H), 8.11 (d, J=8.4 Hz, 1H), 7.80 (t, J=8.0 Hz, 1H),
7.62 (d, J=8.8 Hz, 1H), 7.45-7.40 (m, 2H), 7.25 (d, J=8.8 Hz, 1H),
7.12 (dd, J=2.4, 10.4 Hz, 1H), 6.92 (t, J=8.4 Hz, 1H), 6.10 (s,
1H), 4.63 (hept, J=6.4 Hz, 1H), 2.27 (s, 3H), 1.37 (d, J=6.4 Hz,
6H); MS: (ES) m/z calculated for O.sub.22H.sub.22FN.sub.4O.sub.3S
[M+H].sup.+ 441.2, found 441.2.
Example 30: Synthesis of
N-(1-(8-aminoquinolin-5-yl)-3-methyl-1H-pyrazol-5-yl)-4-t-butyl-3-fluorob-
enzenesulfonamide
##STR00154## ##STR00155##
[0234] a) To a stirring solution of 5-amino-8-bromoquinoline (1.1
g, 5.0 mmol) in 6 N aqueous hydrochloric acid (10 mL) at 0.degree.
C. was slowly added solid NaNO.sub.2 (1.0 g, 14.5 mmol), while
maintaining the internal temperature below 0.degree. C. The
reaction mixture was stirred at 0.degree. C. for 1 h and a solution
of SnCl.sub.2.2H.sub.2O (3.2 g, 12.5 mmol) dissolved in 6 N aqueous
hydrochloric acid (3 mL) was added then dropwise. The mixture was
stirred at room temperature for 2 h and the solution was
neutralized to pH .about.7 with 1 M aqueous sodium hydroxide. The
mixture was extracted with 2:1 CHCl.sub.3/iPrOH and the organic
layer was dried (Na.sub.2SO.sub.4), filtered, and concentrated in
vacuo. The resulting crude product was purified by flash
chromatography (SiO.sub.2, 50% ethyl acetate in hexanes) to give
the desired compound as a yellow solid (0.60 g, 2.6 mmol, 51%).
[0235] b) To a stirring suspension of 8-bromo-5-hydrazinylquinoline
(2.0 g, 8.4 mmol) and 3-oxo-butyronitrile (0.70 g, 8.4 mmol) in
ethanol (20 mL) was heated at 80.degree. C. for 3 h. After cooling
to room temperature, 5 M aqueous sodium hydroxide (1 mL) was added
to the reaction mixture and heated at 80.degree. C. for 1 h. The
resulting mixture was cooled to room temperature and concentrated
in vacuo. The crude residue was dissolved in 1:1
dichloromethane/methanol (40 mL) and the phases were separated. The
organic layer was dried (Na.sub.2SO.sub.4), filtered, and
concentrated in vacuo. The resulting crude was purified by flash
chromatography (SiO.sub.2, 50-100% ethyl acetate in hexanes) to
give a brown product as the desired product (1.1 g, 3.6 mmol,
43%).
[0236] c) A stirring mixture of
4-t-butyl-3-fluorobenzene-1-sulfonyl chloride (prepared from
Example 27 step c, 1.1 g, 4.2 mmol) and
1-(8-bromoquinolin-5-yl)-3-methyl-1H-pyrazol-5-amine (0.97 g, 3.2
mmol) in pyridine (5 mL) was heated at 80.degree. C. for 15 h.
After cooling to room temperature, the reaction mixture was
concentrated in vacuo. The crude solid was recrystallized from hot
ethanol (5 mL) and the resulting solid was collected by filtration
to give the desired compound (0.10 g, 0.19 mmol, 62%).
[0237] d) To a stirring solution of
N-(1-(8-bromoquinolin-5-yl)-3-methyl-1H-pyrazol-5-yl)-4-t-butyl-3-fluorob-
enzenesulfonamide (0.052 g, 0.10 mmol) in ammonium hydroxide (1 mL)
and DMF (1 mL) was added 2,4-pentanedione (0.006 g, 0.06 mmol),
cesium carbonate (Cs.sub.2CO.sub.3, 0.064 g, 0.20 mmol), and
copper(I) iodide (CuI, 0.0095 g, 0.050 mmol). The reaction mixture
was heated at 120.degree. C. in microwave for 2 h. After cooling to
room temperature, ethyl acetate (100 mL) was added to the reaction
mixture and washed with deionized water (20 mL) and brine
(2.times.20 mL). The organic layer was dried (Na.sub.2SO.sub.4),
filtered, and concentrated in vacuo. The resulting crude purified
by reverse phase HPLC (C18 column, acetonitrile-H.sub.2O with 0.1%
TFA as eluent) to give the title compound as a brown solid (0.032
g, 0.070 mmol, 70%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.80
(d, J=3.2 Hz, 1H), 7.53 (dd, J=1.2, 8.4 Hz, 1H), 7.45 (dd, J=4.0,
8.4 Hz, 1H), 7.40 (t, J=8.0 Hz, 1H), 7.32 (dd, J=2.0, 8.4 Hz, 1H),
7.22 (dd, J=2.0, 12.0 Hz, 1H), 7.08 (s, 2H), 6.12 (s, 1H), 2.28 (s,
3H), 1.41 (s, 9H); MS: (ES) m/z calculated for
C.sub.23H.sub.25FN.sub.5O.sub.2S [M+H].sup.+ 454.2, found
454.2.
Example 31: Synthesis of
N-(1-(2-aminoquinolin-5-yl)-3-methyl-1H-pyrazol-5-yl)-4-t-butylbenzenesul-
fonamide
##STR00156##
[0239] a) A mixture of crude
5-(5-amino-3-methyl-1H-pyrazol-1-yl)-N-t-butylquinolin-2-amine
(prepared from Example 28 step c, 0.090 g, 0.31 mmol),
4-t-butylbenzenesulfonyl chloride (0.15 g, 0.65 mmol), and DMAP
(0.022 g, 0.18 mmol) in pyridine (3 mL) was heated at 85.degree. C.
for 2 h with stirring. After cooling to room temperature, 1 M
aqueous lithium hydroxide (1 mL) and 1 M aqueous sodium hydroxide
(1 mL) were added to the reaction mixture and heated at 75.degree.
C. for 1 h. After cooling to room temperature, the reaction mixture
was neutralized with 1 N aqueous hydrochloric acid. The aqueous
layer was extracted with ethyl acetate and the organic layer was
washed with aqueous saturated sodium bicarbonate, dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The crude
material was used directly to the next step.
[0240] b) The crude residue was dissolved in TFA (8 mL) and heated
at 85.degree. C. for 6 h with stirring. After cooling to room
temperature, the reaction mixture was concentrated in vacuo. The
crude product was then suspended in aqueous saturated sodium
bicarbonate and extracted with ethyl acetate. The organic layer was
dried (Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The
resulting crude product was purified by reverse phase HPLC (C18
column, acetonitrile-H.sub.2O with 0.1% TFA as eluent) to give the
title compound as a white solid (0.021 g, 0.048 mmol, 16% for 2
steps). .sup.1H NMR (400 MHz, CD.sub.3OD) 7.55 (d, J=6.4 Hz, 1H),
7.55-7.54 (m, 2H), 7.49 (dd, J=7.2, 8.4 Hz, 1H), 7.43 (d, J=2.0 Hz,
1H), 7.41 (s, 1H), 7.28 (d, J=9.2 Hz, 1H), 6.90 (d, J=7.2 Hz, 1H),
6.71 (d, J=9.2 Hz, 1H), 5.93 (s, 1H), 2.21 (s, 3H), 1.35 (s, 9H);
MS: (ES) m/z calculated for C.sub.23H.sub.26N.sub.5O.sub.2S
[M+H].sup.+ 436.2, found 436.3.
Example 32: Synthesis of
4-t-butyl-N-(3-(fluoromethyl)-1-(quinolin-5-yl)-1H-pyrazol-5-yl)benzenesu-
lfonamide
##STR00157##
[0242] a) To a solution of diethyl oxalate (25.3 g, 173 mmol) in
acetonitrile (100 mL) was added potassium t-butoxide (19.5 g, 173
mmol) over three portions. The orange suspension was stirred at
room temperature for 1.5 h and the solid was collected by
filtration to give a yellow powder as the desired product (24.3 g,
135.8 mmol, 78%).
[0243] b) To a stirring suspension of crude
5-hydrazinylisoquinoline (prepared from Example 25 step a, 6.0 g,
37.7 mmol) and potassium 1-cyano-3-ethoxy-3-oxoprop-1-en-2-olate
(8.1 g, 45.2 mmol) in ethanol (36 mL) was added a solution of 6 N
aqueous hydrochloric acid (7.7 mL, 45.2 mmol) and deionized water
(10 mL). The reaction mixture was heated at 90.degree. C. for 5 h.
After cooling to room temperature, the reaction mixture was
concentrated in vacuo and the resulting residue was extracted with
2:1 chloroform/iPrOH. The organic layer was washed with aqueous
saturated sodium bicarbonate and the organic layer was dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The
resulting solid was suspended in dichloromethane/diethyl ether and
the yellow solid was collected by filtration to give the desired
product (3.14 g, 11.1 mmol, 30%).
[0244] c) To a solution of ethyl
5-amino-1-(quinolin-5-yl)-1H-pyrazole-3-carboxylate (0.25 g, 0.89
mmol) in dichloromethane (5 mL) was added DMAP (0.15 g, 1.2 mmol)
and Boc.sub.2O (0.5 g, 2.3 mmol). The reaction mixture was stirred
at room temperature for 6 h and ethyl acetate was added. The
resulting solution was washed with aqueous saturated sodium
bicarbonate and brine. The organic layer was dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The crude
product was purified by flash chromatography (SiO.sub.2, 20-50%
ethyl acetate in hexanes) to afford the desired product (0.36 g,
0.75 mmol, 84%).
[0245] d) To a solution of ethyl
5-(bis(t-butoxycarbonyl)amino)-1-(quinolin-5-yl)-1H-pyrazole-3-carboxylat-
e (0.20 g, 0.41 mmol) in THF (6 mL) at 0.degree. C. was added a
solution of lithium aluminum hydride (LAH, 2.0 M solution in THF,
0.48 mL, 0.96 mmol). The reaction mixture was stirred at 0.degree.
C. for 5 min and aqueous saturated potassium sodium tartrate was
added to the reaction mixture. The resulting solution was extracted
with ethyl acetate (2.times.5 mL). The combined organic layers were
dried (Na.sub.2SO.sub.4), filtered, and concentrated in vacuo to
give the mono-protected crude product (0.14 g, 0.41 mmol,
100%).
[0246] e) To a stirring solution of t-butyl
3-(hydroxymethyl)-1-(quinolin-5-yl)-1H-pyrazol-5-ylcarbamate (0.20
g, 0.59 mmol) in dichloromethane (6 mL) at -45.degree. C. was added
N,N-diethylaminosulfur trifluoride (DAST, 0.15 mL, 1.2 mmol)
dropwise, and the reaction mixture was stirred at 0.degree. C. for
15 min. The reaction mixture was then poured into ice and aqueous
sodium bicarbonate was added. The aqueous layer was extracted with
ethyl acetate and the organic layer was dried (Na.sub.2SO.sub.4),
filtered, and concentrated in vacuo. The resulting crude residue
was used without further purification (0.20 g, 0.59 mmol,
100%).
[0247] f) To a stirring solution of t-butyl
3-(fluoromethyl)-1-(quinolin-5-yl)-1H-pyrazol-5-ylcarbamate (0.20
g, 0.59 mmol) in dichloromethane (5 mL) and methanol (1 mL) was
added a solution of hydrochloric acid in p-dioxane (4 N solution in
p-dioxane, 10 mL, 40 mmol). The reaction mixture was stirred at
room temperature for 1 h and the organic volatile was removed in
vacuo. The resulting residue was dissolved in 2:1
chloromethane/iPrOH and washed with aqueous 1 M sodium hydroxide
and aqueous saturated sodium bicarbonate. The organic layer was
dried (Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The
crude residue was used without further purification (0.14 g, 0.59
mmol, 100%).
[0248] g) To a mixture of 4-t-butylbenzenesulfonyl chloride (0.085
g, 0.37 mmol),
3-(fluoromethyl)-1-(quinolin-5-yl)-1H-pyrazol-5-amine (0.05 g, 0.21
mmol), and DMAP (0.025 g, 0.19 mmol) in pyridine (1.0 mL) was
heated at 85.degree. C. for 2 h with stirring. After cooling to
room temperature, 1 M aqueous lithium hydroxide (1 mL) and 1 M
aqueous sodium hydroxide (1 mL) were added to the reaction mixture
and heated at 75.degree. C. for 1 h. After cooling to room
temperature, the reaction mixture was neutralized with 1 N aqueous
hydrochloric acid. The aqueous layer was extracted with ethyl
acetate and the organic layer was washed with aqueous saturated
sodium bicarbonate, dried (Na.sub.2SO.sub.4), filtered, and
concentrated in vacuo. The crude residue was purified by reverse
phase HPLC (C18 column, acetonitrile-H.sub.2O with 0.1% TFA as
eluent) to give the title compound as a white solid (0.004 g, 0.009
mmol, 4%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.86 (dd,
J=1.2, 4.0 Hz, 1H), 8.12 (d, J=8.8 Hz, 1H), 7.79 (dd, J=8.4, 8.4
Hz, 1H), 7.65 (d, J=8.4 Hz, 1H), 7.56 (s, 1H), 7.54 (s, 1H),
7.43-7.37 (m, 4H), 6.24 (s, 1H), 5.34 (s, 1H), 5.22 (s, 1H), 1.35
(s, 9H); MS: (ES) m/z calculated for
C.sub.23H.sub.24FN.sub.4O.sub.2S [M+H].sup.+ 439.2, found
439.1.
Example 33: Synthesis of
4-t-butyl-3-fluoro-N-(3-(fluoromethyl)-1-(quinolin-5-yl)-1H-pyrazol-5-yl)-
benzenesulfonamide
##STR00158##
[0250] To a mixture of 4-t-butyl-3-fluorobenzene-1-sulfonyl
chloride (prepared from Example 27 step c, 0.050 g, 0.20 mmol),
3-(fluoromethyl)-1-(quinolin-5-yl)-1H-pyrazol-5-amine (0.025 g,
0.10 mmol), and DMAP (0.012 g, 0.095 mmol) in pyridine (3 mL) was
heated at 85.degree. C. for 2 h with stirring. After cooling to
room temperature, 1 M aqueous lithium hydroxide (1 mL) and 1 M
aqueous sodium hydroxide (1 mL) were added to the reaction mixture
and heated at 75.degree. C. for 1 h. After cooling to room
temperature, the reaction mixture was neutralized with 1 N aqueous
hydrochloric acid. The aqueous layer was extracted with ethyl
acetate and the organic layer was washed with aqueous saturated
sodium bicarbonate, dried (Na.sub.2SO.sub.4), filtered, and
concentrated in vacuo. The crude residue was purified by reverse
phase HPLC (C18 column, acetonitrile-H.sub.2O with 0.1% TFA as
eluent) to give the title compound as a white solid (0.003 g, 0.007
mmol, 7%). .sup.1H NMR (400 MHz, CD.sub.3OD) 8.83 (dd, J=4.4, 11.6
Hz, 1H), 8.10 (dd, J=1.2, 8.8 Hz, 1H), 7.83 (ddd, J=1.6, 7.6, 8.8
Hz, 1H), 7.63 (dd, J=0.8, 8.8 Hz, 1H), 7.53 (dd, J=0.8, 7.6 Hz,
1H), 7.41 (dd, J=1.6, 8.4 Hz, 1H), 7.38-7.31 (m, 2H), 7.24 (dd,
J=1.6, 12.4 Hz, 1H), 6.05 (d, J=1.6 Hz, 1H), 5.28 (s, 1H), 5.16 (s,
1H), 1.40 (d, J=0.8 Hz, 9H); MS: (ES) m/z calculated for
C.sub.23H.sub.26N.sub.5O.sub.2S [M+H].sup.+ 457.2, found 457.2.
Measuring Efficacy of Chemokine Modulators
In Vitro Assays
[0251] A variety of assays can be used to evaluate the compounds
provided herein, including signaling assays, chemotaxis (migration
assays), ligand binding assays, and other assays of cellular
response. Chemokine receptor signaling assays can be used to
measure the ability of a compound, such as a potential CCR(9)
antagonist, to block CCR(9) ligand- (e.g. TECK)-induced signaling.
Blocking such signaling can be useful in treating various diseases
such as inflammatory bowel diseases, an allergic disease,
psoriasis, atopic dermatitis, asthma, fibrotic diseases, graft
rejection, immune mediated food allergies, autoimmune diseases,
Celiac disease, rheumatoid arthritis, thymoma, thymic carcinoma,
leukemia, solid tumor, acute lymphocytic leukemia, melanoma,
primary sclerosing cholangitis, hepatitis, inflammatory hepatic
disease, or post-operative ileus. A chemotaxis assay can be used to
measure the ability of a compound of interest, such as a possible
chemokine antagonist, to block chemokine-mediated cell migration in
vitro. The latter is believed to resemble chemokine-induced cell
migration in vivo. A ligand binding assay can also be used to
measure the ability of a compound, such as a potential CCR(9)
antagonist, to block the interaction of TECK or other CCR(9)
ligands with their receptor.
[0252] In a suitable assay, a chemokine protein (whether isolated
or recombinant) or other ligand is used that has at least one
property, activity, or functional characteristic of a mammalian
chemokine protein. The property can be a binding property (to, for
example, a ligand or inhibitor), a signaling activity (e.g.,
activation of a mammalian G protein, induction of rapid and
transient increase in the concentration of cytosolic free calcium
ion), cellular response function (e.g., stimulation of chemotaxis
or inflammatory mediator release by leukocytes), and the like.
[0253] The assay can be a cell-based assay that utilizes cells
stably or transiently transfected with a vector or expression
cassette having a nucleic acid sequence that encodes the chemokine
receptor. Cell lines or isolated primary cells naturally expressing
the chemokine can also be used. The cells are maintained under
conditions appropriate for expression of the receptor and are
contacted with a putative agent under conditions appropriate for
binding to occur. Binding can be detected using standard
techniques. For example, the extent of binding can be determined
relative to a suitable control (for example, relative to background
in the absence of a putative agent, or relative to a known ligand).
Optionally, a cellular fraction, such as a membrane fraction,
containing the receptor can be used in lieu of whole cells.
[0254] Detection of binding or complex formation can be detected
directly or indirectly. For example, the putative agent can be
labeled with a suitable label (e.g., fluorescent label,
chemiluminescent label, isotope label, enzyme label, and the like)
and binding can be determined by detection of the label. Specific
and/or competitive binding can be assessed by competition or
displacement studies, using unlabeled agent or a ligand (e.g.,
TECK) as a competitor.
[0255] Binding inhibition assays can be used to evaluate the
present compounds. In these assays, the compounds are evaluated as
inhibitors of ligand binding using, for example, TECK or small
molecule ligands. The CCR(9) receptor is contacted with a ligand in
the presence or absence of a test agent, and a measure of ligand
binding is made. A reduction in the extent of ligand binding is
indicative of inhibition of binding by the test agent. The binding
inhibition assays can be carried out using whole cells which
express the receptor, or a membrane fraction from cells which
express the receptor.
[0256] Further, the binding of a G protein coupled receptor by, for
example, an agonist, can result in a signaling event by the
receptor. Accordingly, signaling assays can also be used to
evaluate the compounds of the present invention and induction of
signaling function by an agent can be monitored using any suitable
method. For example, G protein activity, such as hydrolysis of GTP
to GDP, or later signaling events triggered by receptor binding can
be assayed by known methods (see, for example, PCT/US97/15915;
Neote et al., Cell, 72:415425 (1993); Van Riper et al., J. Exp.
Med., 177:851-856 (1993) and Dahinden et al., J. Exp. Med.,
179:751-756 (1994)). Calcium signaling assays also measure GPCR
activity, by measuring intra-cellular calcium concentration over
time, preferably before and after receptor/ligand binding in the
presence or absence of a test agent. These assays are useful in
determining the ability of a compound, such as those of the present
invention, to generate the receptor signaling mediator by binding
to a receptor of interest. Also, these assays are useful in
determining the ability of a compound, such as those of the present
invention, to inhibit generation of the receptor signaling mediator
by interfering with binding between a receptor of interest and a
ligand.
[0257] In calcium signaling assays used to determine the ability of
a compound to interfere with binding between a chemokine receptor
and a known chemokine ligand, chemokine receptor-expressing cells
(CCR(9)-expressing cells such as T cell line MOLT-4 cells) are
first incubated with a compound of interest, such as a potential
chemokine antagonist, at increasing concentrations. The cell number
can be from 10.sup.5 to 5.times.10.sup.6 cells per well in a
96-well microtiter plate. The concentration of the compound being
tested may range from 0 to 100 .mu.M. After a period of incubation
(which can range from 5 to 60 minutes), the treated cells are
placed in a Fluorometric Imaging Plate Reader (FLIPR.RTM.)
(available from Molecular Devices Corp., Sunnyvale, Calif.)
according to the manufacturer's instruction. The FLIPR.RTM. system
is well known to those skilled in the art as a standard method of
performing assays. The cells are then stimulated with an
appropriate amount of the chemokine ligand (TECK for CCR(9)) at
5-100 nM final concentration, and the signal of intracellular
calcium increase (also called calcium flux) is recorded. The
efficacy of a compound as an inhibitor of binding between the
chemokine and the ligand can be calculated as an IC50 (the
concentration needed to cause 50% inhibition in signaling) or IC90
(at 90% inhibition).
[0258] Chemotaxis assays can also be used to assess receptor
function and evaluate the compounds provided herein. These assays
are based on the functional migration of cells in vitro or in vivo
induced by an agent, and can be used to assess the binding and/or
effect on chemotaxis of ligands, inhibitors, or agonists. A variety
of chemotaxis assays are known in the art, and any suitable assay
can be used to evaluate the compounds of the present invention.
Examples of suitable assays include those described in
PCT/US97/15915; Springer et al., WO 94/20142; Berman et al.,
Immunol. Invest., 17:625-677 (1988); and Kavanaugh et al., J.
Immunol., 146:4149-4156 (1991)).
[0259] In vitro cell chemotaxis assays can be performed (but are
not limited to this format) using the 96-well microchamber (called
ChemoTX.TM.). The ChemoTX.TM. system is well known to those skilled
in the art as a type of chemotactic/cell migration instrument. In
this assay, CCR(9)-expressing cells (such as MOLT-4) are first
incubated with a compound of interest, such as a possible CCR(9)
antagonist at increasing concentrations. Typically, fifty thousand
cells per well are used, but the amount can range from
10.sup.3-10.sup.6 cells per well. The chemokine ligand (for
example, CCR(9) ligand TECK, typically at 50 nM (but can range from
5-100 nM)), is placed at the lower chamber and the migration
apparatus is assembled. Twenty microliters of test compound-treated
cells are then placed onto the membrane. Migration is allowed to
take place at 37.degree. C. for a period of time, typically 2.5
hours for CCR(9). At the end of the incubation, the number of cells
that migrated across the membrane into the lower chamber is then
quantified. The efficacy of a compound as an inhibitor of
chemokine-mediated cell migration can be calculated as an IC.sub.50
(the concentration needed to reduce cell migration by 50%) or
IC.sub.90 (for 90% inhibition).
In Vivo Efficacy Models for Human IBD
[0260] T cell infiltration into the small intestine and colon have
been linked to the pathogenesis of human inflammatory bowel
diseases which include Coeliac disease, Crohn's disease and
ulcerative colitis. Blocking trafficking of relevant T cell
populations to the intestine is believed to be an effective
approach to treat human IBD. CCR(9) is expressed on gut-homing T
cells in peripheral blood, elevated in patients with small bowel
inflammation such as Crohn's disease and Coeliac disease. CCR(9)
ligand TECK is expressed in the small intestine. It is thus
believed that this ligand-receptor pair plays a role in IBD
development by mediating migration of T cells to the intestine.
Several animal models exist and can be used for evaluating
compounds of interest, such as potential CCR(9) antagonists, for an
ability to affect such T cell migration and/or condition or
disease, which might allow efficacy predictions of antagonists in
humans.
Animal Models with Pathology Similar to Human Ulcerative
Colitis
[0261] A murine model described by Panwala and coworkers (Panwala
et al., J Immunol., 161(10):5733-44 (1998)) involves genetic
deletion of the murine multi-drug resistant gene (MDR). MDR
knockout mice (MDR-/-) are susceptible to developing a severe,
spontaneous intestinal inflammation when maintained under specific
pathogen-free facility conditions. The intestinal inflammation seen
in MDR-/- mice has a pathology similar to that of human
inflammatory bowel disease (IBD) and is defined by Thl type T cells
infiltration into the lamina propria of the large intestine.
[0262] Another murine model was described by Davidson et al., J Exp
Med., 184(1):241-51(1986). In this model, the murine IL-10 gene was
deleted and mice rendered deficient in the production of
interleukin 10 (IL-10-/-). These mice develop a chronic
inflammatory bowel disease (IBD) that predominates in the colon and
shares histopathological features with human IBD.
[0263] Another murine model for IBD has been described by Powrie et
al., Int. Immunol., 5(11):1461-71 (1993), in which a subset of CD4+
T cells (called CD45RB(high)) from immunocompetent mice are
purified and adoptively transferred into immunodeficient mice (such
as C.B-17 scid mice). The animal restored with the CD45RBhighCD4+ T
cell population developed a lethal wasting disease with severe
mononuclear cell infiltrates in the colon, pathologically similar
with human IBD.
[0264] The TNF ARE(-/-) model. The role of TNF in Crohn's disease
in human has been demonstrated more recently by success of
treatment using anti-TNF alpha antibody by Targan et al., N. Engl.
J Med., 337(15):1029-35 (1997). Mice with aberrant production of
TNF-alpha due to genetic alteration in the TNF gene (ARE-/-)
develop Crohn's-like inflammatory bowel diseases (see Kontoyiannis
et al., Immunity, 10(3):387-98 (1999)).
[0265] The SAMP/yit model. This model is described by Kosiewicz et
al., J Clin. Invest., 107(6):695-702 (2001). The mouse strain,
SAMP/Yit, spontaneously develops a chronic inflammation localized
to the terminal ileum. The resulting ileitis is characterized by
massive infiltration of activated T lymphocytes into the lamina
propria, and bears a remarkable resemblance to human Crohn's
disease.
Examples of In Vitro Assays
Reagents
[0266] MOLT-4 cells were obtained from the American Type Culture
Collection (Manassas, Va.) and cultured in RPMI tissue culture
medium supplemented with 10% fetal calf serum (FCS) in a humidified
5% CO.sub.2 incubator at 37.degree. C. Recombinant human chemokine
proteins TECK was obtained from R&D Systems (Minneapolis,
Minn.). ChemoTX.RTM. chemotaxis microchambers were purchased from
Neuro Probe (Gaithersburg, Md.). CyQUANT.RTM. cell proliferation
kits were purchased from Molecular Probes (Eugene, Oreg.). Calcium
indicator dye Fluo-4 AM was purchased from Molecular Devices
(Mountain View, Calif.).
Evaluation of a Test Modulator in a Calcium Mobilization Assay
[0267] A cytoplasmic calcium mobilization assay was used to
determine the efficacy of potential receptor antagonists at
blocking the signals mediated through chemokine receptors, such as
CCR(9). This assay was routinely performed using the Fluorescent
Imaging Plate Reader (FLIPR, Molecular Devices). MOLT-4 cells were
labeled with the fluorescent-indicator dye Fluo-4 (Molecular
Devices) according to the manufacturer's directions. After
labeling, the cells were collected by centrifugation (400.times.g
for 5 min at room temperature) and resuspended in HBSS to a cell
density of 2.5.times.10.sup.6 cells/mL. Test compounds were
prepared in 100% DMSO at 100.times. the final concentration;
generally, a range of concentrations of each compound were tested,
with final concentrations from 0.1 nM to 10,000 nM. Labeled cells
(300 .mu.L) were mixed with compound or an equal volume of DMSO (3
.mu.L) in a 96-well plate; after thorough mixing, 50 .mu.L of this
cell/compound mixture was added to each of four wells of a 384-well
FLIPR plate. The chemokine agonist (i.e., hTECK), prepared in HBSS
at a 5.times. concentration of the previously determined EC.sup.50
concentration, was added to each well and resulting changes in the
fluorescent intensity, indicative of chemokine receptor-mediated
signaling, were recorded on the FLIPR. The compound IC.sup.50
values were calculated with these data using Graphpad Prism
software (Graphpad Software) and a nonlinear regression, one-site
competition model.
Evaluation of a Test Modulator in a Serum Chemotaxis Assay
[0268] A serum chemotaxis assay was used to determine the efficacy
of potential receptor antagonists at blocking the migration
mediated through chemokine receptors, such as CCR(9). This assay
was performed using the ChemoTX.RTM. microchamber system with a
5-.mu.m pore-sized polycarbonate membrane. MOLT-4 cells were
collected by centrifugation at 400.times.g at room temperature,
then suspended at 50 million/ml in human serum, containing 50 mM
HEPES (final pH of 7.2). The compound being tested or an equivalent
volume of its solvent (DMSO) was then added to the cell/serum
mixture at a final DMSO concentration of 0.125% (v/v), and this
mixture was then incubated together at 37.degree. C. for one hour.
Separately, recombinant human TECK was diluted with chemotaxis
buffer (HBSS+0.1% BSA), generally spanning a range from 0.1 nM to
500 nM, after which 29 .mu.l of diluted chemokine was placed in the
lower wells of the ChemoTX.RTM. plate. The 5-.mu.m (pore size)
polycarbonate membrane was placed onto the plate, and 20 .mu.L of
the cell/compound mixture was transferred onto each well of the
membrane. The plates were incubated at 37.degree. C. for 90
minutes, after which the polycarbonate membranes were removed and 5
.mu.l of the DNA-intercalating agent CyQUANT (Invitrogen, Carlsbad,
Calif.) was added to the lower wells. The amount of fluorescence,
corresponding to the number of migrated cells, was measured using a
Spectrafluor Plus plate reader (TECAN, San Jose, Calif.).
[0269] The A2 values were calculated from the following equation,
comparing the efficacy of the test compound with that of the
DMSO-only control at equi-active chemokine levels:
Log(A2)=log[drug(M)]-log [(A'/A)-1]
[0270] where A reflects the potency of the agonist in the absence
of antagonist and A' reflects the potency of the agonist in the
presence of antagonist at a given concentration of drug
([drug(M)]).
Examples of In Vivo Efficacy Assays
Evaluation of a Test Modulator in a CCR(9) Dependent T Cell
Trafficking Model
[0271] Single cell suspensions were prepared from spleens and lymph
nodes of OT-1 Tg CD45.1 mice. 15.times.10.sup.6 total cells (about
3.times.10.sup.6 CD8 T cells) were injected into sex-matched
congenic CD45.2 C57BL/6n mice (8-10 weeks old). 24 hours later,
animals were immunized via oral gavage with 25 mg Ovalbumin protein
(Sigma-Aldrich, St. Louis, Mo.)+10 ug Cholera Toxin (Calbiochem,
San Diego, Calif.). CCR(9) antagonists were administered prior to
oral ovalbumin in a time frame dictated by their mouse
pharmacokinetics and dosed throughout. Five days post immunization,
animals were euthanized, and small intestines were harvested.
Peyer's patches were removed and, after flushing with PBS, the gut
was opened on a wet square of Optima fabric (Allegiance
Healthcare). The mucosa was scraped with a scalpel and then
dissociated by stirring in 50 ml of medium containing 10% newborn
calf serum and DTT (1 mM) for 15 min at room temperature. After
centrifugation, pellets were resuspended in PBS containing 10%
newborn calf serum, vortexed for 3 min, and rapidly passed through
a glass wool column (1.6 g packed in a 20-ml syringe; Fisher
Scientific). IEL were further purified on a Ficoll-Paque gradient
and stained with mAbs for flow cytometry analysis. Transferred OT-1
Tg CD45.1 T cells were detected and quantified by flow cytometry.
In this model treatment with a compound of the invention resulted
in a significant reduction in the frequency of OT-1 Tg CD45.1 T
cells that traffic to the small intestine in response to
antigen.
Evaluation of a Test Modulator in a Cell Transfer Model of
Colitis
[0272] Single cell suspensions of purified CD4+CD25- T cells were
generated from the spleen and lymph nodes of Balb/c mice.
1.times.106 CD4+CD25- T cell were then transferred into sex and
age-matched CB17 SCID mice. CD4+CD25- recipient mice received
either vehicle or a compound of the invention starting 2 hrs prior
to the transfer. Mice body weights were monitored weekly, as mice
develop disease they lose weight. Mice in which the disease
progression has been slowed or inhibited will have a marked
difference in their body weight relative to mice receiving vehicle.
At the end of the study the colons of the mice are weighed and
measured in order to assess the remodeling of the target tissue.
Changes in cytokines were also measured in colonic tissue
homogenates. Treatment with a compound of the invention results in
significant protection from the wasting associated with disease as
well as a normalization of the colonic remodeling and
proinflammatory cytokine levels.
Evaluation of a Test Modulator in a Model of Inhibition of HIV
Spread
[0273] In the bone marrow/liver/thymus, or "BLT" mouse, nonobese
diabetic (NOD)/SCID mice (which lack endogenous T and B cells) are
surgically implanted with fetal thymic and liver organoids, as in
the SCID-hu system. The mice are then sublethally irradiated and
transplanted with autologous CD34.sup.+ stem cells obtained from
fetal liver which take up residence in the murine bone marrow,
effectively receiving a human bone marrow transplant and resulting
in a range of human cells in peripheral blood, including mature T
and B lymphocytes, monocytes, macrophages, and dendritic cells, all
of which show extensive infiltration of organs and tissues
including liver, lung, and gastrointestinal tract. Following
transplantation, a compound of the invention is administered to
transplanted mice to inhibit the trafficking of human cells to the
gastrointestinal tract, a major source of T cell/HIV interaction.
Compound efficacy is measured as a reduction in blood viral load by
standard techniques.
Evaluation of a Test Modulator in a Model of Arthritis
[0274] A 17-day study of type II collagen-induced arthritis is
conducted to evaluate the effects of a modulator on
arthritis-induced clinical ankle swelling. Rat collagen-induced
arthritis is an experimental model of polyarthritis that has been
widely used for preclinical testing of numerous anti-arthritic
agents (see Trentham et al., J. Exp. Med. 146(3):857-868 (1977),
Bendele et al., Toxicologic Pathol. 27:134-142 (1999), Bendele et
al., Arthritis. Rheum. 42:498-506 (1999)). The hallmarks of this
model are reliable onset and progression of robust, easily
measurable polyarticular inflammation, marked cartilage destruction
in association with pannus formation and mild to moderate bone
resorption and periosteal bone proliferation.
[0275] Female Lewis rats (approximately 0.2 kilograms) are
anesthetized with isoflurane and injected with Freund's Incomplete
Adjuvant containing 2 mg/mL bovine type II collagen at the base of
the tail and two sites on the back on days 0 and 6 of this 17-day
study. The test modulator is dosed daily by sub-cutaneous injection
from day 9 to day 17 at a dose of 100 mg/kg and a volume of 1 mL/kg
in the following vehicle (24.5% Cremaphore EL, 24.5% common oil, 1%
Benzylalcohol and 50% Distilled water). Caliper measurements of the
ankle joint diameter are taken daily, and reducing joint swelling
is taken as a measure of efficacy.
Evaluation of a Test Modulator in a Model of Ulcerative Colitis
[0276] The MDR1a-knockout mice, which lack the P-glycoprotein gene,
spontaneously develop colitis under specific pathogen-free
condition. The pathology in these animals has been characterized as
Thl-type T cell-mediated inflammation similar to ulcerative colitis
in humans. Disease normally begins to develop at around 8-10 weeks
after birth. However the ages at which disease emerges and the
ultimate penetrance level often vary considerably among different
animal facilities.
[0277] In a study using the MDR1a-knockout mice, a CCR(9)
antagonist of the invention was evaluated by prophylactic
administration for its ability to delay disease onset. Female mice
(n=34) were dosed with 10-100 mg/kg once a day by subcutaneous
injections for 14 consecutive weeks starting at age 10 weeks. The
study was evaluated for IBD-associated growth retardation, and the
tested compound was shown to be efficacious in this model.
Evaluation of a Test Modulator in a Mouse Model of Asthma
[0278] This example describes a procedure to evaluate the efficacy
of antagonists for treatment of asthma. An animal model of asthma
can be induced by sensitizing rodents to an experimental antigen
(e.g. OVA) by standard immunization, and subsequently introducing
that same antigen into the rodents lung by aerosolization. Three
series of rodent groups, comprising 10 rodents per group, are
actively sensitized on Day 0 by a single i.p. injection with 100 ug
OVA in phosphate-buffered saline (PBS), along with an adjuvant e.g.
aluminum hydroxide. At 11 days after sensitization, the animals are
placed in a Plexiglas chamber and challenged with aerosolized OVA
(1%) for 30 minutes using the ultrasonic nebulizer (De Vilbliss).
One series of mice additionally receives PBS and Tween 0.5% i.p. at
the initial sensitization, and at different dosing schedules
thereafter, up until the aerosolized OVA challenge. A second series
consists of groups of mice receiving different doses of the CCR4
antagonist given either intraperitoneally, intra-venously,
sub-cutaneously, intra-muscularly, orally, or via any other mode of
administration at the initial sensitization, and at different
dosing schedules thereafter, up until the aerosolized OVA
challenge. A third series of mice, serving as positive control,
consists of groups treated with either mouse IL-10 i.p., anti-lL4
antibodies i.p., or anti-IL5 antibodies i.p. at the initial
sensitization, and at different dosing schedules thereafter, up
until the aerosolized OV A challenge. Animals are subsequently
analyzed at different time points after the aerosolized OVA
challenge for pulmonary function, cellular infiltrates in
bronchoalveolar lavage (BAL), histological examination of lungs,
and measurement of serum OVA specific IgE titers.
[0279] It is therefore intended that the foregoing detailed
description be regarded as illustrative rather than limiting, and
that it be understood that it is the following claims, including
all equivalents, that are intended to define the spirit and scope
of this invention.
* * * * *